TARGETING TUMOUR MICROENVIRONMENT: DEVELOPMENT OF CARBONIC ANHYDRASE IX NUCLEAR IMAGING AGENTS

by

Joseph Cheong Chun Lau

B.Sc., The University of British Columbia, 2011

A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF

DOCTOR OF PHILOSOPHY

in

THE FACULTY OF GRADUATE AND POSTDOCTORAL STUDIES

(Interdisciplinary Oncology)

THE UNIVERSITY OF BRITISH COLUMBIA

(Vancouver)

August 2016

© Joseph Cheong Chun Lau, 2016
Abstract

Tumour hypoxia has long been recognized as an impediment to radiotherapy and chemotherapy. Cancers that are hypoxic tend to be aggressive, with high propensity for distant metastasis. As hypoxia is a salient feature of most solid cancers, targeting components of the hypoxia-induced signaling cascade has been proposed as a means for oncologic treatment. The key enzyme mediating hypoxia-induced stress response in cancers is carbonic anhydrase IX (CA-IX). Regulated by hypoxia-inducible factor 1α (HIF-1α), CA-IX catalyzes the reversible hydration of carbon dioxide to bicarbonate ion. CA-IX promotes cancer cell survival by transporting bicarbonate ions into the cell to maintain pH homeostasis during glycolysis. CA-IX is well-established as a surrogate marker for cellular hypoxia. Overexpression of CA-IX has been observed in a broad spectrum of cancers including: breast, cervix, ovarian, bladder, brain, colon, lung, kidney, head and neck cancers. In healthy individuals, CA-IX is expressed at low levels except in the gastrointestinal tract where it is involved in the process of cell differentiation. As CA-IX is pathologically expressed by cancer cells and located at the cell surface, it has emerged as a promising imaging/therapeutic target.

In this thesis, we communicate the development of molecular antigen recognition molecules as potential radiotracers for CA-IX targeted nuclear imaging. We identified two classes of sulfonamide derivatives that successfully delineated CA-IX expression in tumour-bearing mice. Isoform selectivity, the major challenge for small molecule inhibitor-based imaging, was achieved via a multivalent approach or by conjugating pharmacophores to polyaminocarboxylate chelators. With good tumour-to-nontarget ratios and fast pharmacokinetics, some of these agents warrant further investigation as surrogate hypoxia imaging agents. Additionally we radiolabeled three novel monoclonal antibodies (mAbs) and one affibody for CA-IX imaging, with one mAb in particular showing significant accumulation in tumours. Collectively, this research provides a non-invasive platform to characterize and quantify expression of CA-IX in primary lesions and across metastatic sites. The diagnostic information can be readily integrated with emergent pharmaceuticals to increase effectiveness and safety of CA-IX or hypoxia-directed treatments for cancer patients.
Preface

A version of Chapter 2 has been published [Pan J, Lau J, Mesak F, Hundal N, Pourghiasian M, Liu Z, Bénard F, Dedhar S, Supuran CT, Lin KS. Synthesis and evaluation of $^{18}$F-labeled carbonic anhydrase IX inhibitors for imaging with positron emission tomography. J Enzyme Inhib Med Chem, 2014; 29(2):249-255]. Pan J and I were the lead investigators, responsible for all major areas of concept formation, data collection and analysis, as well as the majority of manuscript composition. Mesak F, Hundal N, Pourghiasian M, and Liu Z were involved in radiochemistry and imaging experiments. Supuran CT provided the binding affinity measurements. Bénard F, Dedhar S, Supuran CT, and Lin KS were the supervisory authors on this project and were involved throughout the project in concept formation and manuscript composition.

A version of Chapter 3 has been published [Lau J, Pan J, Zhang Z, Hundal N, Liu Z, Bénard F, Lin KS. Synthesis and Evaluation of $^{18}$F-Labeled Tertiary Sulfonamides for Imaging Carbonic Anhydrase IX expression in Tumours with Positron Emission Tomography. Bioorg Med Chem Lett, 2014; 24(14):3064-3068]. I was the lead investigator, responsible for all major areas of concept formation, data collection and analysis, as well as the majority of manuscript composition. Pan J, Zhang Z, Hundal N, and Liu Z were involved in radiochemistry and imaging experiments. Bénard F and Lin KS were the supervisory authors on this project and were involved throughout the project in concept formation and manuscript composition.

A version of Chapter 4 has been published [Lau J, Liu Z, Lin KS, Pan J, Zhang Z, Vullo D, Supuran CT, Perrin DM, Bénard F. Trimeric Radiofluorinated Sulfonamide Derivatives to Achieve In Vivo Selectivity for Carbonic Anhydrase IX-Targeted Cancer Imaging. J Nuc Med, 2015;56(9): 1434-1440]. Liu Z and I were the lead investigators, responsible for all major areas of concept formation, data collection and analysis, as well as the majority of manuscript composition. Pan J, Zhang Z, and Vullo D were involved in binding affinity and radiochemistry experiments. Lin KS, Supuran CT, Perrin DM, and Bénard F were the supervisory authors on
this project and were involved throughout the project in concept formation and manuscript composition.

A version of Chapter 5 has been published [Lau J, Zhang Z, Jenni S, Kuo HT, Liu Z, Vullo D, Supuran CT, Lin KS, Bénard F. ET Imaging of Carbonic Anhydrase IX Expression of HT-29 Tumor Xenograft Mice with $^{68}$Ga-Labeled Benzenesulfonamides. Mol Pharm, 2016;13(3): 1137-1146]. Zhang Z and I were the lead investigators, responsible for all major areas of concept formation, data collection and analysis, as well as the majority of manuscript composition. Jenni S, Kuo HT, Liu Z, and Vullo D were involved in binding affinity, radiochemistry, and imaging experiments. Supuran CT, Lin KS, and Bénard F were the supervisory authors on this project and were involved throughout the project in concept formation and manuscript composition.

In Chapter 6, the CA-IX monoclonal antibodies were obtained through a collaboration with Drs. Shoukat Dedhar (BC Cancer Agency), Anne Lenferink (National Research Council), and Maureen O’Connor (National Research Council). Internal names are used for the antibodies. The biological and physical characterizations of the antibodies were performed by Dr. Paul McDonald (Dedhar’s Lab).

The research in this thesis was conducted under animal protocols A11-0238 and A11-0185, which were approved by the Institutional Animal Care Committee of the University of British Columbia in compliance with the Canadian Council on Animal Care Guidelines.
Table of Contents

Abstract .......................................................................................................................................... ii
Preface ........................................................................................................................................... iii
Table of Contents ........................................................................................................................... v
List of Tables ................................................................................................................................ xi
List of Figures .............................................................................................................................. xii
List of Abbreviations and Symbols .......................................................................................... xiv
Acknowledgements .................................................................................................................... xxi
Dedication .................................................................................................................................. xxii

Chapter 1: Introduction ................................................................................................................1

1.1 Nuclear Imaging ..................................................................................................................... 1

1.1.1 Single Photon Emission Computed Tomography .............................................................. 3

1.1.2 Positron Emission Tomography ....................................................................................... 3

1.1.2.1 Cancer Patient Management with PET .................................................................. 4

1.1.2.2 18F-FDG Imaging .................................................................................................... 5

1.1.3 Role of Functional Imaging in Personalized Cancer Medicine ....................................... 5

1.2 Cancer and Tumour Microenvironment .......................................................................... 7

1.2.1 Hypoxia ............................................................................................................................ 7

1.2.1.1 Methods for Detection of Tumour Hypoxia ............................................................ 8

1.3 Carbonic Anhydrase IX as a Surrogate Marker of Hypoxia ............................................... 9

1.3.1 Biochemical Structure of CA-IX ..................................................................................... 12

1.3.2 Physiological Function of CA-IX in Cancer ................................................................. 12

1.3.2.1 Intracellular pH Regulation and Survival .............................................................. 12

1.3.2.2 Cell Adhesion, Migration, Invasion, and Metastasis ............................................ 13

1.3.3 Regulation of CA-IX Activity and Abundance ............................................................. 13

1.3.4 Distribution of CA-IX in Normal Tissues and Malignancies ......................................... 14

1.3.5 Tumour Models Used for CA-IX Imaging ................................................................... 15

1.3.6 CA-IX Nuclear Imaging Agents ..................................................................................... 15
1.3.6.1 Monoclonal Antibodies ................................................................. 16
1.3.6.2 Small Molecule Inhibitors .............................................................. 16
1.3.6.3 Peptides ......................................................................................... 18
1.3.6.4 Affibodies ....................................................................................... 19
1.4 Other Imaging Modalities ................................................................. 20
1.4.1 Optical Imaging .................................................................................. 20
1.4.2 Magnetic Resonance ......................................................................... 21
1.5 CA-IX Therapeutics in Clinical Development ..................................... 21
1.6 Thesis Theme and Rationale ............................................................... 22
1.6.1 Objectives and Hypotheses ............................................................... 23

Chapter 2: $^{18}$F-labeled Carbonic Anhydrase IX Inhibitors for Imaging with Positron Emission Tomography ................................................................. 24

2.1 Introduction ......................................................................................... 24
2.2 Materials and Methods ...................................................................... 25
  2.2.1 Chemicals and Instrumentation ...................................................... 25
  2.2.2 Synthesis of 7-(2-fluoroethoxy)coumarin (FEC) .......................... 25
  2.2.3 Synthesis of 7-(2-tosyloxyethoxy)coumarin .............................. 26
  2.2.4 Binding Affinity Measurement ..................................................... 26
  2.2.5 Radiosynthesis of $^{18}$F-FEC ........................................................... 27
  2.2.6 Radiosynthesis of $^{18}$F-U-104 ....................................................... 28
  2.2.7 Stability in Mouse Plasma ............................................................. 29
  2.2.8 In Vivo Experiments ..................................................................... 29
    2.2.8.1 Tumour Implantation .............................................................. 29
    2.2.8.2 Biodistribution Studies .......................................................... 29
    2.2.8.3 PET Imaging and Data Analysis: ........................................... 30
  2.2.9 Immunohistochemistry ................................................................. 30
  2.3 Results and Discussion .................................................................... 30
  2.4 Conclusion ......................................................................................... 36

Chapter 3: $^{18}$F-labeled Tertiary Substituted Sulfonamides for PET CA-IX Imaging ........ 37

3.1 Introduction ......................................................................................... 37
3.2 Materials and Methods ................................................................. 38
  3.2.1 Chemicals and Instrumentation ................................................... 38
  3.2.2 Syntheses of Precursors and Standards ....................................... 38
    3.2.2.1 \(N\)-(2-hydroxypropyl)-4-methyl-\(N\)-(4-methylphenyl)benzenesulfonamide (2a) 38
    3.2.2.2 \(N\)-(4-Acetylphenyl)-\(N\)-(2-hydroxypropyl)-4-methylbenzenesulfonamide (2b) 39
    3.2.2.3 \(N\)-(4-Chlorophenyl)-\(N\)-(2-hydroxypropyl)-4-methylbenzenesulfonamide (2c) 39
    3.2.2.4 4-Methyl-\(N\)-(4-methylphenyl)-\(N\)-(2-tosyloxypropyl)benzenesulfonamide (3a) 40
    3.2.2.5 \(N\)-(4-Acetylphenyl)-4-methyl-\(N\)-(2-tosyloxypropyl)benzenesulfonamide (3b) 40
    3.2.2.6 \(N\)-(4-Chlorophenyl)-4-methyl-\(N\)-(2-tosyloxypropyl)benzenesulfonamide (3c) 40
    3.2.2.7 \(N\)-(2-Fluoropropyl)-4-methyl-\(N\)-(4-methylphenyl)benzenesulfonamide (4a) 41
    3.2.2.8 \(N\)-(4-Acetylphenyl)-\(N\)-(2-fluoropropyl)-4-methylbenzenesulfonamide (4b) 41
    3.2.2.9 \(N\)-(4-Chlorophenyl)-\(N\)-(2-fluoropropyl)-4-methylbenzenesulfonamide (4c) 42
  3.2.3 Radiosyntheses of \([^{18}F]4a-c\) ...................................................... 42
  3.2.4 Stability in Mouse Plasma .......................................................... 43
  3.2.5 LogD\(_{7.4}\) Measurements .......................................................... 43
  3.2.6 In Vivo Experiments ................................................................. 43
    3.2.6.1 Tumour Implantation ............................................................. 44
    3.2.6.2 PET Imaging and Biodistribution Studies ................................. 44
  3.3 Results and Discussion ............................................................... 44
  3.4 Conclusion .................................................................................... 49

Chapter 4: Multivalent Approach to Achieve In Vivo Selectivity for CA-IX ........ 50
  4.1 Introduction ................................................................................. 50
  4.2 Methods and Materials .............................................................. 52
    4.2.1 HPLC Analysis ....................................................................... 53
    4.2.2 Synthesis of Azidoacetyl-AEBS (1) .......................................... 53
    4.2.3 Synthesis of Azidoacetyl-ABS (2) ............................................. 54
    4.2.4 Synthesis of AmBF\(_3\)-AEBS .................................................... 54
    4.2.5 Synthesis of AmBF\(_3\)-ABS ..................................................... 54
    4.2.6 Synthesis of AmBF\(_3\)-(AEBS)\(_3\) .............................................. 55

vii
4.2.7 Synthesis of AmBF$_3$-(ABS)$_3$ ................................................................. 55
4.2.8 Binding Affinity Measurements ............................................................... 55
4.2.9 Radiolabeling ............................................................................................ 56
4.2.10 Stability in Mouse Plasma ...................................................................... 56
4.2.11 LogD$_{7.4}$ measurements ......................................................................... 56
4.2.12 In Vivo Experiments ................................................................................ 57
  4.2.12.1 Cell Line and Animal Model .............................................................. 57
  4.2.12.2 Biodistribution Studies ....................................................................... 57
  4.2.12.3 PET/CT Imaging ................................................................................ 57
  4.2.12.4 Data Analysis ..................................................................................... 58
4.3 Results and Discussion .................................................................................. 58
4.4 Conclusion .................................................................................................... 66

Chapter 5: Polyaminocarboxylate Conjugated Sulfonamides for $^{68}$Ga-labeling and PET Imaging ................................................................. 68
  5.1 Introduction .................................................................................................. 68
  5.2 Methods ....................................................................................................... 70
    5.2.1 Reagents and Instrumentation .............................................................. 70
    5.2.2 Chemistry and Radiolabeling ............................................................... 71
      5.2.2.1 Synthesis of 1,4,7,10-tetraazacyclododecane-1,4,7-tris($t$-butylacetate)-10-p-sulfonamidophenylethylacetamide (2) ................................................................. 71
      5.2.2.2 Synthesis of 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid, 10-p-sulfonamidophenylethylacetamide (DOTA-AEBSA, 3) ................................................. 72
      5.2.2.3 Synthesis of 1,4,7,10-tetraazacyclododecane-1,4-bis($t$-butylacetate)-7,10-bis-p-sulfonamidophenylethylacetamide (6) ....................................................... 72
      5.2.2.4 Synthesis of 1,4,7,10-tetraazacyclododecane-1,7-diaceaic acid, 4,10-bis-p-sulfonamidophenylethylacetamide (DOTA-(AEBSA)$_2$, 7) ................................. 73
      5.2.2.5 Synthesis of 1,4,7-triazacyclononane-1,4,7-tris-glutamic acid-$\alpha$-$\text{tert}$-butyl ester-$\gamma$-p-sulfonamidophenylethylamide (10) .......................................................... 73
      5.2.2.6 Synthesis of 1,4,7-triazacyclononane-1,4,7-tris-glutamic acid-$\gamma$-p-sulfonamidophenylethylamide (NOTGA-(AEBSA)$_3$, 11) ............................................... 74
5.2.2.7 General Procedure for the Synthesis of Cold Gallium Standard ...................... 74
5.2.2.8 General Procedure for the Synthesis of $^{68}$Ga Tracers ....................................... 75
5.2.3 Binding Affinity Measurement ................................................................................. 75
5.2.4 Stability in Mouse Plasma ........................................................................................ 75
5.2.5 Lipophilicity Measurement ....................................................................................... 76
5.2.6 Cell Line.................................................................................................................... 76
5.2.7 Immunofluorescence of HT-29 Colonies .................................................................. 76
5.2.8 PET Imaging and Biodistribution Studies ............................................................... 77
5.2.9 Statistical Analysis .................................................................................................... 78
5.3 Results and Discussion ............................................................................................... 78
5.4 Conclusion .................................................................................................................. 86

Chapter 6: Antibodies and Antibody Mimetics for Imaging – Pilot Studies ................. 88
6.1 Introduction................................................................................................................... 88
6.2 Materials and Methods............................................................................................... 90
6.2.1 Conjugation of $p$-SCN-Bn-DTPA to mAbs .......................................................... 90
6.2.2 $^{111}$In Radiolabeling for $p$-SCN-Bn-DTPA-mAbs ................................................. 90
6.2.3 Synthesis of Cys-Z09781 ....................................................................................... 91
6.2.4 Conjugation of NOTA to Cys-Z09781 ................................................................... 91
6.2.5 $^{68}$Ga Radiolabeling for Cys[NOTA]-Z09781 ........................................................ 92
6.2.6 In Vivo Evaluations ............................................................................................... 92
6.2.6.1 Biodistribution Studies...................................................................................... 92
6.2.6.2 SPECT/CT Imaging ......................................................................................... 93
6.2.6.3 PET/CT Imaging ............................................................................................. 93
6.3 Results and Discussion ............................................................................................... 94
6.4 Conclusion .................................................................................................................. 102

Chapter 7: Conclusion ....................................................................................................... 104
7.1 Summary of Study and Findings................................................................................ 104
7.2 Strengths and Limitations of this Study................................................................. 105
7.3 Overall Significance and Implications of Research Finding .................................... 106
7.4 Future Research Directions ..................................................................................... 106
7.4.1 Design of Cationic Sulfonamides ................................................................. 106
7.4.2 CA-IX Tracers as Surrogate Hypoxia Imaging Agents ................................. 107
7.4.3 Radiotherapy .................................................................................................. 108
7.4.4 Clinical Translation of CA-IX Imaging Agents .............................................. 108

Bibliography .................................................................................................................... 110

Appendix .................................................................................................................................. 127
List of Tables

Table 1.1 Properties of common nuclear imaging radioisotopes .......................................................... 2
Table 1.2 Organ/tissue distribution, subcellular localization, CO₂ hydrase activity, and affinity for sulfonamides of the 15 human carbonic anhydrases ........................................................................ 11
Table 1.3 CA-IX tissue microarray studies .......................................................................................... 15
Table 1.4 CA-IX therapeutic agents in clinical development .............................................................. 22
Table 2.1 Biodistribution data (1 h p.i.; n = 4) of ¹⁸F-FEC and ¹⁸F-U-104 in NSG mice bearing HT-29 human colorectal tumour xenografts ................................................................................. 34
Table 3.1 Biodistribution data (1 h p.i.; n = 4) of [¹⁸F]4a-c in NSG mice bearing HT-29 human colorectal tumour xenografts ........................................................................................................ 46
Table 3.2 Reported inhibition constants (Kᵢ, nM) of acetazolamide, HS680, U-104, and tertiary sulfonamides 4a-c to human CA isoenzymes I, II, IX, XII .................................................................................. 49
Table 4.1 HPLC conditions for AmBF₃ sulfonamides ........................................................................... 53
Table 4.2 Inhibition constants of ¹⁸F-AmBF₃-sulfonamides to human CA isoenzymes I, II, IX and XII ........................................................................................................................................ 60
Table 4.3 Biodistribution and tumour-to-nontarget ratios for ¹⁸F-AmBF₃ sulfonamides ................. 64
Table 5.1 HPLC conditions used for purification, QC and plasma stability assays ....................... 71
Table 5.2 Molecular weight and radiolabeling data of ⁶⁸Ga CA-IX inhibitors ........................................ 80
Table 5.3 Binding affinity (Kᵢ) of sulfonamide inhibitors to CA-I, CA-II, CA-IX and CA-XII were determined via a stopped-flow CO₂ hydration assays ........................................................................ 81
Table 5.4 Biodistribution and tumour-to-nontarget ratios for ⁶⁸Ga CA-IX inhibitors ..................... 84
Table 6.1 Characterization of mAbs raised against the extracellular domain of CA-IX ................. 89
Table 6.2 Biodistribution and tumour-to-nontarget ratios for ¹¹¹In-SCN-Bn-DTPA-mAbs ............ 99
Table 6.3 Biodistribution of radiolabeled cG250 immunoconjugates ............................................. 100
List of Figures

**Figure 1.1** MicroPET and microSPECT scanners used for preclinical imaging studies at the BC Cancer Research Centre .................................................................................................................. 1

**Figure 1.2** Breast cancer PET imaging with $^{18}$F-FDG and $^{18}$F-fluoroestradiol ....................... 5

**Figure 1.3** Molecular structures of four commonly used $^{18}$F-labeled hypoxia PET tracers in the clinic ................................................................................................................................................ 9

**Figure 1.4** Regulation of HIF-1α by proline hydroxylation............................................................. 10

**Figure 1.5** Crystal structure of the catalytic domain of CA-IX ................................................... 12

**Figure 1.6** Structures of small molecule inhibitors proposed or used for CA-IX imaging .......... 18

**Figure 2.1** Chemical structures of 7-(2-fluoroethoxy)coumarin (Left) and U-104 (Right) ......... 24

**Figure 2.2** Synthetic scheme for the preparation of FEC and its radiolabeling precursor .......... 31

**Figure 2.3** Radiosynthesis of (A) $^{18}$F-FEC and (B) $^{18}$F-U-104 .................................................. 32

**Figure 2.4** CA-IX expression in HT-29 colorectal cancer model ................................................ 33

**Figure 2.5** Representative PET image of $^{18}$F-FEC in HT-29 xenograft mice at 55 min p.i. ........ 34

**Figure 2.6** Time-activity curve of $^{18}$F-FEC in tumour and selected organs/tissues .......... 35

**Figure 2.7** (A) Metabolism of 7-ethoxycoumarin and (B) proposed metabolism of $^{18}$F-FEC by ECOD ............................................................................................................................................. 35

**Figure 3.1** Chemical structures of fluorinated tertiary substituted sulfonamides ......................... 37

**Figure 3.2** Syntheses of (A) precursors 3a-c and (B-C) standards 4a-c of tertiary sulfonamide CA-IX inhibitors, and (D) their $^{18}$F-labeled analogs $[^{18}F]4a$-c ................................................................. 45

**Figure 3.3** Representative PET maximum intensity projection images of $[^{18}F]4a$-c at 1 h p.i. in NSG mice bearing CA-IX expressing HT-29 human colorectal tumour xenografts .......... 48

**Figure 4.1** Chemical structures of $^{18}$F-AmBF$_3$-AEBS, $^{18}$F-AmBF$_3$-ABS, $^{18}$F-AmBF$_3$-(AEBS)$_3$ and $^{18}$F-AmBF$_3$-(ABS)$_3$ ............................................................................................................................................. 51

**Figure 4.2** Synthesis of (A) azidoacetyl-AEBS 1, (B) azidoacetyl-ABS 2, (C) AmBF$_3$-AEBS and AmBF$_3$-ABS, and (D) AmBF$_3$-(AEBS)$_3$ and AmBF$_3$-(ABS)$_3$ ........................................................................................................ 59

**Figure 4.3** Radiosynthesis of (A) $^{18}$F-AmBF$_3$-AEBS and $^{18}$F-AmBF$_3$-ABS, and (B) $^{18}$F-AmBF$_3$-(AEBS)$_3$ and $^{18}$F-AmBF$_3$-(ABS)$_3$ via $^{18}$F-$^{19}$F isotope exchange reaction ........................................................................ 62
Figure 4.4 Tumour-to-muscle ratios for $^{18}$F-AmBF₃ sulfonamides at 1 h p.i. ............................. 65
Figure 4.5 PET/CT images of monomeric $^{18}$F-sulfonamides at 1 h p.i. ..................................... 65
Figure 4.6 PET/CT images of trimeric $^{18}$F-sulfonamides at 1 h p.i. ............................................ 66
Figure 5.1 Chemical structures of $^{68}$Ga-DOTA-AEBSA, $^{68}$Ga-DOTA-(AEBSA)$_2$ and $^{68}$Ga-
NOTGA-(AEBSA)$_3$ ...................................................................................................................... 69
Figure 5.2 Synthetic scheme for precursors and cold standards .................................................. 79
Figure 5.3 Stability of $^{68}$Ga CA-IX inhibitors in mouse plasma ................................................ 80
Figure 5.4 CA-IX expression in HT-29 colorectal cancer model .................................................. 82
Figure 5.5 Maximal intensity projections of PET/CT and PET with $^{68}$Ga tracers at 1 h p.i. ....... 82
Figure 5.6 Two-way ANOVA analysis of tumour/muscle ratio, kidney and liver uptake for $^{68}$Ga
CA-IX inhibitors ........................................................................................................................... 83
Figure 5.7 Longitudinal study: uptake of $^{68}$Ga-DOTA-AEBSA in HT-29 tumour xenograft
increases as tumour grows ............................................................................................................ 85
Figure 6.1 Engineered protein scaffolds ........................................................................................ 89
Figure 6.2 DTPA conjugations for mAbs .................................................................................... 94
Figure 6.3 Typical radiochromatogram of an $^{111}$In radiolabeled mAb, before and after centrifugal
filtration to remove unbound radioisotopes ..................................................................................... 95
Figure 6.4 Sequential SPECT/CT images obtained with $^{111}$In-SCN-Bn-DTPA-Ab01 and $^{111}$In-
SCN-Bn-DTPA-Ab02 ....................................................................................................................... 96
Figure 6.5 Sequential SPECT/CT images obtained with $^{111}$In-SCN-Bn-DTPA-Ab03 and $^{111}$In-
SCN-Bn-DTPA-IgG ......................................................................................................................... 97
Figure 6.6 Site-specific conjugation of NOTA to Cys-Z09781 ...................................................... 101
Figure 6.7 PET/CT images of $^{68}$Ga-Cys[NOTA]-Z09781 at 2 h p.i. ............................................. 102
Figure 6.8 Biodistribution of $^{68}$Ga-Cys[NOTA]-Z09781 in tumour and selected organs at 2 h p.i.
(n = 6) .......................................................................................................................................... 102
Figure 7.1 Maximal intensity projections of PET/CT (Left) and PET alone (Right) with $^{18}$F-
FMISO at 3 h p.i. .......................................................................................................................... 107
**List of Abbreviations and Symbols**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>%ID/g</td>
<td>Percentage of injected radioactive dose per gram of tissue</td>
</tr>
<tr>
<td>α</td>
<td>Alpha particle</td>
</tr>
<tr>
<td>β⁺</td>
<td>Positron</td>
</tr>
<tr>
<td>β⁻</td>
<td>Beta particle</td>
</tr>
<tr>
<td>γ</td>
<td>Gamma ray</td>
</tr>
<tr>
<td>°C</td>
<td>Degrees Celsius</td>
</tr>
<tr>
<td>A</td>
<td>Ampere</td>
</tr>
<tr>
<td>aa</td>
<td>Amino acid</td>
</tr>
<tr>
<td>ABS</td>
<td>4-Aminobenzenesulfonamide</td>
</tr>
<tr>
<td>ADC</td>
<td>Antibody-drug conjugate</td>
</tr>
<tr>
<td>ADCC</td>
<td>Antibody-dependent cell-mediated cytotoxicity</td>
</tr>
<tr>
<td>ADCP</td>
<td>Antibody-dependent cell phagocytosis</td>
</tr>
<tr>
<td>AEBS</td>
<td>4-(2-Aminoethyl)benzenesulfonamide</td>
</tr>
<tr>
<td>AMP</td>
<td>Adenosine monophosphate</td>
</tr>
<tr>
<td>ANOVA</td>
<td>Analysis of variance</td>
</tr>
<tr>
<td>Au</td>
<td>Arbitrary unit</td>
</tr>
<tr>
<td>AU</td>
<td>Absorbance unit</td>
</tr>
<tr>
<td>AZA</td>
<td>Acetazolamide</td>
</tr>
<tr>
<td>BCCA</td>
<td>British Columbia Cancer Agency</td>
</tr>
<tr>
<td>Bn</td>
<td>Benzyl</td>
</tr>
<tr>
<td>Boc</td>
<td>tert-Butyloxycarbonyl protecting group</td>
</tr>
<tr>
<td>Bq</td>
<td>Becquerel</td>
</tr>
<tr>
<td><strong>BRCA1/2</strong></td>
<td>Breast cancer 1/2 gene</td>
</tr>
<tr>
<td>CA</td>
<td>Carbonic anhydrase</td>
</tr>
<tr>
<td>Calcd</td>
<td>Calculated</td>
</tr>
<tr>
<td>cc</td>
<td>Cubic centimeter</td>
</tr>
<tr>
<td><strong>CCRCC</strong></td>
<td>Clear cell renal cell carcinoma</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Term</td>
</tr>
<tr>
<td>--------------</td>
<td>------</td>
</tr>
<tr>
<td>CDC</td>
<td>Complement dependent cytotoxicity</td>
</tr>
<tr>
<td>CDCl₃</td>
<td>Deuterated chloroform</td>
</tr>
<tr>
<td>CH₂Cl₂</td>
<td>Dichloromethane</td>
</tr>
<tr>
<td>CH₃CN</td>
<td>Acetonitrile</td>
</tr>
<tr>
<td>Ci</td>
<td>Curie</td>
</tr>
<tr>
<td>Cl⁻</td>
<td>Chloride ion</td>
</tr>
<tr>
<td>CML</td>
<td>Chronic myeloid leukemia</td>
</tr>
<tr>
<td>CO₂</td>
<td>Carbon dioxide</td>
</tr>
<tr>
<td>CT</td>
<td>Computed tomography</td>
</tr>
<tr>
<td>CuSO₄</td>
<td>Copper sulfate</td>
</tr>
<tr>
<td>Cys</td>
<td>Cysteine</td>
</tr>
<tr>
<td>d</td>
<td>Day</td>
</tr>
<tr>
<td>Da</td>
<td>Dalton</td>
</tr>
<tr>
<td>DAST</td>
<td>Diethylamino-sulfur trifluoride</td>
</tr>
<tr>
<td>DCC</td>
<td>N,N'-Dicyclocyclohexylcarbodiimine</td>
</tr>
<tr>
<td>DI</td>
<td>Deionized</td>
</tr>
<tr>
<td>DIEA</td>
<td>N,N-Diisopropylethylamine</td>
</tr>
<tr>
<td>Df</td>
<td>Desferrioxamine</td>
</tr>
<tr>
<td>DMF</td>
<td>N,N-Dimethylformamide</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribose nucleic acid</td>
</tr>
<tr>
<td>DOTA</td>
<td>1,4,7,10-Tetraazacyclododecane-N,N',N″,N‴-tetraacetic acid</td>
</tr>
<tr>
<td>DTPA</td>
<td>Diethylene-triamine-pentaacetic acid</td>
</tr>
<tr>
<td>E-I</td>
<td>Enzyme-Inhibitor</td>
</tr>
<tr>
<td>EC</td>
<td>Electron capture</td>
</tr>
<tr>
<td>ECOD</td>
<td>7-Ethoxycoumarin O-deethylase</td>
</tr>
<tr>
<td>EDC•HCl</td>
<td>N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride</td>
</tr>
<tr>
<td>EDT</td>
<td>Ethane dithiol</td>
</tr>
<tr>
<td>EF5</td>
<td>2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide</td>
</tr>
<tr>
<td>EGF</td>
<td>Epidermal growth factor</td>
</tr>
<tr>
<td>EGFR</td>
<td>Epidermal growth factor receptor</td>
</tr>
</tbody>
</table>
ELISA  Enzyme-linked immunosorbent assay
EMT  Epithelial mesenchymal transition
EOS  End of synthesis
EPR  Enhanced permeability and retention
eq  Equivalent
ER  Estrogen receptor
ESI  Electronspray ionization
EtOAc  Ethyl acetate
eV  Electron volt
FAZA  Fluoroazomycin-arabinofuranoside
FEC  7-(2-Fluoroethoxy)coumarin
FDA  The Food and Drug Administration
$^{18}$F-FDG  2-Deoxy-2-[${}^{18}$F]fluoro-D-glucose
Fe$_3$O$_4$  Iron oxide
FMISO  Fluoromisonidazole
Fmoc  Fluorenylmethyloxycarbonyl
g  Gram
GLP  Good laboratory practice
h  Hour
H$^+$  Hydrogen ion/proton
H$_2$O  Water
HBTU  3-[Bis(dimethylamino)methyl]imiumyl]-3$H$-benzotriazol-1-oxide
       hexafluorophosphate
HCl  Hydrochloric acid
HCO$_3^-$  Bicarbonate ion
He  Helium gas
HEPES  4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid
HER2  Human epidermal growth factor 2 receptor
HER3  Human epidermal growth factor 3 receptor
HIF-1$\alpha/\beta$  Hypoxia-inducible factor 1 alpha/beta
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIF-2α</td>
<td>Hypoxia-inducible factor 2 alpha</td>
</tr>
<tr>
<td>HF</td>
<td>Hydrogen fluoride</td>
</tr>
<tr>
<td>HOBT</td>
<td>Hydroxybenzotriazole</td>
</tr>
<tr>
<td>HPLC</td>
<td>High performance liquid chromatography</td>
</tr>
<tr>
<td>HRE</td>
<td>Hypoxia response element</td>
</tr>
<tr>
<td>HRP</td>
<td>Horseradish peroxidase</td>
</tr>
<tr>
<td>HX4</td>
<td>Flortanidazole</td>
</tr>
<tr>
<td>i.v.</td>
<td>Intravenous</td>
</tr>
<tr>
<td>IC₅₀</td>
<td>Half maximal inhibitory concentration</td>
</tr>
<tr>
<td>IHC</td>
<td>Immunohistochemistry</td>
</tr>
<tr>
<td>IGF-1R</td>
<td>Insulin-like growth factor 1 receptor</td>
</tr>
<tr>
<td>IgG</td>
<td>Immunoglobulin</td>
</tr>
<tr>
<td>IND</td>
<td>Investigational New Drug</td>
</tr>
<tr>
<td>IRW</td>
<td>Inveon Research Workplace software</td>
</tr>
<tr>
<td>IT</td>
<td>Isomeric transition</td>
</tr>
<tr>
<td>K₂₂₂</td>
<td>Kryptofix 222</td>
</tr>
<tr>
<td>Kᵢ</td>
<td>Inhibition constant</td>
</tr>
<tr>
<td>Kₐ</td>
<td>Dissociation constant</td>
</tr>
<tr>
<td>K₂CO₃</td>
<td>Potassium carbonate</td>
</tr>
<tr>
<td>L</td>
<td>Litre</td>
</tr>
<tr>
<td>LET</td>
<td>Linear energy transfer</td>
</tr>
<tr>
<td>LogD₇.₄</td>
<td>Log value of distribution coefficient at pH 7.4,</td>
</tr>
<tr>
<td>M</td>
<td>Molar concentration</td>
</tr>
<tr>
<td>m</td>
<td>Meter</td>
</tr>
<tr>
<td>m/z</td>
<td>Mass-to-charge ratio</td>
</tr>
<tr>
<td>mAb</td>
<td>Monoclonal antibody</td>
</tr>
<tr>
<td>MAG3</td>
<td>Mercaptoacetyltriglycine</td>
</tr>
<tr>
<td>MBHA</td>
<td>4-Methylbenzhydrylamine</td>
</tr>
<tr>
<td>MeOH</td>
<td>Methanol</td>
</tr>
<tr>
<td>MIBG</td>
<td>Metaiodobenzylguanidine</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>min</td>
<td>Minute</td>
</tr>
<tr>
<td>MgSO₄</td>
<td>Magnesium sulfate</td>
</tr>
<tr>
<td>mmHg</td>
<td>Millimeter of mercury</td>
</tr>
<tr>
<td>mol</td>
<td>Mole</td>
</tr>
<tr>
<td>mp</td>
<td>Melting point</td>
</tr>
<tr>
<td>MR</td>
<td>Magnetic resonance</td>
</tr>
<tr>
<td>MTT</td>
<td>Molecular targeted therapies</td>
</tr>
<tr>
<td>MW</td>
<td>Molecular weight</td>
</tr>
<tr>
<td>N₂</td>
<td>Nitrogen gas</td>
</tr>
<tr>
<td>Na⁺</td>
<td>Sodium ion</td>
</tr>
<tr>
<td>NaBH₄</td>
<td>Sodium borohydride</td>
</tr>
<tr>
<td>NaCl</td>
<td>Sodium chloride</td>
</tr>
<tr>
<td>NaHCO₃</td>
<td>Sodium bicarbonate</td>
</tr>
<tr>
<td>NaH₂PO₄</td>
<td>Monosodium phosphate</td>
</tr>
<tr>
<td>NaI</td>
<td>Sodium iodide</td>
</tr>
<tr>
<td>NaN₃</td>
<td>Sodium azide</td>
</tr>
<tr>
<td>NaOH</td>
<td>Sodium hydroxide</td>
</tr>
<tr>
<td>Na₂CO₃</td>
<td>Sodium carbonate</td>
</tr>
<tr>
<td>Na₂HPO₄</td>
<td>Disodium phosphate</td>
</tr>
<tr>
<td>NH₄OH</td>
<td>Ammonium hydroxide</td>
</tr>
<tr>
<td>NHS</td>
<td>N-Hydroxysuccinimde</td>
</tr>
<tr>
<td>NMR</td>
<td>Nuclear magnetic resonance</td>
</tr>
<tr>
<td>NOTA</td>
<td>1,4,7-Triazacyclononane-1,4,7-trisacetic acid</td>
</tr>
<tr>
<td>NOTGA</td>
<td>1,4,7-Triazacyclononane-1,4,7-tris-(glutaric acid)</td>
</tr>
<tr>
<td>NIR</td>
<td>Near-infrared</td>
</tr>
<tr>
<td>NRC</td>
<td>National Research Council</td>
</tr>
<tr>
<td>NSCLC</td>
<td>Non-small cell lung carcinoma</td>
</tr>
<tr>
<td>NSG</td>
<td>NOD.Cg-Prkd&lt;sup&gt;acid&lt;/sup&gt; Il2rg&lt;sup&gt;ém1Wjl&lt;/sup&gt;/SzJ</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate-buffered saline</td>
</tr>
<tr>
<td>Pd/C</td>
<td>Palladium on carbon</td>
</tr>
</tbody>
</table>
PDGFβ  Beta-type platelet-derived growth factor receptor
PDX  Patient derived xenograft
PET  Positron emission tomography
PG  Proteoglycan-like
pH$_i$  Intracellular pH
p.i.  Post-injection
PI3K  Phosphoinositide 3-kinase
PKA  Protein kinase A
pO$_2$  Partial pressure of oxygen
ROI  Region of interest
rpm  Revolutions per minute
s  Second
SbF$_5$  Antimony pentafluoride
SCN  Isothiocyanate
SD  Standard deviation
SEC  Size-exclusion column
SPECT  Single photon emission computed tomography
$t_{1/2}$  Physical half-life
$t_R$  Retention time
TBAF  Tetrabutylammonium fluoride
TBAHCO$_3$  Tetrabutylammonium bicarbonate
TCEP  Tris(2-carboxyethyl)phosphine hydrochloride
TFA  Trifluoroacetic acid
THF  Tetrahydrofuran
TIS  Triisopropylsilane
TMA  Trimethylamine
TNFα  Tumour necrosis factor alpha
TOF  Time of flight
UBC  University of British Columbia
UV  Ultraviolet
**VEGF**  Vascular endothelial growth factor

**VHL**  von Hippel-Lindau gene

**WHO**  World Health Organization
Acknowledgements

I would like to thank my supervisor Dr. François Bénard for his guidance and support during my research. Thank you for believing in me, and giving me the academic freedom to pursue my research interests. I was constantly inspired by your passion and sagacity for cancer research. You hold your students to the highest standard and I thank you for always demanding the best of me.

My sincerest gratitude to the members of my supervisory committee: Drs. Kuo-Shyan Lin, Paul Schaffer, and Urs Hafeli. Thank you for enriching my understanding of nuclear medicine, and providing me with research and career advice. Special thanks to Dr. Samuel Aparicio for introducing me to medical research as a Co-op student, and encouraging me to pursue a graduate degree. I would like to thank all past and present members of the Bénard (NH, NC, MP, GMD, HL, ID, GA, MC, FM, SJ, HM, KS, JZ, CCZ, JR, PT, JG, MV, WE, and JK) and Lin (JP, ZZ, HTK, and SP) labs. Without your support and camaraderie, this project would not have been successful.

I would like to acknowledge our collaborators, Drs. Shoukat Dedhar, Claudiu T. Supuran and David M. Perrin, Anne Lenferink, Maureen O’Connor, and generous scholarship support from the Canadian Institutes of Health Research Frederick Banting and Charles Best Canada Graduate Scholarship Doctoral Award, the University of British Columbia Four Year Doctoral Fellowship, and the RIX Family Leading Edge Student Award.

The research presented in this thesis was funded by the following granting agencies: Canadian Institutes of Health Research, Canadian Cancer Society Research Institute, BC Cancer Foundation, and BC Leading Edge Endowment Fund.

Finally, my deepest thanks to my friends and family for their unwavering love and support throughout my years of education. Thank you for all of your sacrifices.
Dedication

To my parents, Anne Lau and James Lau.
Chapter 1: Introduction

1.1 Nuclear Imaging

Nuclear imaging modalities like positron emission tomography (PET) and single photon emission tomography (SPECT) enable the visualization of pathological processes at high resolution in real time\(^1\)\(^2\). Both modalities use radioactive biomolecules (small molecule inhibitors, peptides, antibodies, antibody mimetics etc.) as imaging agents to offer high sensitivity and quantification capabilities\(^2\). Depending on the imaging agent administered, PET and SPECT can be used to annotate drug target expression, or to understand biological mechanisms that underlie different disease states. In combination with either computed tomography (CT) or magnetic resonance (MR) to increase anatomic resolution or soft tissue contrast respectively, PET plays an increasingly important role in cancer diagnosis and management\(^3\). Functional imaging is particularly useful in the case of recurrent or metastatic cancer, where biopsies may be scarce or unavailable. Given that inter- and intra-tumoural heterogeneity can significantly affect potential response to treatment, the ability to systemically characterize primary and metastatic lesions can improve patient outcomes. Figure 1.1 shows the two preclinical nuclear imaging systems used in this thesis, while Table 1.1 is a list of commonly used radioisotopes for imaging applications.

\[\text{Figure 1.1 MicroPET and microSPECT scanners used for preclinical imaging studies at the BC Cancer Research Centre.} \text{ Left: Inveon PET/CT scanner with 1.3 mm spatial resolution. Right: MiLabs USPECT/CT II scanner with 0.4 mm spatial resolution. Of note, preclinical SPECT scanners have better spatial resolution than their clinical counterparts due to the use of highly focused multipinhole collimators.}\]
Table 1.1 Properties of common nuclear imaging radioisotopes. Adapted with permissions from Fani and Maecke\textsuperscript{4}, and Holland et al.\textsuperscript{5}

<table>
<thead>
<tr>
<th>Isotope</th>
<th>$t_{1/2}$</th>
<th>Decay mode (%)</th>
<th>$E_\gamma$ or $E_{\beta^+}$ (keV) (%)</th>
<th>Production method</th>
</tr>
</thead>
<tbody>
<tr>
<td>SPECT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$^{67}$Ga</td>
<td>3.26 d</td>
<td>EC (100)</td>
<td>93 (39)</td>
<td>Cyclotron</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Auger, $\gamma$</td>
<td>184 (21)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$\gamma$</td>
<td>300 (17)</td>
<td></td>
</tr>
<tr>
<td>$^{99m}$Tc</td>
<td>6.02 h</td>
<td>IT (100), $\gamma$</td>
<td>141 (91)</td>
<td>$^{99}$Mo/$^{99m}$Tc generator</td>
</tr>
<tr>
<td>$^{111}$In</td>
<td>2.80 d</td>
<td>EC (100)</td>
<td>141 (91)</td>
<td>Cyclotron</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Auger, $\gamma$</td>
<td>171 (90)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>$\gamma$</td>
<td>245 (94)</td>
<td></td>
</tr>
<tr>
<td>$^{123}$I</td>
<td>13.2 h</td>
<td>EC (100), $\gamma$</td>
<td>159 (84)</td>
<td>Cyclotron</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$\gamma$</td>
<td>27 (71)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>31 (16)</td>
<td></td>
</tr>
<tr>
<td>PET</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$^{11}$C</td>
<td>20.4 min</td>
<td>$\beta^+$ (100)</td>
<td>961 (100)</td>
<td>Cyclotron</td>
</tr>
<tr>
<td>$^{13}$N</td>
<td>9.97 min</td>
<td>$\beta^+$ (100)</td>
<td>1198 (100)</td>
<td>Cyclotron</td>
</tr>
<tr>
<td>$^{15}$O</td>
<td>2.04 min</td>
<td>$\beta^+$ (100)</td>
<td>1735 (100)</td>
<td>Cyclotron</td>
</tr>
<tr>
<td>$^{18}$F</td>
<td>1.83 h</td>
<td>$\beta^+$ (97)</td>
<td>634 (97)</td>
<td>Cyclotron</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EC (3)</td>
<td>656 (18)</td>
<td>Cyclotron</td>
</tr>
<tr>
<td>$^{64}$Cu</td>
<td>12.7 h</td>
<td>$\beta^+$ (19)</td>
<td>656 (18)</td>
<td>Cyclotron</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$\beta^+$ (40)</td>
<td>656 (18)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>EC (41)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$^{68}$Ga</td>
<td>1.13 h</td>
<td>$\beta^+$ (89)</td>
<td>1899 (88)</td>
<td>$^{68}$Ge/$^{68}$Ga generator</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EC (11)</td>
<td>1899 (88)</td>
<td></td>
</tr>
<tr>
<td>$^{89}$Zr</td>
<td>3.27 d</td>
<td>$\beta^+$ (23)</td>
<td>908 (23)</td>
<td>Cyclotron</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EC (76)</td>
<td>908 (23)</td>
<td></td>
</tr>
<tr>
<td>$^{124}$I</td>
<td>4.18 d</td>
<td>$\beta^+$ (23)</td>
<td>1314 (7)</td>
<td>Cyclotron</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EC (77)</td>
<td>1314 (7)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1409 (14)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1474 (9)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1545 (6)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1988 (4)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2242 (13)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>3160 (24)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2556 (25)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>2137 (11)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1535 (12)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>866 (11)</td>
<td></td>
</tr>
</tbody>
</table>

$\beta^+$ decay is accompanied by 511 keV annihilation gamma radiation
EC = electron capture; IT = isomeric transition
1.1.1 Single Photon Emission Computed Tomography

SPECT imaging is performed by administrating a gamma-emitting radioisotope into a patient, usually by an intravenous injection. The radioactive decay of the radionuclide emits single non-directional photons that are detected by gamma cameras. The detected signals are reconstructed using computer algorithms to generate 2D projections or 3D data sets. SPECT is widely used clinically due to the availability of $^{99m}$Tc ($^{99}$Mo/$^{99m}$Tc generators), an isotope used in over 80% of nuclear medicine procedures. SPECT instruments have a large clinical base and are used routinely for procedures such as bone scans ($^{99m}$Tc-methyl disphosponate), myocardial perfusion imaging ($^{99m}$Tc-tetrofosmin or $^{99m}$Tc-sestamibi), and functional brain imaging ($^{99m}$Tc-exametazime). Since single photon emitters are non-directional, lead collimators are used in clinical instruments to block emissions that are not perpendicular to the detector. This leads to lower sensitivity and relatively poor spatial resolution, which reduces the detection rate of small tumours. However, SPECT remains a viable option for imaging selected cancers. For example, $^{123}$I-metaiodobenzylguanidine ($^{123}$I-MIBG) is an iodinated norepinephrine analogue that targets the norepinephrine transporters. An $^{123}$I-MIBG scan is a highly specific test used to detect neuroectodermally derived tumours like pheochromocytoma, ganglioneuroma, ganglioneuroblastoma, paraganglioma, carcinoid tumour and neuroblastoma. With continued improvement in collimation technologies, image reconstruction and processing methods, SPECT may soon have an expanded role in cancer management.

1.1.2 Positron Emission Tomography

PET imaging adheres to similar principles to SPECT, with the main difference being the utilization of positron emitters instead of single photon emitters. Positron particles ($\beta^+$, anti-electrons) are emitted upon decay, and travel a short distance before interacting with electrons. An interaction event leads to the annihilation of both a positron and an electron, and produces two 511 keV photons ejected at almost exactly 180° apart. Simultaneous detection of these two photons enables the instrument to replace physical collimation with coincidence detection, greatly enhancing spatial resolution and sensitivity. The paired coincidence events are used for image reconstruction to localize the source of $\beta^+$ emission in the patient. Compared to SPECT instruments, clinical PET scanners are more sensitive, and produce higher contrast images.
leading to improved diagnostic accuracy. Commonly used PET isotopes include $^{11}$C ($t_{1/2}$: 20.4 min), $^{18}$F ($t_{1/2}$: 1.83 h), $^{68}$Ga ($t_{1/2}$: 1.13 h), $^{64}$Cu ($t_{1/2}$: 12.7 h), $^{124}$I ($t_{1/2}$: 4.18 d), $^{89}$Zr ($t_{1/2}$: 3.27 d). $^{18}$F is the most popular PET isotope due to its ease of production via a medical cyclotron, and the widespread use of $^{18}$F-FDG for cancer assessment. $^{68}$Ga is obtained from commercially available $^{68}$Ge/$^{68}$Ga generator. Together with $^{64}$Cu, these isotopes are commonly used for radiolabeling peptide derivatives/small molecules for cancer imaging. With relatively long half-lives, $^{89}$Zr and $^{124}$I are mainly used for labeling monoclonal antibodies that have long circulation times.

### 1.1.2.1 Cancer Patient Management with PET

PET has a significant role in cancer management including diagnosis and staging, treatment planning, and treatment monitoring. PET is widely considered as a cost-effective diagnostic modality for many cancers including lung cancer, colorectal cancer, and lymphomas. In a large prospective study (22975 scans at 1178 centers in USA), Hillner et al. reported that PET imaging changed the intended patient management in > 36.5% of all cases. A change in management strategy is defined as a change in intended treatment (e.g., from surgery to chemotherapy) or in treatment intent (e.g., from curative to palliative). Up to 70% of the patients were able to avoid invasive surgical procedures after imaging. While the primary objective of a PET scan is to facilitate informed decision making by patients and oncologists, this does not always result in improved outcomes. Patient outcomes are mostly predicated on the efficacy of available therapeutic options, and there are situations where the best medical course for a patient is palliative care.

In Canada, there are currently 45 publicly funded PET scanners in 34 centers across the ten provinces. Based on a national report, 62668 PET scans were performed from 2011 to 2012. The primary application for PET is oncology, with selected provinces offering scanning services for cardiology and neurology. Our institution, the British Columbia Cancer Agency (BCCA), houses 2 clinical scanners and is funded to perform a total of 7775 scans per year. The demand and utilization for PET/CT is expected to grow with the continually increasing cancer incidence rates.
1.1.2.2 18F-FDG Imaging

The uptake mechanism of 18F-FDG is based on the enhanced metabolic and glycolytic rates of malignant tumours (Warburg effect)\(^\text{19, 20}\). As a glucose analogue, 18F-FDG is taken up by cells via glucose transporters and phosphorylated by hexokinase to form 18F-FDG-6-phosphate. Unable to be further catabolized, 18F-FDG-6-phosphate becomes metabolically trapped inside the cell and provides the signal for image acquisition\(^\text{21}\). Although 18F-FDG is considered the gold standard for cancer imaging, it is not a cancer-specific agent\(^\text{22}\). 18F-FDG uptake has been described in hypermetabolic brown adipose-tissues\(^\text{23}\), as well as in non-neoplastic inflammatory processes like sarcoidosis, fungal infections, and tuberculosis\(^\text{24-26}\). Tumours with low glucose metabolism, such as prostate cancer, low-grade sarcomas, low-grade non-Hodgkin’s lymphomas, and lobular breast carcinoma, may also have low avidity for 18F-FDG (Figure 1.2)\(^\text{27}\). The latter serves as an impetus to develop novel radiopharmaceuticals to target cancers when 18F-FDG imaging is insufficient for addressing clinical needs.

![Figure 1.2 Breast cancer PET imaging with 18F-FDG and 18F-fluoroestradiol.](image)

A patient suspected of recurrent breast cancer that underwent 18F-FDG (left) and 18F-fluoroestradiol (right) imaging. The scans identified ER positive metastatic mediastinal lymph nodes, indicated by red arrows, which were non-FDG avid. This case study shows how PET allows for molecular correlation and scientific hypothesis generation. Images courtesy of Dr. François Bénard (BCCA).

1.1.3 Role of Functional Imaging in Personalized Cancer Medicine

Personalized cancer medicine is a medical model that seeks to provide intervention, treatment, and care based on individual patient profiles\(^\text{28, 29}\). Conventional cancer treatment
focuses on factors such as age, familial history, tumour stage, nodal status, histological subtype and hormonal status\textsuperscript{28, 29}. This treatment model fails to account for the genetic aberrations and molecular mechanisms that drive the complex phenotypes of cancer\textsuperscript{30, 31}. The advent of molecular profiling techniques like next generation DNA sequencing, transcriptome analysis, proteome analysis, and metabolic assays, has provided tools to investigate the complex biology underpinning cancer\textsuperscript{30, 31}. Germline mutations in genes may predispose individuals to specific cancers. For example, females with \textit{BRCA1/2} mutations have greater a risk of developing familial breast and ovarian cancer\textsuperscript{32}. With personalized cancer medicine, at risk individuals may elect to have prophylactic mastectomy or oophorectomy\textsuperscript{33}. Another extension of personalized cancer medicine is molecular targeted therapies (MTT). MTT specifically targets molecules or pathways that promote tumourigenesis and tumour growth\textsuperscript{34}, and is best exemplified by the success of imatinib for chronic myeloid leukemia (CML) patients\textsuperscript{35-37}. Patients diagnosed with CML are screened for reciprocal translocation between chromosomes 9 and 22. This genomic rearrangement known as the Philadelphia chromosome results in the expression of BCR-Abl, an oncofusion protein found exclusively in malignant cells and is inhibited by imatinib\textsuperscript{35-37}. Continued research has led to the FDA approval and clinical adoption of an assortment of MTT regimens for cancer\textsuperscript{38}.

So how does functional imaging fit with personalized cancer medicine? The non-invasive assessment of drug target expression across multiple sites assists physicians to select the most effective therapy based on the unique molecular properties of the tumour and the genetic makeup of the patient\textsuperscript{39}. Functional imaging can be used to distinguish potential responders from non-responders. This stratification prevents patients from receiving ineffective treatments and expedites the allocation of medical resources. In addition to established regimens, functional imaging can be used to accelerate the drug development process. PET or SPECT imaging can be used to determine the pharmacokinetic (distribution, metabolism, and excretion) behaviour of a prospective drug, assuming a radiolabeled derivative is available\textsuperscript{40}. In other cases, \textsuperscript{18}F-FDG imaging can be used as a clinical endpoint to assess the efficacy of new drugs compared to current standards of care\textsuperscript{40}. 

\textbf{So how does functional imaging fit with personalized cancer medicine? The non-invasive assessment of drug target expression across multiple sites assists physicians to select the most effective therapy based on the unique molecular properties of the tumour and the genetic makeup of the patient. Functional imaging can be used to distinguish potential responders from non-responders. This stratification prevents patients from receiving ineffective treatments and expedites the allocation of medical resources. In addition to established regimens, functional imaging can be used to accelerate the drug development process. PET or SPECT imaging can be used to determine the pharmacokinetic (distribution, metabolism, and excretion) behaviour of a prospective drug, assuming a radiolabeled derivative is available. In other cases, \textsuperscript{18}F-FDG imaging can be used as a clinical endpoint to assess the efficacy of new drugs compared to current standards of care.}
1.2 Cancer and Tumour Microenvironment

Cancer is a complex multifactorial disease. According to Hanahan and Weinberg, cells acquire biological attributes or hallmarks through genomic instability that potentiates incipient lesions to develop into full frank tumours\textsuperscript{30, 31}. These hallmarks include sustained proliferation, desensitization to growth suppressors, apoptotic evasion, replicative immortality, angiogenesis promotion, and invasion and metastasis\textsuperscript{30}. In 2011, two additional hallmarks were postulated: reprogramming of energy metabolism and immune system evasion\textsuperscript{31}. Adding to the biological complexity is the dynamic tumour microenvironment which can exert selection pressures\textsuperscript{41}. The tumour microenvironment can be divided into cellular and non-cellular components. The cellular component is made up of stromal cells (endothelial cells, pericytes, inflammatory cells and fibroblasts)\textsuperscript{42}, while the non-cellular component include gradients in nutrients, waste, signalling molecules, pH and hypoxia\textsuperscript{43, 44}.

1.2.1 Hypoxia

Hypoxia arises when oxygen supply is insufficient to meet the metabolic demands of a growing tumour\textsuperscript{45}. Hypoxia can be classified as perfusion limited (acute hypoxia) or diffusion limited (chronic hypoxia)\textsuperscript{46}. All solid tumours are susceptible to developing hypoxia, and this process is independent of tumour size, stage, grade, or histology\textsuperscript{46}. According to Bennewith and Dedhar, the population of cells in a tumour that is exposed to low oxygen tension (pO\textsubscript{2} value < 10 mmHg, eq. to < 1.3% O\textsubscript{2} in vitro) can vary substantially from < 1% to > 50%\textsuperscript{47}. Tumours that are hypoxic tend to be highly aggressive with enhanced propensity for metastasis\textsuperscript{47}. Hypoxia has been well-studied because its negative effect on radiotherapy and chemotherapy.

In radiotherapy, radiolysis of water produces free radicals that induce DNA damage in cancer cells\textsuperscript{48, 49}. Molecular oxygen reacts with damaged DNA to make damage less repairable\textsuperscript{50, 51}. Gray \textit{et al.} described that an approximate three-fold higher radiation dose is required to kill oxygen-deprived cells than well-oxygenated cells\textsuperscript{52}. In chemotherapy, tumour vasculature or lack thereof limits the delivery and extravascular distribution of anti-cancer drugs\textsuperscript{53}. Hypoxic tumours often upregulate drug efflux pumps like P-glycoprotein and multidrug resistance protein 1 to further reduce drug accumulation\textsuperscript{54}. Tumour cells also adapt to low oxygen availability by reducing their growth rates. This confers resistance and insensitivity to chemotherapeutic drugs.
that are anti-proliferation agents\textsuperscript{55}. As hypoxia is a salient feature of most solid cancers, targeting components of the hypoxia-induced signaling cascade has been proposed as a means for oncologic treatment\textsuperscript{56,57}.

1.2.1.1 Methods for Detection of Tumour Hypoxia

At present, oxygen electrodes are considered the gold standard for measuring hypoxia as they provide direct measurement of pO\textsubscript{2} level in tissues\textsuperscript{58}. However, the sampling procedure is invasive and restricted to superficial or readily accessible tumours\textsuperscript{59}. This methodology is further limited in the fact that it cannot differentiate between necrotic and hypoxic tissues\textsuperscript{59}. In the past two decades, technological development for the detection of hypoxia has focused on the use of non-invasive imaging modalities like PET\textsuperscript{59}.

Many of the hypoxia PET imaging agents are based on fluorinated nitroimidazole analogues such as FMISO, FAZA, EF5 and HX4 (Figure 1.3)\textsuperscript{55,59,60}. These tracers enter cells by passive diffusion and undergo reduction via a one-electron-transfer reaction to form reactive intermediate species\textsuperscript{55,59,60}. Under normoxia this process is reversed as the nitro-radical anion is re-oxidized to reform the parent 2-nitroimidazole derivative, at which point the tracer can permeate out of the cell\textsuperscript{55,59,60}. In hypoxic conditions, the nitro-radical anion is further reduced into metabolites that can bind to macromolecules like protein or DNA\textsuperscript{55,59,60}. This intracellular trapping mechanism leads to accumulation of radioactivity within hypoxic cells\textsuperscript{55,59,60}. Of the tracers mentioned, \textsuperscript{18}F-FMISO is the tracer that has been utilized most extensively in the clinic\textsuperscript{59}. However \textsuperscript{18}F-FMISO is not used routinely due to its pharmacokinetic profile with slow clearance from normal tissues\textsuperscript{59,60}. Consequently, \textsuperscript{18}F-FMISO often yields images with modest contrast. For example, Rajendran \textit{et al.} used a tumour to background ratio of 1.2 at 2 h p.i. as a cut-off for defining tumour hypoxia with \textsuperscript{18}F-FMISO in a cohort of sarcoma patients\textsuperscript{61}. Novel hypoxia PET tracers with higher sensitivity and faster pharmacokinetic are needed to improve treatment planning and prognostic accuracy.
Figure 1.3 Molecular structures of four commonly used $^{18}$F-labeled hypoxia PET tracers in the clinic. These hypoxia tracers are 2-nitroimidazole derivatives and vary in their lipophilicity. Figure was adapted from Fleming et al.\textsuperscript{59}

1.3 Carbonic Anhydrase IX as a Surrogate Marker of Hypoxia

To cope with stress associated with a hypoxic microenvironment, cancer cells undergo substantial gene expression changes. The hypoxia-inducible factor (HIF) family of transcription factors act as the principal regulators of this homeostatic response\textsuperscript{57, 62}. Under hypoxia, HIF-1$\alpha$ is translocated into the nucleus where it binds to the constitutively expressed HIF-1$\beta$ subunit to form a heterodimer\textsuperscript{63}. The HIF-1$\alpha$/$\beta$ complex binds to hypoxia-response elements (HREs) within the promoter sequences of target genes, and recruits transcriptional co-activators to promote transcription (Figure 1.4)\textsuperscript{63}. Depending on which genes are activated by HIF-1$\alpha$, there is a wide range of biological responses that can occur including angiogenesis, erythropoiesis, apoptosis, cell proliferation and survival, proteolysis, pH homeostasis, and glucose metabolism\textsuperscript{63}.

Carbonic anhydrase IX (CA-IX) is the protein that is most strongly upregulated by hypoxia and HIF-1$\alpha$\textsuperscript{64}. Initially termed MN-protein, CA-IX was first identified by Pasterokova et al. as a membrane surface protein expressed in HeLa human cervical carcinoma cell line\textsuperscript{65, 66}. As a member of the $\alpha$-family of carbonic anhydrases, CA-IX is 1 of 15 unique but closely related zinc metalloenzymes (Table 1.2)\textsuperscript{67}. Of the different isoforms, the expression of CA-IX is most strongly associated with cancer progression. In fact, CA-IX mediates several physiological responses within the hypoxic milieu of solid tumours (Section 1.3.2). CA-IX has a biological half-life of approximately 38 h in re-oxygenated cells\textsuperscript{68}, which raises concerns whether CA-IX can reliably infer hypoxia status without overestimating hypoxic fractions. By comparison, the time required for oxygen-dependent degradation of HIF-1$\alpha$ has been reported to be between 5-8 min\textsuperscript{69}. According to Kulaz et al., CA-IX expression reflects the transcriptional activity of HIF-1$\alpha$, as opposed to the abundance of HIF-1$\alpha$\textsuperscript{70}. Indeed discordant expression between CA-IX and
HIF-1α has been described in vivo; however, CA-IX is still considered one of the most sensitive endogenous marker for cellular hypoxia\textsuperscript{70}. Many research groups use CA-IX as an endogenous biomarker to complement pimonidazole staining to validate hypoxia status in tumors\textsuperscript{71, 72}. It should be noted that there are scenarios where CA-IX may not be expressed under hypoxia. Mutations in HIF-1α leading to a loss of function has been previously described in cell lines\textsuperscript{73}, and there are certain cancers that preferentially express HIF-2α and HIF-2α-targeted genes\textsuperscript{74, 75}.

**Figure 1.4 Regulation of HIF-1α by proline hydroxylation.** Under normoxic conditions with O\textsubscript{2}, Fe\textsuperscript{2+}, 2-oxoglutarate (2-OG) and ascorbate present, hypoxia-inducible factor (HIF)-1α is hydroxylated by proline hydroxylases (PHD1, 2 and 3). Hydroxylated HIF-1α becomes a binding partner of pVHL (von Hippel-Lindau tumour suppressor protein). The pVHL/HIF-1α complex is poly-ubiquitinated and targeted for degradation by proteasomes. In addition to hydroxylation (OH), HIF-1α can undergo acetylation (OAc) to facilitate pVHL binding. Under hypoxic conditions, HIF-1α hydroxylation is inhibited and HIF-1α accumulates in the cytosol. HIF-1α is translocated into the nucleus where it forms a heterodimer with HIF-1β. The HIF-1α/β heterodimer binds to hypoxia-response elements (HREs) within the promoter sequences of the target genes and recruits transcriptional co-activators (ex. p300/CREB binding protein) to enable transcription. As indicated, HIF-1α regulated genes mediate many cellular functions. Figure was adapted from Carroll and Ashcroft\textsuperscript{63} with permission.
<table>
<thead>
<tr>
<th>Isoform</th>
<th>Organ/tissue distribution</th>
<th>Subcellular location</th>
<th>Catalytic activity (CO₂ hydration)</th>
<th>Affinity for sulfonamides</th>
</tr>
</thead>
<tbody>
<tr>
<td>CA-I</td>
<td>erythrocytes, gastrointestinal tract, eye</td>
<td>cytosol</td>
<td>Low</td>
<td>medium</td>
</tr>
<tr>
<td>CA-II</td>
<td>erythrocytes, eye, gastrointestinal tract, bone osteoclasts, kidney, lung, testis, brain</td>
<td>cytosol</td>
<td>high</td>
<td>very high</td>
</tr>
<tr>
<td>CA-III</td>
<td>skeletal muscle, adipocytes</td>
<td>cytosol, membrane-bound</td>
<td>very low</td>
<td>very low</td>
</tr>
<tr>
<td>CA-IV</td>
<td>kidney, lung, pancreas, brain capillaries, colon, heart muscle, eye</td>
<td>cytosol</td>
<td>medium</td>
<td>high</td>
</tr>
<tr>
<td>CA-VA</td>
<td>liver</td>
<td>mitochondria</td>
<td>Low</td>
<td>high</td>
</tr>
<tr>
<td>CA-VB</td>
<td>heart and skeletal muscle, pancreas, kidney, spinal cord, gastrointestinal tract</td>
<td>mitochondria</td>
<td>high</td>
<td>high</td>
</tr>
<tr>
<td>CA-VI</td>
<td>salivary and mammary glands</td>
<td>secreted into saliva and milk cytosol</td>
<td>Low</td>
<td>very high</td>
</tr>
<tr>
<td>CA-VII</td>
<td>central nervous system</td>
<td>cytosol</td>
<td>high</td>
<td>very high</td>
</tr>
<tr>
<td>CA-VIII</td>
<td>central nervous system</td>
<td>cytosol</td>
<td>acatalytic</td>
<td>ND&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>CA-IX</td>
<td>tumours, gastrointestinal mucosa</td>
<td>transmembrane</td>
<td>high</td>
<td>high</td>
</tr>
<tr>
<td>CA-X</td>
<td>central nervous system</td>
<td>cytosol</td>
<td>acatalytic</td>
<td>ND&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>CA-XI</td>
<td>central nervous system</td>
<td>cytosol</td>
<td>acatalytic</td>
<td>ND&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>CA-XII</td>
<td>kidney, intestine, reproductive epithelia, eye, tumours</td>
<td>transmembrane</td>
<td>Low</td>
<td>very high</td>
</tr>
<tr>
<td>CA-XIII</td>
<td>kidney, brain, lung, gut, reproductive tract</td>
<td>cytosol</td>
<td>Low</td>
<td>high</td>
</tr>
<tr>
<td>CA-XIV</td>
<td>kidney, brain, liver, eye</td>
<td>transmembrane</td>
<td>Low</td>
<td>high</td>
</tr>
</tbody>
</table>

<sup>a</sup>ND = not determined.
1.3.1 Biochemical Structure of CA-IX

CA-IX is made up of 459 amino acids (aa), which comprises 5 different protein domains (Figure 1.5)\textsuperscript{76}. The domains are classified as signal peptide domain, proteoglycan (PG)-like domain, catalytic domain, transmembrane domain, and intracellular domain, with each mediating different biological functions\textsuperscript{76}. During protein maturation, the $N$-terminus signal peptide is truncated leaving the PG-like domain (59 aa) and catalytic domain (257 aa) to form the ectodomain\textsuperscript{76}. The catalytic domain is highly conserved amongst the CA family\textsuperscript{77}, but the adjacent PG-like domain is unique to CA-IX and serves as a potential allosteric binding site (Section 1.3.2.2)\textsuperscript{76}. CA-IX is localized at the cell surface, in a homodimer configuration\textsuperscript{77}.

![Crystal structure of the catalytic domain of CA-IX](image)

**Figure 1.5 Crystal structure of the catalytic domain of CA-IX.** Top: CA-IX forms an intermolecular disulfide bridge with another CA-IX subunit, and is observed as a homodimer at the cell surface. The crystal structure of the catalytic pocket was resolved by Alterio \textit{et al.}\textsuperscript{77}, and is used to guide the design of CA-IX inhibitors (Protein Data Bank ID: 3IAI). Bottom: a schematic representation of the 5 protein domains of CA-IX. SP: signal protein, PG: proteoglycan-like, CA: catalytic, TM: transmembrane, IC: intracellular.

1.3.2 Physiological Function of CA-IX in Cancer

1.3.2.1 Intracellular pH Regulation and Survival

As oxidative phosphorylation is restricted under hypoxic conditions, HIF-1$\alpha$ activated tumour cells adapt by engaging in glycolysis for catabolism\textsuperscript{42, 43}. Glycolysis offers a selective
advantage for cancer cells as byproducts can participate in downstream anabolic pathways. However, this glycolytic switch also produces acidic metabolites that lower intracellular pH (pHi). Disruption of pHi negatively impacts biological processes including membrane stability, proliferation, and metabolism. CA-IX is part of the cellular machinery that maintains pHi homeostasis. Like other CA isoforms, CA-IX is an efficient catalyst for the reversible hydration of carbon dioxide to bicarbonate ion and proton (H₂O + CO₂ ↔ HCO₃⁻ + H⁺). HCO₃⁻ ions are subsequently brought into the cell by transporter systems (e.g., Na⁺/ HCO₃⁻ cotransporter, Na⁺ dependent Cl⁻/ HCO₃⁻ exchanger, anion exchanger) to maintain an alkaline pHi. Attenuation of CA-IX activity within hypoxic niches by either small molecule inhibitors or RNA interference has been shown to reduce cell survival and proliferation.

1.3.2.2 Cell Adhesion, Migration, Invasion, and Metastasis

CA-IX is involved in the processes of cell adhesion, migration, invasion, and metastasis. It has been reported that CA-IX binds competitively to β-catenin via its PG-like domain, to modulate E-cadherin-mediated adherent junctions between cells. By interfering with E-cadherin/β-catenin binding, CA-IX destabilizes cell-cell adhesions and promotes cell motility. Cytoskeletal rearrangement occurs, followed by cellular detachment. The increase in migratory capability contributes to epithelial-mesenchymal transition (EMT) and metastasis. CA-IX further initiates the metastatic cascade by acidifying the extracellular environment. In the process of converting CO₂ into HCO₃⁻, CA-IX generates H⁺ that can degrade the extracellular matrix and activate matrix metalloproteinases. Pharmacological inhibition of CA-IX has been shown by our collaborator, Dr. Shoukat Dedhar (BCCA), to obviate pulmonary metastasis in an aggressive preclinical breast cancer model.

1.3.3 Regulation of CA-IX Activity and Abundance

Studies have revealed that the intracellular domain of CA-IX is critical for enzymatic activity. There are three aa residues (⁴⁴₃T, ⁴⁴₈S, and ⁴⁴⁹Y) that serve as potential phosphorylation sites for protein interaction and signal transduction. Under hypoxia, cyclic-AMP activates PKA kinase which phosphorylates ⁴⁴₃T to increase CA-IX activity. On the other hand, ⁴⁴⁹Y phosphorylation is mediated by epidermal growth factor (EGF) and allows
CA-IX to interact with PI3K to activate Akt signaling in a positive feedback loop\textsuperscript{92}. As for \textsuperscript{448}S, its phosphorylation is considered a negative regulator for CA-IX activity\textsuperscript{65}.

A manner in which CA-IX abundance is regulated is through metalloproteinase-mediated cleavage of the extracellular domain. This cleavage, also called ectodomain shedding, can be carried out passively or actively by a TNF\textalpha-converting enzyme (TACE/ADAM17)\textsuperscript{93}. Elevated levels of CA-IX in serum have been reported in renal, vulvar, and breast cancer patients\textsuperscript{94-96}, presumably as a result of ectodomain shedding. It is hypothesized that this process correlates with tumour burden in patients, and mediates autocrine and paracrine signaling at the cellular level. A recent preclinical study has shown that circulating CA-IX ectodomain can be an indicator of apoptosis in response to cytotoxic drugs\textsuperscript{97}. It is plausible that this process can negatively impact therapy and imaging, as the accumulation of ectodomain in circulation may divert CA-IX targeting agents away from tumour sites\textsuperscript{98}.

1.3.4 Distribution of CA-IX in Normal Tissues and Malignancies

In normal physiological conditions, CA-IX expression is generally restricted to the gastrointestinal tract (duodenum, jejunum and ileum) where it is involved in the process of differentiation\textsuperscript{99}. Diffuse expression of CA-IX has also been observed in male efferent epithelial ducts\textsuperscript{100}, and in the basolateral membrane of acinar and ductal epithelia of the pancreas\textsuperscript{101}. In malignancies, overexpression of CA-IX has been observed in a broad spectrum of cancers including: breast, lung, colon, cervix, ovary, head and neck, bladder, and renal cancers\textsuperscript{85, 102-113}. Several tumour microarray studies (Table 1.3) performed with IHC staining have shown that CA-IX expression is correlated with poor prognosis. CA-IX positivity and staining intensity depend on the tumour subtype being investigated. CA-IX staining is generally regional as opposed to a ubiquitous distribution. The pathological expression of CA-IX complemented with a limited profile in normal tissues makes it an attractive therapeutic target.
Table 1.3 CA-IX tissue microarray studies. Table reproduced from McDonald et al.\textsuperscript{56}

<table>
<thead>
<tr>
<th>Cancer subtype</th>
<th># of Samples</th>
<th>Total CA-IX +ve %</th>
<th>Prognostic marker</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Univariate analysis</td>
<td>Multivariate analysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>DSS</td>
<td>OS</td>
</tr>
<tr>
<td>Breast</td>
<td>3630</td>
<td>16</td>
<td>Yes</td>
<td>NR</td>
</tr>
<tr>
<td>Breast</td>
<td>144</td>
<td>26</td>
<td>NR</td>
<td>Yes</td>
</tr>
<tr>
<td>NSCLC</td>
<td>555</td>
<td>24</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Ovarian</td>
<td>205</td>
<td>26</td>
<td>NR</td>
<td>Yes</td>
</tr>
<tr>
<td>Bladder</td>
<td>340</td>
<td>71</td>
<td>NR</td>
<td>Yes</td>
</tr>
<tr>
<td>Astrocytoma</td>
<td>362</td>
<td>78</td>
<td>NR</td>
<td>Yes</td>
</tr>
</tbody>
</table>

DSS = disease specific survival; OS = overall survival; MFS = metastasis free survival; NSCLC = non-small cell lung carcinoma; NS = not significant; NR = not reported

1.3.5 Tumour Models Used for CA-IX Imaging

Although the pathological role of CA-IX has been studied in many cancer subtypes, two human cancer models are used extensively in preclinical studies for the development of CA-IX imaging agents. They are the HT-29 colorectal adenocarcinoma cell line and the SK-RC-52 clear cell renal cell carcinoma (CCRCC) cell line. The HT-29 cell line was established in Dr. Jorgen Fogh’s lab (Memorial Sloan Kettering Cancer Center)\textsuperscript{116}, while the SK-RC-52 cell line was established in Dr. Lloyd Old’s lab (Memorial Sloan Kettering Cancer Center)\textsuperscript{117}. For the HT-29 model, CA-IX expression is observed near perinecrotic areas because of low vasculature density and diffusion limited hypoxia\textsuperscript{118}. In the SK-RC-52 model, a high expression of CA-IX is observed due to impaired functionality of the \textit{VHL} gene leading to constitutive HIF-1α activation\textsuperscript{113, 119, 120}. Biallelic mutations, loss of heterozygosity or epigenetic silencing are common causes of \textit{VHL} inactivation in CCRCC\textsuperscript{121, 122}. Although CA-IX is considered a good diagnostic/therapeutic target for CCRCC, its expression can be independent of the cellular hypoxia-response.

1.3.6 CA-IX Nuclear Imaging Agents

This section is meant to provide an overview of the different classes of pharmacological agents that have been radiolabeled for PET or SPECT imaging. The development and biological evaluations of CA-IX radiotracers by our group will be discussed in subsequent chapters.
1.3.6.1 Monoclonal Antibodies

Monoclonal antibodies (mAbs) are a highly successful class of antigen recognition molecules for cancer diagnosis and therapy. Given their high specificity to target antigens, mAbs were hailed as “magic bullets” for cancer. Today, many humanized mAbs like trastuzumab, bevacizumab, cetuximab, rituximab, and alemtuzumab are employed as cancer therapeutics\textsuperscript{123, 124}. In the case of CA-IX, two mAbs have been at the forefront for clinical use: M75 and cG250. Both mAbs bind to the PG-like domain of CA-IX and have been evaluated as imaging agents. M75 was radiolabeled with $^{125}$I for preclinical imaging studies\textsuperscript{118, 125}, and is now commercially available as part of an ELISA kit from Siemens\textsuperscript{126}. On the other hand, cG250 (marketed by WILEX AG as Rencarex\textsuperscript{®}) has been radiolabeled with an assortment of imaging isotopes including $^{124}$I, $^{111}$In, and $^{89}$Zr\textsuperscript{127-129}. In a phase III trial (REDUCTANE study), $^{124}$I-cG250 had higher average sensitivity and specificity for the diagnosis of CCRCC compared to contrast-enhanced computed tomography alone (86.2% and 85.9% for PET/CT vs. 75.5% and 46.8% for CT)\textsuperscript{127}. Despite the success of mAbs, there is significant interest in developing alternative approaches for imaging CA-IX in vivo. The high molecular weight of mAbs, combined with tumour interstitial pressure and aberrant vasculature, could limit tissue penetrance and ability to bind CA-IX in hypoxic niches\textsuperscript{130}. Moreover, due to slow pharmacokinetic clearance mAb imaging typically requires a non-ideal delay of 4-7 days post-injection (p.i.) to achieve high contrast images.

1.3.6.2 Small Molecule Inhibitors

Small molecule inhibitors are promising alternatives to mAb-based imaging. Due to their low molecular weights, small molecules generally exhibit higher tumour penetration and faster pharmacokinetics. Furthermore, small molecules are non-immunogenic and easier and less expensive to produce. Sulfonamides and coumarins are two classes of small molecules that are efficacious in inhibiting CA-IX activity, but differ in their mechanism of action. Sulfonamides and isoether derivatives, sulfamates and sulfamides, inhibit CA-IX by forming coordination with Zn$^{2+}$ ion of the catalytic domain and displacing H$_2$O\textsuperscript{131}. In contrast, coumarins are suicide inhibitors that undergo hydrolysis to bind irreversibly at the entrance leading to the catalytic domain. By sterically hindering substrate binding, coumarins inhibit CA-IX activity\textsuperscript{132}. However
given the large number of human CA isoenzymes and the homology shared for the catalytic
domain, it is very challenging to design potent inhibitors specifically targeting a single isoform

Of the small molecule inhibitors that have been radiolabeled for CA-IX imaging, only a
subset of them has been evaluated in vivo (Figure 1.6). Apte et al. reported the synthesis of an
$^{18}$F-labeled sulfonamide derivative (compound A), but no biological data were presented. Lu
et al. reported the synthesis of a series of $^{99m}$Tc/Re-labeled benzenesulfonamide derivatives.
Among them, $^{99m}$Tc-3d (compound B) exhibited high binding affinity (IC$_{50}$ = 9 nM) to hypoxic
CA-IX expressing HeLa cells, but no further evaluation in animal imaging study was presented.
Asakawa et al. reported $^{11}$C-labeling of three potent benzenesulfonamides (compounds C), but
no biological evaluation data were presented either. Akurathi et al. reported biodistribution data
for $^{99m}$Tc-labeled sulfonamide derivatives (compounds D-H) in HT-29 tumour xenografts.
Tracers showed limited retention in tumours (≤ 0.5 %ID/g at 0.5 - 4 h p.i.) with low contrast (≤
1.0 tumour-to-blood ratio). $^{18}$F-VM4-037 (compound I) is an ethoxzolamide derivative
developed by Siemens that completed phase II studies. $^{18}$F-VM4-037 showed moderate uptake
in primary CCRCC lesions, but lesions were difficult to visualize without an accompanying CT
due to high background uptake in normal renal parenchyma. $^{18}$F-VM4-037 was able to detect
extrarenal lesions for patients that had metastatic disease. Interestingly, Peeters et al. published
preclinical biodistribution/imaging data for $^{18}$F-VM4-037 with the tracer reportedly failing to
detect CA-IX expression in either glioma or colorectal cancer xenograft models. Krall et al.
reported the synthesis and evaluation of a $^{99m}$Tc-labeled acetazolamide derivative (compound J)
with excellent tumour targeting (22 %ID/g at 3 h p.i.) and image contrast, but results were
obtained with the CA-IX overexpressing SK-RC-52 tumour xenograft model.
Figure 1.6 Structures of small molecule inhibitors proposed or used for CA-IX imaging. Binding affinities to CA-IX (K_i), where available, were taken from literature.

1.3.6.3 Peptides

Like small molecule inhibitors, peptides offer advantages as imaging vectors in terms of ease of production, lack of immunogenicity, rapid tumour targeting and pharmacokinetic properties. The primary concerns of peptide-based imaging are metabolic lability and potential nephrotoxicity from renal retention. As peptides can be subjected to peptidase degradation in vivo, common strategies to improve stability include substituting D-amino acids for L-amino acids, incorporating unnatural amino acids, pseudo-peptide bonds, or intramolecular cyclization. As for nephrotoxicity, administration of positively charged aa like L-arginine and L-lysine, gelofusion or amifostine have been used to reduce renal uptake of peptide tracers. The efficacy of these strategies varies between individual peptide/target systems.

There is no natural peptide ligand for CA-IX; therefore, those that have been explored for molecular imaging have been derived from phage display technology. Askoxylakis et al. reported the isolation of CaIX-P1, a dodecapeptide (sequence: YNTNHVPLSPKY) that was raised against the extracellular domain of CA-IX. In biodistribution studies with SK-RC-52
xenograft mice, $^{131}$I-CalIX-P1 displayed modest tumour uptake (~2.5 %ID/g) with tumour to muscle ratio of 4.11 ± 2.44 at 1 h p.i. Attempts to optimize CalIX-P1 via alanine scanning and truncations led to the identification of CalIX-P1-4-10 (NHVPLSPy)$^{145}$. Although CalIX-P1-4-10 had approximately 6-fold higher binding ratio than CalIX-P1 in vitro, planar scintigraphy with $^{125}$I-CalIX-P1-4-10 was unable to delineate tumour xenografts from background. Due to concerns of isoform selectivity, the Heidelberg group performed a secondary screen against the PG-like domain of CA-IX and isolated the dodapeptide PGLR-P1 (NMPKDVTRMS)$^{146}$. However, $^{125}$I-PGLR-P1 exhibited micromolar affinity, and uptake value in tumour (0.48 ± 0.20 at 1 h p.i.) was lower than most normal tissues.

1.3.6.4 Affibodies

Affibody molecules are a class of antibody mimetics that were originally derived from the B-domain in the IgG-binding region of staphylococcal protein A$^{147}$. Affibodies are cysteine free proteins of 58 aa residues (6-7 kDa) that fold into three alpha-helix bundle structures$^{147}$. Target specificity is mediated by 13 aa residues$^{147}$. Tolerant to high temperatures, extreme pHs, and structural modifications, these scaffolds typically exhibit nano to picomolar affinities to their targets of interest$^{147,148}$. Dr. Vladimir Tolmachev’s group in Uppsala University, Sweden are experts of this technology, and successfully developed affibodies for imaging HER2, EGFR, IGF-1R, PDGFRβ, HER3, and CA-IX$^{149-154}$.

Honarvar et al. reported the successful affibody-mediated imaging of CA-IX expression in SK-RC-52 xenograft mice with $^{99m}$Tc-HEHEHE-ZCAIX:1$^{154}$. $^{99m}$Tc-HEHEHE-ZCAIX:1 exhibited rapid clearance from blood and normal tissues. At 4 h p.i., tumour uptake was 9.7 ± 0.7 %ID/g, which corresponded to tumour-to-muscle and tumour-to-blood ratios of 104 ± 52 and 53 ± 10 respectively. $^{99m}$Tc-HEHEHE-ZCAIX:1 generated high contrast SPECT images, despite high retention in kidneys (141 ± 45 %ID/g). The authors concluded that $^{99m}$Tc-HEHEHE-ZCAIX:1 may not be suitable for imaging CCRCC; however, it represents a highly promising imaging vector for detecting CA-IX expression for other cancers pending further investigations. The high renal uptake of affibodies can be mitigated by the use of non-residualizing radionuclides or through pre-targeting approaches, with the latter showing great promise with a HER2-specific affibody$^{155,156}$. 
1.4 Other Imaging Modalities

1.4.1 Optical Imaging

Similar to SPECT and PET, optical imaging requires the administration of a targeting probe; however, the imaging probe is labeled with a fluorescent molecule in lieu of a radionuclide\(^ {157}\). Following an uptake period, the target fluorescent molecule is excited by an external laser of appropriate wavelength\(^ {157}\). This produces an emission of a longer-wavelength light, which is detected for acquisition and image processing\(^ {157}\). Optical imaging agents are generally limited in terms of tissue penetrance (cm range) due to signal attenuation, but they have an emerging role as a complementary intraoperative imaging modality\(^ {158}\). Optical agents can be used by surgeons to ensure that clean/negative surgical resection margins are reached\(^ {158}\).

Muselaers et al. used cG250 as a pharmacological vector to produce \(^ {125}\)I-labeled girentuximab-IRDye800CW, with optical images demonstrating good concordance with SPECT images (31.5 ± 9.6 %ID/g in SK-RC-52 tumours at 72 h p.i.)\(^ {159}\). Tafreshi et al. took a commercially available CA-IX antibody and conjugated it with VivoTag-S 680, termed CA9Ab-680, for imaging breast cancer lymph node metastasis\(^ {160}\). van Brussel et al. used a phage display library to identify a nanobody, single domain antibody, for optical imaging with IRDye800CW\(^ {161}\). At 2 h p.i., the uptake in CA-IX overexpressing ductal carcinoma in situ mouse cancer model was 14.1 ± 1.1 %ID/g. Groves et al. reported a series of sulfonamide derivatives conjugated to near-infrared (NIR) fluorochromes\(^ {162}\). One acetazolamide derivative in particular, HS680, generated high contrast fluorescence molecular tomography images for tumour-bearing mice (10 %ID in HT-29 tumours at 24 h p.i.) that underwent in vivo hypoxia induction (48 h at 8% O\(_2\) levels)\(^ {163}\). Wichert and colleagues decribed the use of a dual pharmacophore DNA-encoded chemical library to identify ligand pairs and facilitate affinity maturation for pharmacodelivery applications. They identified a novel CA-IX inhibitor consisting of a 4,4-bis(4-hydroxyphenyl)valeric acid and a succinyl acetazolamide group (A-493/B-202 pair). After conjugating the A-493/B-202 pair to a NIR dye (compound 8c), imaging studies were performed in SK-RC-52 tumour-bearing mice. Compound 8c showed high and sustained tumour uptake (10 ± 2 %ID/g) at 24 h p.i.\(^ {164}\). More recently, Ly et al. reported the synthesis and evaluation of HypoxyFluor, a dimeric sulfonamide inhibitor conjugated to a S0456 NIR dye\(^ {165}\). Although
biodistribution data was not available, high contrast images were obtained for HT-29 xenograft mice at 4 h p.i.

1.4.2 Magnetic Resonance

Magnetic resonance (MR) imaging is a diagnostic modality that can performed without exposing patients to ionizing radiation. To perform a study, a patient rests in an MR scanner and is subjected to a magnetic field. A radiofrequency pulse is applied to the body, which causes hydrogen atoms to alter their magnetization alignment relative to the magnetic field. The radiofrequency pulse is subsequently switched off to allow the hydrogen atoms to return to their equilibrium or resting states. This process emits radio waves that are detected by receiver coils surrounding the patient. An MR scan is made up of a series of such pulse sequences. The contrast observed between tissues is dependent on the differences in relaxation rates. As hydrogen atoms are found in abundance in fat and water, MR can produce high contrast images of soft tissues.

Probes containing exogenous contrast agents (ex. gadolinium or iron oxide) or stable isotopes (ex. $^{13}$C or $^{15}$N) can be used for molecular targeting with MR. Compared to optical imaging, there has been limited development for CA-IX targeted MR imaging. As CAs are responsible for catalyzing the interconversion of CO$_2$ and HCO$_3^-$, Gallagher et al. used $^{13}$C-labelled HCO$_3^-$ as a probe/substrate to assess the functional activity of CA-IX in colorectal cancer xenograft models. Chen et al. conjugated CA-IX targeting sulfonamides onto Fe$_3$O$_4$ magnetic nanoparticles for tumour imaging. According to the authors, higher uptake in HT-29 tumour xenograft was observed compared to control nanoparticles (Fe$_3$O$_4$ particles alone); however, no quantitative measurements were provided for in vivo studies. Rami et al. reported the synthesis of a series of sulfonamides that were conjugated to macrocyclic rings that can bind gadolinium(III), but no imaging experiments were performed.

1.5 CA-IX Therapeutics in Clinical Development

As summarized in Table 1.4, different CA-IX therapeutic agents have been investigated in clinical trials. cG250 advanced to a phase III trial (ARISER study), but failed to meet primary endpoint as an adjuvant therapy for CCRCC patients. Meanwhile cG250 radiolabeled with
cytotoxic radionuclide $^{177}$Lu recently concluded phase II clinical studies, with disease stabilization observed for 9 of 14 patients that had progressive metastatic CCRCC$^{173}$. However, myelotoxicity prevented some patients from receiving additional treatment courses. BAY-79-4620 is an antibody-drug conjugate (ADC) with monomethyl auristatin E as a neoplastic agent$^{174}$. During the phase I study, several patients experienced severe adverse events including death$^{175}$. This led to the termination of the phase I study, and subsequent discontinuation of clinical development for BAY-79-4620. SLC-0111 is an ureido-sulfonamide inhibitor developed for solid tumours$^{176}$. SLC-0111 is currently in phase I clinical study at three Canadian health institutions including the BC Cancer Agency. Dubois et al. developed DH-348, a dual-targeting bioreductive nitroimidazole based sulfonamide that can inhibit CA-IX activity and also act as a radiation sensitizer$^{177}$. With promising preclinical results, phase I study for DH-348 is scheduled to commence in 2016.

**Table 1.4 CA-IX therapeutic agents in clinical development.**

<table>
<thead>
<tr>
<th>Compound</th>
<th>Generic name</th>
<th>Category</th>
<th>Indication(s)</th>
<th>Stage$^a$</th>
</tr>
</thead>
<tbody>
<tr>
<td>cG250</td>
<td>Girentuximab or</td>
<td>Chimeric antibody</td>
<td>Kidney cancer</td>
<td>Phase III$^b$</td>
</tr>
<tr>
<td>$^{177}$Lu-cG250</td>
<td>Rencarex® $^{177}$</td>
<td>Radiolabeled antibody</td>
<td>Kidney cancer</td>
<td>Phase II</td>
</tr>
<tr>
<td>3ee9–MMAE</td>
<td>BAY-79-4620</td>
<td>Antibody–drug conjugate</td>
<td>Solid tumours</td>
<td>Phase I$^b$</td>
</tr>
<tr>
<td>U-104</td>
<td>SLC-0111</td>
<td>Small molecule inhibitor</td>
<td>Solid tumours</td>
<td>Phase I</td>
</tr>
<tr>
<td>DH-348</td>
<td>DTP348</td>
<td>Small molecule inhibitor</td>
<td>Solid tumours, Head and neck neoplasms</td>
<td>-</td>
</tr>
</tbody>
</table>

$^a$Highest clinical stage reached to date; $^b$No longer in clinical development

### 1.6 Thesis Theme and Rationale

Pharmacologic inhibition of CA-IX is achievable through mAbs or small molecule inhibitors; however, there remains a need for an effective platform to screen for cancers that will respond to these drugs. Herein, we propose targeting CA-IX and for the diagnosis of aggressive cancers using PET or SPECT imaging. PET and SPECT are non-invasive imaging modalities that use radioisotopes to measure metabolic activities or cancer progression. The detection of
CA-IX in vivo will allow physicians to prescribe personalized therapeutic treatments, to monitor treatment response and in turn improve patient outcomes.

Moreover, considering the role of CA-IX in hypoxia-induced signaling, CA-IX radiotracers have the potential to be surrogate hypoxia imaging agents. The ability to delineate hypoxic volumes can improve radiation planning (ex. intensity modulated radiotherapy or image-guided radiotherapy) or direct hypoxia therapeutics (ex. Tirapazamine).

1.6.1 Objectives and Hypotheses

We studied existing and novel ligands which bind to CA-IX expressing tumours to develop tools to predict and monitor successful response to CA-IX inhibition. Ideal CA-IX radiotracers are ones that can be easily synthesized with high specific activity and radiochemical purity. The radiotracer(s) should be stable in plasma, and stay in circulation long enough to facilitate binding to target tissue. Most significantly, the radiotracer(s) should bind selectively to CA-IX expressing cancers and be rapidly cleared from non-target tissues (to provide good tumour to background signal and to reduce effective dose). Therefore, binding affinity, radiolabeling efficiency, plasma stability, pharmacokinetics, and image quality are criterions that were evaluated for each prospective CA-IX radiotracer.

For this thesis, we proposed the following hypotheses:

1) Antigen recognition molecules such as small molecule inhibitors, affibodies, and antibodies can be radiolabelled for in vivo imaging using $^{18}$F, $^{68}$Ga, $^{111}$In, and $^{89}$Zr.
2) By matching the appropriate isotope with the biological half-life of the targeting probe, the expression of CA-IX can be measured with high contrast in vivo by PET or SPECT imaging.
3) CA-IX tracers will show improved tumour-to-nontarget ratios and pharmacokinetics over established hypoxia PET tracers.
Chapter 2: $^{18}$F-labeled Carbonic Anhydrase IX Inhibitors for Imaging with Positron Emission Tomography

2.1 Introduction

PET imaging can be used to guide the development of novel therapeutics by assessing their distribution and accumulation in tissues of interest, provided that radiolabeled analogues are available. In turn, promising therapeutic agents can serve as lead candidates for the development of novel radiotracers. As discussed, different small molecule inhibitors have been radiolabeled for CA-IX targeted imaging. In Chapter 2, we report the synthesis, $^{18}$F labeling, and evaluation of two CA-IX inhibitors, 7-(2-fluoroethoxy)coumarin (FEC) and U-104 (Figure 2.1), as potential tracers for imaging CA-IX expression with PET. Coumarin and sulfonamide derivatives represent the two primary classes of small molecules that have been successful in inhibiting CA-IX activity. U-104, a sulfonamide that demonstrated anti-metastatic potential in preclinical breast cancer models, is currently under evaluation in a multi-center phase I clinical study to determine maximum tolerable dose and pharmacokinetics in cancer patients (ClinicalTrials.gov: Safety study of SLC-0111 in subjects with advanced solid tumours).

![Figure 2.1](image)

**Figure 2.1 Chemical structures of 7-(2-fluoroethoxy)coumarin (Left) and U-104 (Right).** Both tracers were radiolabeled with $^{18}$F-fluoride for PET imaging.


Jinhe Pan¹, Joseph Lau¹, Felix Mesak¹, Navjit Hundal¹, Maral Pourghiasian¹, Zhibo Liu², Francois Benard¹, Shoukat Dedhar³, Claudiu T. Supuran⁴, Kuo-Shyan Lin¹

¹ Department of Molecular Oncology, BC Cancer Research Centre, BC Cancer Agency, Vancouver, BC, Canada
² Department of Chemistry, University of British Columbia, Vancouver, BC, Canada
³ Department of Integrative Oncology, BC Cancer Research Centre, BC Cancer Agency, Vancouver, BC, Canada
⁴ Dipartimento Neurofarba and Laboratorio di Chimica Bioinorganica, Università degli Studi di Firenze, Florence, Italy

FB and KSL designed the study. JP, JL, FM, NH, MP, and ZL were involved in the experiments. CTS provided the affinity measurements. JP and JL were involved in acquisition of data and interpretation of the analysis. JP and JL wrote the manuscript.
2.2 Materials and Methods

2.2.1 Chemicals and Instrumentation

U-104 and its radiolabeling precursor 4-nitrophenyl 4-sulfamoylcarbanilate were prepared according to previously published procedures. All other chemicals and solvents were obtained from commercial sources, and used without further purification. Proton NMR spectra were obtained using a Bruker (Billerica, MA, USA) Avance 400 inv Spectrometer, and were reported in parts per million downfield from internal tetramethylsilane. Mass analyses were performed using a Bruker Esquire-LC/MS system with ESI ion source. Purification and quality control of 18F-labeled CA-IX inhibitors were performed on an Agilent (Santa Clara, CA, USA) HPLC System equipped with a model 1200 quaternary pump, a model 1200 UV absorbance detector, and a Bioscan (Washington DC, USA) NaI scintillation detector. The radio-detector was connected to a Bioscan B-FC-1000 Flow-count System, and the output from the Bioscan Flow-count system was fed into an Agilent 35900E Interface which converted the analog signal to digital signal. The operation of the Agilent HPLC system was controlled using the Agilent ChemStation software. The HPLC columns used were a semipreparative column (Phenomenex C18, 5 µ, 250 × 10 mm) and an analytical column (Eclipse XOB-C18, 5 µ, 150 × 4 mm). 18F-Fluoride was produced by the 18O(p, n)18F reaction using an Advanced Cyclotron Systems Inc. (Richmond, BC, Canada) TR19 cyclotron. Radioactivity of 18F-labeled tracers were measured using a Capintec (Ramsey, NJ, USA) CRC®-25R/W dose calibrator, and the radioactivity of mouse tissues collected from biodistribution studies were counted using a Packard Cobra II 5000 Series auto-gamma counter. PET imaging experiments were conducted using a Siemens Inveon microPET/CT scanner.

2.2.2 Synthesis of 7-(2-fluoroethoxy)coumarin (FEC)

A mixture of 7-hydroxycoumarin (0.81 g, 5 mmol), 1-fluoro-2-tosyloxyethane (1.56 g, 7.1 mmol) and K2CO3 (3.45 g, 25 mmol) in DMF (15 mL) was heated at 70 °C for 24 h. After cooling to room temperature, CH2Cl2 (100 mL) was added to the mixture, and the resulted solution was washed with water (100 mL × 3). The CH2Cl2 phase was dried with anhydrous MgSO4, concentrated under reduced pressure, and purified by flash column chromatography on
silica gel using 4:6 EtOAc/hexanes to obtain the desired product FEC as a white solid (0.918 g, 84%).

\[ \text{1H NMR (CDCl}_3\text{) } \delta 4.28 \text{ (dt, } J = 27.6, 4.0 \text{ Hz, 2H), } 4.80 \text{ (dt, } J = 47.2, 4.0 \text{ Hz, 2H), } 6.27 \text{ (d, } J = 9.2 \text{ Hz, 1H), } 6.83 \text{ (d, } J = 2.4 \text{ Hz, 1H), } 6.89 \text{ (dd, } J = 8.4, 2.4 \text{ Hz, 1H), } 7.40 \text{ (d, } J = 8.4 \text{ Hz, 1H), } 7.65 \text{ (d, } J = 9.2 \text{ Hz, 1H); MS (ESI) calculated for } C_{11}H_9FO_3 \text{ (M + H)+ } 209.1, \text{ found } 209.0. \]

2.2.3 Synthesis of 7-(2-tosyloxyethoxy)coumarin

A solution of 7-hydroxycoumarin (0.81 g, 5 mmol), 1,2-bis(tosyloxy)ethane (2.78 g, 7.5 mmol) and K$_2$CO$_3$ (3.45 g, 25 mmol) in DMF (15 mL) was heated at 70 °C for 18 h. After cooling to room temperature, CH$_2$Cl$_2$ (100 mL) was added and the solution was washed with water (100 mL × 3). The CH$_2$Cl$_2$ layer was dried with anhydrous MgSO$_4$, concentrated under reduced pressure, and chromatographed on silica gel using 1:99 CH$_3$CN/CH$_2$Cl$_2$ to obtain the desired product as a white solid (0.282 g, 16%). \[ \text{1H NMR (CDCl}_3\text{) } \delta 2.47 \text{ (s, 3H), } 4.19-4.25 \text{ (m, 2H), } 4.39-4.45 \text{ (m, 2H), } 6.28 \text{ (d, } J = 9.2 \text{ Hz, 1H), } 6.68 \text{ (d, } J = 2.4 \text{ Hz, 1H), } 6.76 \text{ (dd, } J = 8.4, 2.4 \text{ Hz, 1H), } 7.34-7.39 \text{ (m, 3H), } 7.64 \text{ (d, } J = 9.2 \text{ Hz, 1H), } 7.83 \text{ (d, } J = 8.4 \text{ Hz, 1H); MS (ESI) calculated for } C_{18}H_{16}O_6S \text{ (M + H)+ } 361.1, \text{ found } 361.1. \]

2.2.4 Binding Affinity Measurement

Inhibition constants (K$_i$) for CA-I, CA-II, CA-IX and CA-XII were determined following published procedures$^{178}$. An Applied Photophysics stopped-flow instrument was used for assaying the CA catalyzed CO$_2$ hydration activity. Phenol red (at 0.2 mM) was used as indicator, working at the absorbance maximum of 557 nm, with 20 mM HEPES (pH 7.4) and 20 mM NaBF$_4$ (for maintaining constant the ionic strength), following the initial rates of the CA-catalyzed CO$_2$ hydration reaction for 10-100 s. The CO$_2$ concentrations ranged from 1.7 to 17 mM for the determination of the kinetic parameters and inhibition constants. For each inhibitor, at least six traces of the initial 5-10% of the reaction were used for determining the initial velocity. The uncatalyzed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of inhibitor (10 mM) were prepared in distilled-deionized water, and dilutions up to 0.01 nM were done thereafter with distilled-deionized water. Inhibitor and enzyme solutions were preincubated together for 15 min at room temperature prior to assay
in order to allow for the formation of the E-I complex. The inhibition constants were obtained by nonlinear least-squares methods using PRISM 3, whereas the kinetic parameters for the uninhibited enzymes were from Lineweaver-Burk plots, and represent the mean from at least three different determinations.

2.2.5 Radiosynthesis of $^{18}\text{F}$-FEC

The proton-bombardeed $\text{H}_2[^{18}\text{O}]$O was transferred via He gas push from the cyclotron target station to a Waters QMA light Sep-Pak cartridge set up in the hot cell. The $^{18}\text{F}$-fluoride was trapped in the QMA cartridge, and eluted out into a 4-mL V-shaped reaction vial with a mixture of water (0.3 mL) and $\text{CH}_3\text{CN}$ (0.3 mL) containing $\text{K}_2\text{CO}_3$ (7 mg) and kryptofix 222 ($\text{K}_{222}$). The uncapped reaction vial was placed in a heating block, and the solution was heated at 120 °C. After most of the solvents evaporated, $\text{CH}_3\text{CN}$ (1mL × 2) was added to the reaction vial to facilitate complete removal of water. A solution of 7-(2-tosyloxyethoxy)coumarin (3 mg) in DMF (0.5 mL) was added to the reaction vial containing dry $\text{K}[^{18}\text{F}]\text{F}/\text{K}_{222}$. The vial was capped, and the mixture was heated at 70 °C for 30 min. At the end of heating, the mixture was diluted with water (1 mL) and purified by HPLC using the semipreparative column eluted with 35% CH$_3$CN/65% H$_2$O at a flow rate of 4.5 mL/min. The retention time of $^{18}\text{F}$-FEC was 17.4 min. The eluting fraction containing $^{18}\text{F}$-FEC was collected, diluted with water (50 mL), and trapped on a Waters tC18 light Sep-Pak cartridge. After washing the tC18 light Sep-Pak cartridge with water (10 mL), $^{18}\text{F}$-FEC was eluted out with ethanol (0.4 mL), and formulated with saline (4 mL) for plasma stability study and µPET/CT imaging study. The quality control was performed by HPLC on the analytical column eluted with 25% CH$_3$CN/75% H$_2$O at a flow rate of 2 mL/min. The retention time of $^{18}\text{F}$-FEC was 8.5 min. The specific activity of $^{18}\text{F}$-FEC was measured using the analytical HPLC system. It was calculated by dividing the injected radioactivity in 0.2 mL of final $^{18}\text{F}$-FEC solution by the mass of FEC in the injected solution. The mass of FEC was estimated by comparing the UV absorbance obtained from the injection with a previously prepared standard curve.
2.2.6 Radiosynthesis of $^{18}$F-U-104

(1) Radiosynthesis of 1-$[^{18}\text{F}]$fluoro-4-nitrobenzene: A solution of 1,4-dinitrobenzene (4 mg) in DMSO (0.5 mL) was added to a 4-mL reaction vial containing dry K$[^{18}\text{F}]$F/K$_{222}$. The vial was capped, and the mixture was heated at 125 °C for 10 min. At the end of the heating, the mixture was diluted with water (10 mL). The resulted solution was passed through a Waters tC18 plus Sep-Pak cartridge, and the cartridge was washed with water (10 mL). The trapped 1-$[^{18}\text{F}]$fluoro-4-nitrobenzene was eluted out of Sep-Pak cartridge with methanol (1.5 mL).

(2) Radiosynthesis of 4-$[^{18}\text{F}]$fluoroaniline: The above solution of 1-$[^{18}\text{F}]$fluoro-4-nitrobenzene in methanol was added to a vial containing 10% palladium on carbon (4 mg) and sodium borohydride (10 mg). The resulted mixture was incubated at room temperature for 5 min. The reaction was quenched by adding 0.1 mL of concentrated HCl and diluted with 1 M NaOH (20 mL). The resulted solution was passed through a Lichrolut EN column (500 mg). The trapped 4-$[^{18}\text{F}]$fluoroaniline in the Lichrolut EN column was eluted out with THF (2 mL) and dried by passing the THF solution through a pre-packed column containing celite (125 mg) and anhydrous MgSO$_4$ (125 mg).

(3) Radiosynthesis of $^{18}$F-U-104: The above solution of 4-$[^{18}\text{F}]$fluoroaniline in THF was added to a 4-mL reaction vial containing 4-nitrophenyl 4-sulfamoylcarbanilate (8 mg) and DIEA (10 µL) in DMF (0.5 mL). The resulted mixture was heated at 125 °C for 15 min, diluted with water (1 mL), and purified by HPLC using the semipreparative column eluted with 40% MeOH/60% H$_2$O at a flow rate of 4.5 mL/min. The retention time of $^{18}$F-U-104 was 27.4 min. The eluting fraction containing $^{18}$F-U-104 was collected, diluted with water (50 mL), and passed through a Waters tC18 light Sep-Pak cartridge. The trapped $^{18}$F-U-104 on the Sep-Pak cartridge was eluted out with ethanol (0.4 mL), and formulated with saline (4 mL) for plasma stability and biodistribution studies. The quality control of $^{18}$F-U-104 was performed on HPLC using the analytical column eluted with 25% CH$_3$CN/75% H$_2$O at a flow rate of 2 mL/min. The retention time of $^{18}$F-U-104 was 7.7 min. The specific activity of $^{18}$F-U-104 was measured following same procedures as described for the calculation of specific activity of $^{18}$F-FEC.
2.2.7 Stability in Mouse Plasma

Aliquots (100 µL) of the $^{18}$F-labeled tracer ($^{18}$F-FEC or $^{18}$F-U-104) were incubated with 400 µL of BALB/c mouse plasma (Innovative Research) for 5, 15, 30, 60, and 120 minutes at 37°C. At the end of each incubation period, samples were passed through a 0.45 micron filter. The filtered sample was loaded onto the analytical HPLC to check for metabolite(s) formation, and analysis was conducted with Agilent ChemStation software.

2.2.8 In Vivo Experiments

HT-29 human colorectal cancer cells were obtained as a gift from Dr. Donald Yapp (BC Cancer Research Centre, Vancouver, Canada). Cells were cultured in Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin-streptomycin, and non-essential amino acids. Mice were maintained and the experiments were conducted in accordance with the guidelines established by the Canadian Council on Animal Care and approved by the Animal Ethics Committee of the University of British Columbia.

2.2.8.1 Tumour Implantation

All experiments were performed using NOD.Cg-Prkdc<sup>scid</sup>/Il2rg<sup>tm1Wjl</sup>/SzJ (NSG) mice bred in-house at the Animal Research Centre, British Columbia Cancer Research Centre, Vancouver, Canada. Mice were anesthetized briefly with 2.5% isoflurane in 2.0 L/min of oxygen during cell implantation. After wiping skin surrounding the injection site with an alcohol prep pad, a 28.5-Gauge needle was used to subcutaneously implant $5 \times 10^6$ HT-29 cells (in 100 µL of 1xPBS and BD Matrigel Matrix at 1:1 ratio) under the right shoulder. Biodistribution studies and PET/CT imaging were performed when tumours reached 5-7 mm in diameter.

2.2.8.2 Biodistribution Studies

Tumour bearing mice were injected with $\sim 3.7$ MBq of $^{18}$F-U-104 (100 – 200 µL in saline, i.v.). After an uptake period of 1 h, mice were euthanized by CO$_2$ asphyxiation. Blood was promptly withdrawn, and organs/tissues of interest were harvested, rinsed with saline, blotted dry and
weighed. Radioactivity in collected tissues was counted, normalized to the injected dose and expressed as the percentage of the injected dose per gram of tissue (%ID/g).

2.2.8.3 PET Imaging and Data Analysis:

Under anesthesia, 3.7-7.4 MBq of $^{18}$F-FEC was administered intravenously through the caudal vein into HT-29 tumour bearing mice ($n = 4$). CT scan was performed before a PET dynamic image sequence of 10 or 55 minutes. PET data were acquired in list mode acquisition. At 1 h p.i., mice were euthanized by CO$_2$ asphyxiation followed by cervical dislocation. The tissues of interest were harvested, weighed, and counted as described in the above Biodistribution Studies section. The PET data were reconstructed using the 3d-OSEM-MAP algorithm with CT-based attenuation correction. 3D regions of interest (ROI) were placed on the reconstructed images to determine the %ID/g of tissue using the Inveon Research Workplace software (IRW).

2.2.9 Immunohistochemistry

For validation of CA-IX expression in HT-29 tumours, histologic tissue analysis was performed. Tumours were harvested and fixed in 4% paraformaldehyde in PBS for 48 h at room temperature. After dehydration, tissues were embedded in paraffin and 4 µm sections were mounted onto poly-L-lysine slides. Immunostaining was performed by the Centre of Translational Applied Genomics at the BC Cancer Agency using the Ventana Discovery XT instrument. Slides were incubated with a goat anti-human CA-IX antibody (R&D AF2188) for 1 h without heat at a 1:200 dilution in CC1 antigen retrieval buffer. A rabbit anti-goat linker (1:500) was applied for 32 min followed by a 16-min incubation with Ultramap anti-rabbit HRP detection kit. The stained sections were examined and photographed with a Leica EC3 microscope.

2.3 Results and Discussion

FEC is a coumarin derivative, whereas U-104 is an ureido-substituted benzenesulfonamide. Both coumarins and benzenesulfonamides have been shown to be potent inhibitors of CA-IX$^{131, 132}$. In addition, U-104 has been previously reported to inhibit tumour
growth and metastasis in spontaneous and experimental models of metastasis, without inhibitory
effects on CA-IX-negative tumours. As shown in Figure 2.2, the FEC standard was synthesized
in 84% yield by coupling 7-hydroxycoumarin with 1-fluoro-2-tosyloxyethane.

\[
\begin{align*}
(A) & \quad \text{HO-} \quad \text{O} \quad \text{F} \quad \text{O} \\
& \quad \text{O} \quad \text{H} \quad \text{O} \\
& \quad + \quad \text{F} \quad \text{OTs} \\
& \quad \text{K}_2\text{CO}_3 \quad \text{DMF}
\end{align*}
\]

\[
\begin{align*}
(B) & \quad \text{HO-} \quad \text{O} \quad \text{TsO} \\
& \quad \text{O} \quad \text{TsO} \\
& \quad + \quad \text{TsO} \quad \text{OTs} \\
& \quad \text{K}_2\text{CO}_3 \quad \text{DMF}
\end{align*}
\]

Figure 2.2 Synthetic scheme for the preparation of FEC and its radiolabeling precursor.
(A) Cold standard. (B) Labeling precursor.

For the development of CA-IX targeted tracers, one concern is the binding to other major
CA isoforms including I, II and XII. Cytosolic CA-I and CA-II are expressed in red blood
cells and the binding of CA-IX targeted radiotracers to either isoform would increase
background signal and reduce image contrast. On the contrary, binding of these CA-IX targeted
radiotracers to CA-XII could be beneficial as CA-XII is expressed on membranes and is also up-
regulated in hypoxic tumours. The inhibition constants (K_i) for human CA isoenzymes I, II,
IX, and XII were 4622, > 100000, 70, and 88 nM for FEC, respectively. The K_i values for U-104
have been previously reported to be 5080, 96, 45, and 4.5 nM for CA isoenzymes I, II, IX, and
XII, respectively.

The radiolabeling precursor, 7-(2-tosyloxyethoxy)coumarin, was prepared by coupling 7-
hydroxycoumarin with 1,2-bis(tosyloxy)ethane in 16% yield (Figure 2.2B), while radiosynthesis
of \(^{18}\text{F}\)-FEC was prepared via the \(^{18}\text{F}\) aliphatic nucleophilic substitution (Figure 2.3A). After
HPLC purification, \(^{18}\text{F}\)-FEC was obtained in 11-24% decay-corrected yield in 1.6 h synthesis
time with 62.9 – 210.9 GBq/µmol specific activity at the end of synthesis (EOS), and > 99%
radiochemistry purity. The preparation of \(^{18}\text{F}\)-U-104 was depicted in Figure 2.3B. The
radiosynthesis involved three reactions. First, 1-[\(^{18}\text{F}\)]fluoro-4-nitrobenzene was prepared in 40-
60% radiochemical yield by direct aromatic nucleophilic substitution reaction using \(^{18}\text{F}\)-fluoride
and dinitrobenzene. The isolated 1-[\(^{18}\text{F}\)]fluoro-4-nitrobenzene was reduced to 4-
[\textsuperscript{18}F]fluoroaniline in > 90% yield following previously published procedure\textsuperscript{184} using NaBH\textsubscript{4} and 10\% Pd/C. At the final step, \textsuperscript{18}F-U-104 was obtained in > 50\% radiochemical yield by reacting 4-[\textsuperscript{18}F]fluoroaniline with 4-nitrophenyl 4-sulfamoylcarbanilate in DMF. However, due to multiple purification steps, \textsuperscript{18}F-U-104 was isolated in only 3-9\% overall decay-corrected yield in 2.5 h synthesis time with > 98\% radiochemical purity, and 558.7-732.6 GBq/\textmu mol specific activity at EOS. The reason that \textsuperscript{18}F-U-104 had much higher specific activity than \textsuperscript{18}F-FEC was because we used Teflon tubing as the H[\textsuperscript{18}F]F/H\textsuperscript{2}\textsuperscript{18}O transfer line while preparing \textsuperscript{18}F-FEC. Before working on \textsuperscript{18}F-U-104, we replaced the Teflon transfer line with peek tubing. This change reduced the amount of fluoride leaching out from the transfer line, and significantly increased the specific activities of \textsuperscript{18}F-labeled tracers including \textsuperscript{18}F-U-104 prepared thereafter.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure2.png}
\caption{Radiosynthesis of (A) \textsuperscript{18}F-FEC and (B) \textsuperscript{18}F-U-104. \textsuperscript{18}F-FEC required one-step fluorination, while the preparation of \textsuperscript{18}F-U-104 was conducted in three-steps.}
\label{fig:2}
\end{figure}

Both \textsuperscript{18}F-U-104 and \textsuperscript{18}F-FEC were stable in mouse plasma with > 99\% of the tracers remaining intact after 2 h incubation at 37 °C. For the imaging/biodistribution studies, we used HT-29 colorectal tumour xenografts as our CA-IX-expressing tumour model, and the expression of CA-IX in the tumours was confirmed by immunohistochemistry (Figure 2.4). Due to its high expression of CA-IX, HT-29 cells have also been used by other investigators as a model for the development of CA-IX targeted tracers.
Figure 2.4 CA-IX expression in HT-29 colorectal cancer model. CA-IX expression in cell model was confirmed ex vivo with immunohistochemistry. Scale bar 0.1 mm.

The biodistribution data of $^{18}$F-U-104 (Table 2.1) indicated that the radioactivity was excreted via both renal and hepatobiliary pathways. The uptake in intestines and kidneys at 1 h p.i. were $13.66 \pm 1.23$ and $9.71 \pm 1.68$ %ID/g, respectively. Tumour uptake (%ID/g) of $^{18}$F-U-104 at 1 h p.i. was $0.83 \pm 0.06$ which was lower than blood ($13.92 \pm 3.07$), muscle ($1.19 \pm 0.20$), and major organs except brain ($0.16 \pm 0.01$). High blood uptake of $^{18}$F-U-104 is likely due to the binding to CA-II in erythrocytes. U-104 has good affinity (96 nM) for CA-II and it has been shown that erythrocytes express high level of CA-II$^{181,182}$. Due to minimal uptake of $^{18}$F-U-104 in HT-29 tumours compared to normal tissues/organs, $^{18}$F-U-104 is not suitable for use for CA-IX targeted imaging.

Biodistribution and PET imaging studies of $^{18}$F-FEC showed that the radioactivity was excreted via both renal and hepatobiliary pathways (Table 2.1, Figure 2.5). In vivo defluorination of $^{18}$F-FEC was likely as uptake in bone ($2.09 \pm 0.50$ %ID/g) was higher than the uptake in both blood ($1.54 \pm 0.44$ %ID/g) and muscle ($0.73 \pm 0.13$ %ID/g) at 1 h p.i. Tumour uptake of $^{18}$F-FEC was $1.16 \pm 0.19$ %ID/g at 1 h p.i. The tumours were not visualized from PET image (Figure 2.5) due to low tumour uptake and very high liver uptake ($33.76 \pm 8.31$ %ID/g at 1 h p.i.). The high uptake in the liver was not simply due to the hepatobiliary excretion of $^{18}$F-FEC as the uptake in intestines was low ($3.14 \pm 1.24$ %ID/g) and the uptake in the liver did not decrease over time (Figure 2.6).
Figure 2.5 Representative PET image of $^{18}$F-FEC in HT-29 xenograft mice at 55 min p.i. (Left) PET/CT overlaid image (Right) PET alone. Arrow indicates tumour.

Table 2.1 Biodistribution data (1 h p.i.; $n = 4$) of $^{18}$F-FEC and $^{18}$F-U-104 in NSG mice bearing HT-29 human colorectal tumour xenografts.

<table>
<thead>
<tr>
<th>Tissues/Organs</th>
<th>$^{18}$F-FEC</th>
<th>$^{18}$F-U-104</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood</td>
<td>$1.54 \pm 0.44$</td>
<td>$13.92 \pm 3.07$</td>
</tr>
<tr>
<td>Intestine</td>
<td>$3.14 \pm 1.24$</td>
<td>$13.66 \pm 1.23$</td>
</tr>
<tr>
<td>Stomach</td>
<td>$0.89 \pm 0.46$</td>
<td>$2.94 \pm 2.28$</td>
</tr>
<tr>
<td>Spleen</td>
<td>$1.89 \pm 0.88$</td>
<td>$6.48 \pm 0.74$</td>
</tr>
<tr>
<td>Liver</td>
<td>$33.76 \pm 8.31$</td>
<td>$6.76 \pm 0.22$</td>
</tr>
<tr>
<td>Pancreas</td>
<td>$0.77 \pm 0.10$</td>
<td>$3.33 \pm 0.11$</td>
</tr>
<tr>
<td>Kidney</td>
<td>$6.97 \pm 3.34$</td>
<td>$9.71 \pm 1.68$</td>
</tr>
<tr>
<td>Lungs</td>
<td>$1.18 \pm 0.24$</td>
<td>$5.71 \pm 0.42$</td>
</tr>
<tr>
<td>Heart</td>
<td>$1.16 \pm 0.27$</td>
<td>$3.46 \pm 0.57$</td>
</tr>
<tr>
<td>Muscle</td>
<td>$0.73 \pm 0.13$</td>
<td>$1.19 \pm 0.20$</td>
</tr>
<tr>
<td>Bone</td>
<td>$2.09 \pm 0.50$</td>
<td>$2.52 \pm 0.81$</td>
</tr>
<tr>
<td>Brain</td>
<td>$0.88 \pm 0.16$</td>
<td>$0.16 \pm 0.01$</td>
</tr>
<tr>
<td>Tumour</td>
<td>$1.16 \pm 0.19$</td>
<td>$0.83 \pm 0.06$</td>
</tr>
</tbody>
</table>

Values (%ID/g) are presented as mean $\pm$ SD

A possible explanation for the high uptake of $^{18}$F-FEC in the liver is the metabolic action of 7-ethoxycoumarin O-deethylase (ECOD). ECOD is a family of cytochrome P450 enzymes that metabolize 7-ethoxycoumarin into 7-hydroxycoumarin and acetaldehyde$^{185}$ as depicted in Figure 2.7. ECOD is highly expressed in the liver, and one of the major ECOD is CYP1A2$^{185,186}$. Due to the similarity of 7-ethoxycoumarin and FEC in their structures, it is likely that ECOD
also metabolizes $^{18}$F-FEC into 7-hydroxycoumarin and 2-[${}^{18}$F]fluoroacetaldehyde (Figure 2.7). The radioactive metabolite 2-[${}^{18}$F]fluoroacetaldehyde can be further metabolized into 2-[${}^{18}$F]fluoroacetate which in turn forms 2-[${}^{18}$F]fluoroacetyl CoA and becomes trapped within the cell\textsuperscript{187}. This hypothesis was supported by the high uptake of $^{18}$F-FEC observed in the nasal cavity (Figure 2.5) as olfactory mucosa is the only extrahepatic tissue expressing high level of CYP1A2\textsuperscript{188}. However, more studies are needed to confirm the trapping mechanism of $^{18}$F-FEC in the liver and nasal cavity.

**Figure 2.6** Time-activity curve of $^{18}$F-FEC in tumour and selected organs/tissues. The Y-axis indicates uptake in %ID/g while the X-axis represents time in minutes.

**Figure 2.7** (A) Metabolism of 7-ethoxycoumarin and (B) proposed metabolism of $^{18}$F-FEC by ECOD
2.4 Conclusion

We have synthesized two $^{18}$F-labeled CA-IX inhibitors, $^{18}$F-FEC and $^{18}$F-U-104, and evaluated their potential as CA-IX targeted PET tracers. Both compounds showed good affinity for CA-IX and excellent stability in mouse plasma. However, their uptake in CA-IX-expressing HT-29 tumours was minimal which precludes their application as CA-IX imaging agents. The unexpected trapping of $^{18}$F-FEC in the liver and nasal cavity could be due to the metabolism of $^{18}$F-FEC by ECOD. Once this is confirmed, $^{18}$F-FEC may be potentially used for imaging the expression/activity of ECOD with PET.
Chapter 3: $^{18}$F-labeled Tertiary Substituted Sulfonamides for PET CA-IX Imaging

3.1 Introduction

As exemplified in Chapter 2, the structural and aa conservation shared by CA isoforms is a challenge for the design of CA-IX imaging agents $^{189}$. Structural analyses identified subtle differences in aa composition within the hydrophilic and hydrophobic pockets of the active site which may be exploited to create “CA selective” agents $^{189, 190}$. Towards this end, our collaborator Dr. Claudiu Supuran (Italy) reported a class of fluorinated tertiary substituted sulfonamides that showed strong selectivity for CA-IX without inhibiting the ubiquitously expressed CA-II isoform $^{191}$. In their deprotonated form, sulfonamides bind to the Zn$^{2+}$ ion to displace catalytic H$_2$O while forming a tetrahedral coordination with aa residues around the active site $^{131}$. However, the unique selectivity of these tertiary substituted sulfonamides is attributed to a new but unresolved mode of binding, as these inhibitors do not undergo deprotonation and thus do not bind to the Zn$^{2+}$ ion $^{192}$. We selected three derivatives within this series that were amendable to $[^{18}$F]$\text{fluorination}$ for small animal PET imaging studies (Figure 3.1).

Figure 3.1 Chemical structures of fluorinated tertiary substituted sulfonamides. Three inhibitors were identified by Métayer et al. as potent and specific CA-IX inhibitors $^{191}$.


Joseph Lau$^1$, Jinhe Pan$^1$, Zhengxing Zhang$^1$, Navjit Hundal$^1$, Zhibo Liu$^2$, Francois Benard$^1$, Kuo-Shyan Lin$^1$

$^1$ Department of Molecular Oncology, BC Cancer Research Centre, BC Cancer Agency, Vancouver, BC, Canada
$^2$ Department of Chemistry, University of British Columbia, Vancouver, BC, Canada

JL, FB and KSL designed the study. JL, JP, NH, and ZL were involved in the experiments. JL and JP were involved in acquisition of data and interpretation of the analysis. JL wrote the manuscript.
3.2 Materials and Methods

3.2.1 Chemicals and Instrumentation

Compounds 1a-c were prepared according to previously published procedures\textsuperscript{191}. All other chemicals and solvents were obtained from commercial sources, and used without further purification. Proton NMR spectra were obtained using a Bruker (Billerica, MA, USA) Avance 400inv Spectrometer, and were reported in parts per million downfield from internal tetramethylsilane. Mass analyses were performed using a Bruker Esquire-LC/MS system with ESI ion source. Melting points were taken on a Fisher-Johns melting point apparatus (Fisher Scientific, Pittsburgh, PA) and were uncorrected. Purification and quality control of \textsuperscript{18}F-labeled 4a-c were performed on an Agilent (Santa Clara, CA, USA) HPLC System equipped with a model 1200 quaternary pump, a model 1200 UV absorbance detector, and a Bioscan (Washington DC, USA) NaI scintillation detector. The radio-detector was connected to a Bioscan B-FC-1000 Flow-count system, and the output from the Bioscan Flow-count system was fed into an Agilent 35900E Interface which converted the analog signal to digital signal. The operation of the Agilent HPLC system was controlled using the Agilent ChemStation software. The HPLC columns used were a semi-preparative column (Phenomenex C18, 5 µ, 250 × 10 mm) and an analytical column (Eclipse XOB-C18, 5 µ, 150 × 4 mm). \textsuperscript{18}F-Fluoride was produced by the \textsuperscript{18}O(p, n)\textsuperscript{18}F reaction using an Advanced Cyclotron Systems Inc. (Richmond, BC, Canada) TR19 cyclotron. Radioactivity of \textsuperscript{18}F-labeled 4a-c were measured using a Capintec (Ramsey, NJ, USA) CRC®-25R/W dose calibrator, and the radioactivity of mouse tissues collected from biodistribution studies were counted using a Packard Cobra II 5000 Series auto-gamma counter. PET imaging experiments were conducted using a Siemens (Malvern, PA, USA) Inveon microPET/CT scanner.

3.2.2 Syntheses of Precursors and Standards

3.2.2.1 \textit{N}-(2-hydroxypropyl)-4-methyl-\textit{N}-(4-methylphenyl)benzenesulfonamide (2a)

A solution of 1a (1.22 g, 4.67 mmol), K\textsubscript{2}CO\textsubscript{3} (1.29 g, 9.35 mmol), and propylene oxide (1.4 mL, 20 mmol) in DMF (6 mL) was heated at 80 °C overnight. After cooling to room temperature, the reaction mixture was diluted with water (100 mL), and extracted with ethyl acetate (100 mL).
The ethyl acetate layer was dried with anhydrous MgSO$_4$, concentrated under reduced pressure, and chromatographed on silica gel using 35:65 ethyl acetate/hexane to obtain the desired product 2a as a light brown oil (1.38 g, 92%). $^1$H NMR (CDCl$_3$) $\delta$ 7.50 (d, $J = 8.2$ Hz, 2H, Ar–H), 7.27 (d, $J = 8.2$ Hz, 2H, Ar–H), 7.12 (d, $J = 8.2$ Hz, 2H, Ar–H), 6.95 (d, $J = 8.2$ Hz, 2H, Ar–H), 3.91 – 3.69 (m, 1H, CH), 3.59 (dd, $J = 13.7$, 8.3 Hz, 1H, CH$_2$), 3.36 (dd, $J = 13.7$, 3.5 Hz, 1H, CH$_2$), 2.44 (s, 3H, CH$_3$), 2.35 (s, 3H, CH$_3$), 1.15 (d, $J = 6.3$ Hz, 3H, CH$_3$). MS (ESI) calculated for C$_{17}$H$_{21}$NO$_3$S 319.1, found (M + H)$^+$ 320.3.

3.2.2.2 $N$-(4-Acetylphenyl)-$N$-(2-hydroxypropyl)-4-methylbenzencesulfonamide (2b)

Following similar procedures as described for the preparation of 2a by starting with 1b (1.07 g, 3.69 mmol), K$_2$CO$_3$ (1.02 g, 7.38 mmol), and propylene oxide (1.4 mL, 20 mmol) in DMF (6 mL), 1.25 g (98%) of 2b was obtained as a colourless oil after chromatography on silica gel using 35:65 ethyl acetate/hexane. $^1$H NMR (CDCl$_3$) $\delta$ 7.50 (d, $J = 8.2$ Hz, 2H, Ar–H), 7.27 (d, $J = 8.2$ Hz, 2H, Ar–H), 7.12 (d, $J = 8.2$ Hz, 2H, Ar–H), 6.95 (d, $J = 8.2$ Hz, 2H, Ar–H), 3.91 – 3.69 (m, 1H, CH), 3.59 (dd, $J = 13.7$, 8.3 Hz, 1H, CH$_2$), 3.36 (dd, $J = 13.7$, 3.5 Hz, 1H, CH$_2$), 2.44 (s, 3H, CH$_3$), 2.35 (s, 3H, CH$_3$), 1.15 (d, $J = 6.3$ Hz, 3H, CH$_3$). MS (ESI) calculated for C$_{18}$H$_{21}$NO$_4$S 347.1, found (M + Na)$^+$ 370.1.

3.2.2.3 $N$-(4-Chlorophenyl)-$N$-(2-hydroxypropyl)-4-methylbenzencesulfonamide (2c)

Following similar procedures as described for the preparation of 2a by starting with 1c (1.41 g, 4.14 mmol), K$_2$CO$_3$ (1.14 g, 8.29 mmol), and propylene oxide (1.4 mL, 20 mmol) in DMF (6 mL), 1.40 g (99%) of 2c was obtained as a colourless oil after chromatography on silica gel using 20:80 ethyl acetate/hexane. $^1$H NMR (CDCl$_3$) $\delta$ 7.48 (d, $J = 8.3$ Hz, 2H, Ar–H), 7.38 – 7.20 (m, 4H, Ar–H), 7.12 – 6.94 (m, 2H, Ar–H), 3.90 – 3.71 (m, 1H, CH), 3.58 (dd, $J = 13.8$, 8.1 Hz, 1H, CH$_2$), 3.38 (dd, $J = 13.8$, 3.8 Hz, 1H, CH$_2$), 2.44 (s, 3H, CH$_3$), 1.17 (d, $J = 6.3$ Hz, 3H, CH$_3$). MS (ESI) calculated for C$_{16}$H$_{18}$ClNO$_3$S 339.1, found (M + H)$^+$ 340.2.
3.2.2.4 4-Methyl-N-(4-methylphenyl)-N-(2-tosyloxypropyl)benzenesulfonamide (3a)

A solution of 2a (1.37 g, 4.29 mmol) in CH₂Cl₂ (20 mL) was added sequentially to p-toluenesulfonyl chloride (1.13 g, 5.95 mmol), trimethylamine hydrochloride (410 mg, 4.29 mmol), and diisopropylethylamine (1.42 mL, 8.58 mmol). After stirring at room temperature overnight, the solution was diluted with CH₂Cl₂ (80 mL), washed with 1N HCl (100 mL), and saturated NaHCO₃ aqueous solution (100 mL). The CH₂Cl₂ layer was dried with anhydrous MgSO₄, concentrated under reduced pressure, and chromatographed on silica gel using 25:75 ethyl acetate/hexane to obtain the desired product 3a as a white solid (1.76 mg, 86%), mp: 123-125°C. ¹H NMR (CDCl₃) δ 7.69 (d, J = 8.2 Hz, 2H, Ar–H), 7.39 (d, J = 8.2 Hz, 2H, Ar–H), 7.34 – 7.19 (m, 4H, Ar –H), 7.06 (d, J = 8.2 Hz, 2H, Ar–H), 6.77 (d, J = 8.2 Hz, 2H, Ar–H), 4.76 – 4.53 (m, 1H, CH), 3.67 (dd, J = 13.8, 5.5 Hz, 1H, CH₂), 3.56 (dd, J = 13.8, 7.1 Hz, 1H, CH₂), 2.46 (s, 3H, CH₃), 2.43 (s, 3H, CH₃), 2.34 (s, 3H, CH₃), 1.33 (d, J = 6.3 Hz, 3H, CH₃). MS (ESI) calculated for C₂₄H₂₇NO₅S₂ 473.1, found (M + H)+ 474.2.

3.2.2.5 N-(4-Acetylphenyl)-4-methyl-N-(2-tosyloxypropyl)benzenesulfonamide (3b)

Following similar procedures as described for the preparation of 3a by starting with 2b (380 mg, 1.09 mmol), p-toluenesulfonyl chloride (313 mg, 1.64 mmol), trimethylamine hydrochloride (105 mg, 1.09 mmol), and diisopropylethylamine (0.38 mL, 2.19 mmol), 424 mg (77%) of 3b was obtained as a white solid after chromatographed on silica gel using 30:70 ethyl acetate/hexane. mp: 112-114 °C ¹H NMR (CDCl₃) δ 7.85 (d, J = 8.5 Hz, 2H, Ar–H), 7.67 (d, J = 8.2 Hz, 2H, Ar–H), 7.37 (d, J = 8.2 Hz, 2H, Ar–H), 7.31 (d, J = 8.1 Hz, 2H, Ar–H), 7.24 (d, J = 8.1 Hz, 2H, Ar–H), 7.05 (d, J = 8.5 Hz, 2H, Ar–H), 4.78 – 4.51 (m, 1H, CH), 3.75 (dd, J = 14.2, 5.6 Hz, 1H, CH₂), 3.65 (dd, J = 14.2, 6.5 Hz, 1H, CH₂), 2.61 (s, 3H, CH₃), 2.46 (s, 3H, CH₃), 2.43 (s, 3H, CH₃), 1.32 (d, J = 6.3 Hz, 3H, CH₃). MS (ESI) calculated for C₂₅H₂₇NO₆S₂ 501.1, found (M + H)+ 502.2.

3.2.2.6 N-(4-Chlorophenyl)-4-methyl-N-(2-tosyloxypropyl)benzenesulfonamide (3c)

Following similar procedures as described for the preparation of 3a by starting with 2c (353 mg, 1.04 mmol), p-toluenesulfonyl chloride (297 mg, 1.56 mmol), trimethylamine hydrochloride
(99.3 mg, 1.04 mmol), and diisopropylethylamine (0.36 mL, 2.08 mmol), 416 mg (91%) of 3c was obtained as a white solid after chromatographed on silica gel using 17:83 ethyl acetate/hexane. mp: 150-151 °C. \(^1\)H NMR (CDCl\(_3\)) \(\delta\) 7.67 (d, \(J = 8.2\) Hz, 2H, Ar–H), 7.39 (d, \(J = 8.2\) Hz, 2H, Ar–H), 7.31 (d, \(J = 8.1\) Hz, 2H, Ar–H), 7.27 – 7.18 (m, 4H, Ar–H), 6.84 (d, \(J = 8.7\) Hz, 2H, Ar–H), 4.75 – 4.55 (m, 1H, CH), 3.69 (dd, \(J = 14.1, 5.5\) Hz, 1H, CH\(_2\)), 3.60 (dd, \(J = 14.1, 6.5\) Hz, 1H, CH\(_2\)), 2.46 (s, 3H, CH\(_3\)), 2.43 (s, 3H, CH\(_3\)), 2.34 (s, 3H, CH\(_3\)), 1.33 (d, \(J = 6.3\) Hz, 3H, CH\(_3\)). MS (ESI) calculated for C\(_{23}\)H\(_{24}\)ClNO\(_5\)S\(_2\) 493.1, found (M + H\(^+\)) 494.1.

3.2.2.7 \textit{N-(2-Fluoropropyl)-4-methyl-\textit{N}(4-methylphenyl)benzenesulfonamide (4a)}

A solution of 3a (614 mg, 1.30 mmol) in THF (5 mL) was added to tetrabutylammonium fluoride (1M solution in THF, 3 mL). The resulting solution was heated at 50 °C overnight. After volatile solvent was removed under reduced pressure, the residue was dissolved in diethyl ether (100 mL), and washed with water (100 mL). The diethyl ether layer was dried with anhydrous MgSO\(_4\), concentrated under reduced pressure, and chromatographed on silica gel using 15:85 ethyl acetate/hexane to obtain the desired product 4a as a white solid (27 mg, 6.5%), mp: 64-65°C. \(^1\)H NMR (CDCl\(_3\)) \(\delta\) 7.49 (d, \(J = 8.2\) Hz, 2H, Ar–H), 7.26 (d, \(J = 8.1\) Hz, 2H, Ar–H), 7.11 (d, \(J = 8.1\) Hz, 2H, Ar–H), 6.95 (d, \(J = 8.2\) Hz, 2H, Ar–H), 4.91 – 4.52 (m, 1H, CH), 3.85 – 3.52 (m, 2H, CH\(_2\)), 2.61 (s, 3H, CH\(_3\)), 2.43. MS (ESI) calculated for C\(_{17}\)H\(_{20}\)FNO\(_2\)S 321.1, found (M + H\(^+\)) 322.3.

3.2.2.8 \textit{N-(4-Acetylphenyl)-\textit{N}(2-fluoropropyl)-4-methylbenzenesulfonamide (4b)}

A solution of diethylaminosulfur trifluoride (0.387 mL, 1.78 mmol) in CH\(_2\)Cl\(_2\) (2 mL) was added dropwise to a solution of 2b (310 mg, 0.89 mmol) in anhydrous CH\(_2\)Cl\(_2\) (10 mL). After stirring at room temperature overnight, the solution was diluted with CH\(_2\)Cl\(_2\) (80 mL) and washed with saturated NaHCO\(_3\) aqueous solution (100 mL). The CH\(_2\)Cl\(_2\) layer was dried with anhydrous MgSO\(_4\), concentrated under reduced pressure, and chromatographed on silica gel using 25:75 ethyl acetate/hexane to obtain the desired product 4b as a white solid (73.2 mg, 23%), mp: 97-99°C. \(^1\)H NMR (CDCl\(_3\)) \(\delta\) 7.91 (d, \(J = 8.5\) Hz, 2H, Ar–H), 7.46 (d, \(J = 8.2\) Hz, 2H, Ar–H), 7.34 – 7.12 (m, 4H, Ar–H), 4.98 – 4.60 (m, 1H, CH), 3.90 – 3.60 (m, 2H, CH\(_2\)), 2.61 (s, 3H, CH\(_3\)), 2.43.
3.2.2.9 *N*-({4-Chlorophenyl})-*N*-(2-fluoropropyl)-4-methylbenzenesulfonamide (4c)

Following similar procedures as described for the preparation of 4b by starting with 2c (500 mg, 1.47 mmol) and diethylaminosulfur trifluoride (0.638 mL, 2.94 mmol), 219 mg (44%) of 4c was obtained as a white solid after chromatography on silica gel using 16:84 ethyl acetate/hexane. mp: 73-74 °C 1H NMR (CDCl 3) δ 7.48 (d, J = 8.2 Hz, 2H, Ar–H), 7.32 – 7.22 (m, 4H, Ar –H), 7.01 (d, J = 8.2 Hz, 2H, Ar–H), 4.93 – 4.56 (m, 1H, CH), 3.81 – 3.55 (m, 2H, CH2), 2.44 (s, 3H, CH3), 1.35 (dd, J = 23.7, 6.3 Hz, 3H, CH3). MS (ESI) calculated for C16H17ClFNO2S 341.1, found (M + H)+ 342.2.

3.2.3 Radiosyntheses of [18F]4a-c

The proton-bombarded H2[18O]O was transferred via He gas from the cyclotron target station to a Waters QMA light Sep-Pak cartridge set up in a hot cell. The 18F-fluoride was trapped in the QMA cartridge, and eluted out into a 4-mL V-shaped reaction vial with a mixture of 0.1 mL TBAHCO3 (0.5 M in CH3CN, 0.1 mL), water (0.3 mL) and CH3CN (0.6 mL). The uncapped reaction vial was placed in a heating block, and the solution was heated at 120 °C. After most of the solvents evaporated, CH3CN (1 mL × 2) was added to the reaction vial to facilitate complete removal of water. A solution of tosylate precursor 3a-c (3 mg) in DMF (0.5 mL) was added to the reaction vial. The vial was capped, and the mixture was heated at 125 °C for 20 min. At the end of heating, the mixture was diluted with water (1 mL) and purified by HPLC using the semi-preparative column eluted with 65% CH3CN in water at a flow rate of 4.5 mL/min for [18F]4a and [18F]4c, or 55% CH3CN at a flow rate of 4.5 mL/min for [18F]4b. The retention times of [18F]4a-c were 14.6, 15.2, and 14.9 min, respectively. The eluting fraction containing the desired 18F-labeled tracer was collected, diluted with water (50 mL), and trapped on a Waters tC18 light Sep-Pak cartridge. After washing the tC18 light Sep-Pak cartridge with water (10 mL), 18F-labeled tracer was eluted out with ethanol (0.4 mL), and formulated with saline (4 mL) for plasma stability, biodistribution, and μPET/CT imaging studies. Quality control was performed by HPLC on the analytical column eluted with 65% CH3CN in water at a flow rate of 2.0
mL/min for $[^{18}F]4a$ and $[^{18}F]4c$, and 55% CH$_3$CN in water at a flow rate of 2.0 mL/min for $[^{18}F]4b$. The retention times of $[^{18}F]4a$-$c$ were 7.12, 8.14, and 8.17 min, respectively. The specific activities of $[^{18}F]4a$-$c$ were measured using the analytical HPLC system. It was calculated by dividing the injected radioactivity in 0.2 mL of final $^{18}$F-labeled tracer solution by the mass of the tracer in the injected solution. The mass of the tracer was estimated by comparing the UV absorbance obtained from the injection with a previously prepared standard curve.

### 3.2.4 Stability in Mouse Plasma

100 µL aliquots of $[^{18}F]4a$-$c$ were incubated with 400 µL of BALB/c mouse plasma (available from Innovative Research) for 5, 15, 30, 60, and 120 minutes at 37 °C. At the end of each incubation period, samples were passed through a 0.45 micron filter. The filtered samples were loaded onto the analytical radio-HPLC to check for the presence of metabolite(s), and analyses were conducted with Agilent ChemStation software.

### 3.2.5 LogD$_{7.4}$ Measurements

LogD$_{7.4}$ was determined according to previously published procedures$^{193}$. Briefly, an aliquot of $^{18}$F-labeled tracer was added to a vial containing 2.5 ml of octanol and 2.5 ml of 0.1 M phosphate buffer (pH=7.4). The mixture was vortexed for 2 min and then centrifuged at 5,000 rpm for 2 min. A sample of the octanol (0.1 ml) and buffer (1 ml) layers was taken and counted in a well-type counter. LogD$_{7.4}$ was calculated using the following equation: $\text{LogD}_{7.4} = \log_{10} \left[ \frac{(\text{counts in octanol phase}) \times 10}{(\text{counts in buffer phase})} \right]$. The major portion of the octanol layer (2.0 ml) was diluted with 0.5 ml of octanol and mixed with a fresh portion of 2.5 ml of phosphate buffer. The equilibration procedure described above was repeated until a constant value of LogD$_{7.4}$ was obtained.

### 3.2.6 In Vivo Experiments

Mice were maintained and in vivo experiments were conducted in accordance with the guidelines established by the Canadian Council on Animal Care and approved by the Animal Ethics Committee of the University of British Columbia.
3.2.6.1 Tumour Implantation

All experiments were performed using NOD.Cg-Prkdc<sup>scid</sup>Il2rg<sup>tm1Wjl</sup>/SzJ (NSG) mice bred in-house at the Animal Research Centre, British Columbia Cancer Research Centre, Vancouver, Canada. Mice were anesthetized briefly with 2.5% isoflurane in 2.0 L/min of oxygen during cells implantation. After wiping skin surrounding the injection site with an alcohol prep pad, a 31-Gauge needle was used to subcutaneously implant 5 x 10<sup>6</sup> HT-29 cells (in 100 µL of 1 x PBS and BD Matrigel Matrix at 1:1 ratio) under the right shoulder. Biodistribution studies and PET/CT imaging were performed when tumours reached 5-7mm in diameter.

3.2.6.2 PET Imaging and Biodistribution Studies

Under anesthesia, 3.7-7.4 MBq of <sup>18</sup>F-labeled tracer was administered intravenously through the caudal vein into HT-29 tumour bearing mice (n = 4 per tracer). CT scan was performed before a PET dynamic image sequence of 55 minutes. PET data were acquired in list mode acquisition. At 1 h p.i. mice were euthanized by CO<sub>2</sub> asphyxiation followed by cervical dislocation. Tissues of interest (blood, fat, intestine, stomach, spleen, liver, pancreas, kidney, lung, heart, muscle, bone, brain, and tumour) were harvested. Tissues of interest were rinsed with saline (exception of blood), blotted dry, weighed and counted to determine the percentage of injected dose per gram (%ID/g) of tissue. The PET data were reconstructed using the 3d-OSEM-MAP algorithm with CT-based attenuation correction. 3D regions of interest (ROI) were placed on the reconstructed images to determine the %ID/g of tissue using the Inveon Research Workplace software (IRW).

3.3 Results and Discussion

The synthesis of standards 4a-c and their respective radiolabeling tosylate precursors 3a-c are illustrated in Figure 3.2. The starting sulfonamides 1a-c were prepared according to published procedures<sup>191</sup>. Coupling of sulfonamides 1a-c with excess propylene oxide in DMF in the presence of K<sub>2</sub>CO<sub>3</sub> as base afforded the desired secondary alcohols 2a-c in excellent yield (92-99%). Initially, we attempted to prepare mesylate precursors for radiolabeling. However, we found out that it was difficult to separate the desired mesylates from their respective alcohol
reactants 2a-c by flash column chromatography. Therefore, tosylate precursors were prepared instead as they could be easily separated from respective alcohol reactants 2a-c due to the additional benzene on their structures. By using diisopropylethylamine as the base and trimethylamine hydrochloride as the catalyst\textsuperscript{194}, the reaction of alcohols 2a-c with p-toluenesulfonyl chloride proceeded smoothly in CH$_2$Cl$_2$, and provided the desired tosylate precursors 3a-c in 77-91% yield. Previously, standards 4a-c were prepared by the reaction of HF/SbF$_5$ with their respective N-allylic intermediates\textsuperscript{191}. However, due to safety concern with HF, different strategies for the preparation of standards 4a-c were investigated. For the preparation of 4a, tosylate 3a was refluxed in THF in the presence of excess tetrabutylammonium fluoride (TBAF). However, the yield (6.5%) of desired product 4a was low due to the formation of elimination by-product. Therefore, standards 4b-c were prepared by directly converting alcohols 2b-c to fluorides using diethylamino sulfon trifluoride (DAST), and better yields (23-44%) of 4b-c were obtained.

![Figure 3.2 Syntheses of (A) precursors 3a-c and (B-C) standards 4a-c of tertiary sulfonamide CA-IX inhibitors, and (D) their $^{18}$F-labeled analogs $[^{18}$F]4a-c.](image-url)

\[ \text{A: R = Me} \]
\[ \text{B: R= Ac} \]
\[ \text{C: R = Cl} \]
As illustrated in Figure 3.2 (part D), the radiofluorination of [$^{18}$F]$^4$a-c was performed via aliphatic nucleophilic substitution reactions between tosylate precursors $^3$a-c and TBA[$^{18}$F]F in DMF at 125 °C. After HPLC purification, [$^{18}$F]$^4$a-c were obtained in 7.1 - 43% decay-corrected yields with > 99% radiochemical purity, and > 740 GBq/μmol specific activity at the end of synthesis (~100 min). The stability of [$^{18}$F]$^4$a-c was determined in mouse plasma, and no detectable metabolites of [$^{18}$F]$^4$a-c were observed by HPLC analysis after 2 h incubation at 37 °C. The logD$_{7.4}$ (D: distribution coefficient) values of [$^{18}$F]$^4$a-c were 3.45 ± 0.04, 3.05 ± 0.01, and 3.51 ± 0.27, respectively, as measured using the traditional shake flask method. These values were used to assess if [$^{18}$F]$^4$a-c could cross cell membrane freely, and potentially bind to intracellular off targets CA-I and -II which are expressed abundantly in erythrocytes$^{181,182}$. Since the molecular weights (MW) and logD$_{7.4}$ values of $^4$a-c are in the range of 321-349 Daltons, and 3.05-3.51, respectively, they are likely to be cell permeable according to the Lipinski’s rule of five (MW < 500 and logD$_{7.4}$ < 5)$^{195}$.

Table 3.1 Biodistribution data (1 h p.i.; n = 4) of [$^{18}$F]$^4$a-c in NSG mice bearing HT-29 human colorectal tumour xenografts.

| Tissues/Organs | Radiotracers | | | |
|----------------|-------------|-------------|-------------|
|                | [$^{18}$F]$^4$a | [$^{18}$F]$^4$b | [$^{18}$F]$^4$c |
| Blood          | 0.58 ± 0.49  | 0.37 ± 0.11  | 0.98 ± 0.36  |
| Fat            | 0.76 ± 0.55  | 1.48 ± 0.53  | 0.94 ± 0.51  |
| Intestine      | 7.47 ± 7.46  | 16.7 ± 5.85  | 2.64 ± 0.26  |
| Stomach        | 1.35 ± 2.21  | 1.25 ± 0.98  | 0.40 ± 0.16  |
| Spleen         | 0.68 ± 0.53  | 0.82 ± 0.23  | 0.81 ± 0.35  |
| Liver          | 9.77 ± 8.43  | 3.35 ± 1.72  | 3.57 ± 1.80  |
| Pancreas       | 0.81 ± 0.83  | 0.75 ± 0.26  | 0.61 ± 0.20  |
| Kidney         | 1.68 ± 1.66  | 2.03 ± 0.65  | 2.34 ± 1.04  |
| Lungs          | 1.22 ± 0.90  | 1.46 ± 1.07  | 1.51 ± 0.42  |
| Heart          | 0.59 ± 0.46  | 0.48 ± 0.11  | 0.93 ± 0.38  |
| Muscle         | 0.52 ± 0.47  | 0.51 ± 0.18  | 0.92 ± 0.50  |
| Bone           | 0.91 ± 0.70  | 2.72 ± 0.57  | 12.61 ± 5.18 |
| Brain          | 0.32 ± 0.28  | 0.20 ± 0.06  | 0.33 ± 0.05  |
| Tumour         | 0.51 ± 0.45  | 0.59 ± 0.29  | 0.98 ± 0.48  |

Values (%ID/g) are presented as mean ± SD
To evaluate the potential of $^{18}$F$4a$-$c$ for imaging CA-IX expression, biodistribution and PET imaging studies were performed in mice bearing HT-29 human colorectal tumour xenografts. As shown in Table 3.1, fast blood clearance of $^{18}$F$4a$-$c$ was observed with only 0.58 ± 0.49, 0.37 ± 0.11, and 0.98 ± 0.36 %ID/g, respectively, retained in blood at 1 h p.i. These numbers are substantially lower than the previously reported 13.92 ± 3.07 %ID/g obtained with $^{18}$F-labeled U-104$^{196}$ indicating no significant binding of $^{18}$F$4a$-$c$ to the intracellular off target CA-II. However, the uptake of $^{18}$F$4a$-$c$ in HT-29 tumours did not improve as only 0.51 ± 0.45, 0.59 ± 0.29, and 0.98 ± 0.48 %ID/g, respectively, were observed at 1 h p.i. The majority of $^{18}$F$4a$-$b$ radioactivity was excreted via the hepatobiliary pathway reflecting the lipophilic nature of these two radiotracers. For $^{18}$F$4c$ very high bone uptake (12.61 ± 5.18 %ID/g at 1 h p.i.) was observed which indicated extensive defluorination of $^{18}$F$4c$ in vivo. However, it is unclear at this stage why it was $^{18}$F$4c$ but not $^{18}$F$4b$ that resulted in massive defluorination. Based on their chemical structures, the 4-acetyl group in $4b$ is the most electron-withdrawing group followed by the 4-chloro group in $4c$, and the 4-methyl group in $4a$. Presumably, the 4-acetyl group would make the nitrogen of sulfonamide $4b$ more electron deficient, and the adjacent fluoro a better leaving group, resulting in a higher degree of in vivo defluorination. Although bone uptake of $^{18}$F$4b$ was higher than $^{18}$F$4a$ (2.72 ± 0.57 vs. 0.91 ± 0.70 %ID/g at 1 h p.i.), these numbers were much lower than 12.61 ± 5.18 %ID/g obtained by using $^{18}$F$4c$ suggesting other factors might contribute to the in vivo defluorination of these compounds. Since the uptake of $^{18}$F$4a$-$c$ in HT-29 tumours was not significantly higher than the uptake values in the surrounding tissues (blood, fat, muscle and bone), no clear tumour visualization was obtained from the PET images (Figure 3.3).

Compounds $4a$-$c$ were explored for imaging CA-IX expression in HT-29 tumours because they were reported to have nanomolar binding affinity for CA-IX, and most importantly to be the first sulfonamides to show no interaction with CA-II in CO$_2$ hydration assays (Table 3.2). The binding of $4a$-$c$ to CA-XII could be beneficial as CA-XII, a transmembrane protein, is also up-regulated in hypoxic tumours$^{197}$. Cytosolic CA-I and -II are expressed in large quantities in erythrocytes$^{153, 154}$ and the binding of CA-IX-targeting tracers to CA-I and -II would reduce imaging contrast. Previously, we observed slow blood clearance of $^{18}$F-labeled U-104 presumably due to binding with CA-II ($K_i = 95$ nM, Table 3.1)$^{196}$. In this study, we did not
observe much retention of $[^{18}F]4a$-$c$ in blood at 1 h p.i. despite their suitable physical characteristics (neutral, lipophilic, and with MW < 500 Daltons) to cross cell membrane, and good binding affinity to CA-I ($K_i = 73.1 - 89.1$ nM, Table 3.2). Possible explanations for the low tumour uptake and blood retention of $[^{18}F]4a$-$c$ could be due to relatively fast metabolism and/or blood clearance of these tracers, and in the case of $[^{18}F]4c$, rapid in vivo defluorination.

![Figure 3.3](image)

Figure 3.3 Representative PET maximum intensity projection images of $[^{18}F]4a$-$c$ at 1 h p.i. in NSG mice bearing CA-IX expressing HT-29 human colorectal tumour xenografts. Arrows indicate location of the tumours.

Although no small sulfonamide-based radiotracers have been reported to visualize CA-IX-expressing tumours in preclinical imaging studies, a successful optical imaging probe HS680 is already commercially available. HS680, a conjugate of acetazolamide and the near-infrared fluorochrome VivoTag 680 developed by PerkinElmer, showed impressive 10% injected dose accumulation in HT-29 tumour xenografts in mice at 24 h p.i.163. Acetazolamide is a promiscuous CA inhibitor, and therefore the derivatives of acetazolamide including HS680 are expected to have good binding affinity to most CAs including the intracellular isoenzymes I and II (Table 3.2). However, the conjugation of acetazolamide with the highly charged and bulky
(MW > 1,000 Daltons) VivoTag 680 prevents it from crossing the cell membrane and binding to intracellular off targets. The success of HS680 could be a valuable lesson for the future design of radiotracers for imaging CA-IX expression with PET or SPECT. Instead of radiolabeling CA-IX-specific inhibitors which may be difficult to synthesize, the design of cell-impermeable sulfonamide-based radiotracers represents an easier and quicker solution. This could be achieved, for example, by conjugating the CA-targeting sulfonamide moiety with a polyaminocarboxylate chelator for labeling with radiometal such as $^{68}$Ga, $^{64}$Cu, or $^{111}$In for imaging. The radiometal-polyaminocarboxylate-chelator complexes are generally highly hydrophilic and charged, and would prevent the radiolabeled sulfonamide conjugates from entering cells. Another promising alternative is the use of a multivalent design. This approach combines several CA-targeting sulfonamides into one single molecule, which could potentially enhance binding affinity to CA-IX and afford cell impermeability from accumulation of MW.

Table 3.2 Reported inhibition constants ($K_i$, nM) of acetazolamide$^{178}$, HS680$^{162}$, U-104$^{178}$, and tertiary sulfonamides $4a$-$c$\textsuperscript{191} to human CA isoenzymes I, II, IX and XII.

<table>
<thead>
<tr>
<th>Compounds</th>
<th>CA-I</th>
<th>CA-II</th>
<th>CA-IX</th>
<th>CA-XII</th>
</tr>
</thead>
<tbody>
<tr>
<td>acetazolamide</td>
<td>250</td>
<td>12</td>
<td>25</td>
<td>5.7</td>
</tr>
<tr>
<td>HS680</td>
<td>-</td>
<td>248</td>
<td>7.5</td>
<td>35</td>
</tr>
<tr>
<td>U-104</td>
<td>5,080</td>
<td>95</td>
<td>45</td>
<td>4.5</td>
</tr>
<tr>
<td>$4a$ (R = Me)</td>
<td>73.1</td>
<td>Not active</td>
<td>9.3</td>
<td>33.6</td>
</tr>
<tr>
<td>$4b$ (R = Ac)</td>
<td>89.1</td>
<td>Not active</td>
<td>9.6</td>
<td>83.8</td>
</tr>
<tr>
<td>$4c$ (R = Cl)</td>
<td>77.3</td>
<td>Not active</td>
<td>9.1</td>
<td>100</td>
</tr>
</tbody>
</table>

Errors in the range of 5-10% of the reported value from three different assays.

### 3.4 Conclusion

In conclusion, we successfully synthesized and radiolabeled tertiary benzenesulfonamides $4a$-$c$, and evaluated their potential as CA-IX imaging agents. Despite their good affinity and selectivity for CA-IX, imaging and biodistribution data showed only minimal tumour uptake in xenograft mice relative to normal tissues. Therefore, $[^{18}\text{F}]4a$-$c$ are not suitable for CA-IX targeted molecular imaging.
Chapter 4: Multivalent Approach to Achieve In Vivo Selectivity for CA-IX

4.1 Introduction

The application of small molecule inhibitors as PET tracers can be challenged by several effects such as non-specific uptake in cells, poor clearance from blood\(^\text{198}\), and rapid metabolic defluorination with accompanying bone uptake\(^\text{199, 200}\). In addition, \(^{18}\text{F}\)-labeling in high yield and at high specific activity often presents a significant challenge in the development of new PET tracers\(^\text{201}\). Yet even when conditions for clinically useful radiolabeling have been met, non-specific uptake due to association with off-target enzyme isoforms of greater abundance can result in images marked by low tumour to background ratios. Lipophilicity can also enhance non-specific uptake in some cases. As shown in Chapters 2 and 3, the development of CA-IX targeting agents can be hindered by a combination of these factors.

We hypothesized that a multivalent enzyme inhibitor would restrict intracellular accumulation and enhance specific binding to an extracellular tumour target. To accomplish this, we utilized a radiosynthon that readily enables grafting of various ligands to a pentaerythritol core while allowing for facile radiolabeling at high specific activity with Curie-levels of \(^{18}\text{F}\)-activity. Recently, we communicated this method for linking both peptides and small molecule inhibitors in a trivalent motif\(^\text{202}\). Here we expand the application of this method to address the imaging potential of two related enzyme inhibitors and report detailed findings on how this method can be used to reduce nonspecific intracellular accumulation.
Our previous attempt using $^{18}$F-U-104 resulted in very high uptake in blood (13.97 ± 3.07 %ID/g at 1 h p.i.)$^{196}$ presumably due to the binding of $^{18}$F-U-104 to intracellular off-targets CA-I and CA-II that are abundant in erythrocytes$^{203}$. We hypothesized that cell-impermeant tracers would disfavor binding to intracellular CA isoforms, and in turn provide high contrast images. To do this we sought multivalent inhibitors to increase both avidity and molecular weight. In the present study, we synthesized and evaluated two monomeric (as controls) and two trimeric $^{18}$F-labeled sulfonamides using 4-(2-aminoethyl)benzenesulfonamide (AEBS) and 4-aminobenzensulfonamide (ABS) as our pharmacophores for imaging CA-IX expression with PET (Figure 4.1). In terms of a radioprosthetic group, we chose the zwitterionic organotrifluoroborate$^{202}$, the polarity of which would likely further reduce lipophilicity and membrane permeability.
4.2 Methods and Materials

AmBF$_3$-conjugated alkyne $3^{204}$, AmBF$_3$-conjugated alkyne $4^{205}$, and 2-chloro-N-(4-sulfamoyl-phenyl)-acetamide$^{206}$ were prepared according to published procedures. Other chemicals were obtained from commercial sources, and used without further purification. $^{18}$F-fluoride Trap & Release columns were purchased from ORTG Inc. (Oakdale, TN). C18 light Sep-Pak cartridges (1cc, 50 mg) were obtained from Waters (Milford, MA). BALB/c mouse plasma was obtained from Innovative Research (Novi, MI). Mass analyses were performed using a Bruker (Billerica, MA) Esquire-LC/MS system with ESI ion source. Purification and quality control of cold and $^{18}$F-labeled sulfonamides were performed on an Agilent HPLC system equipped with a model 1200 quaternary pump, a model 1200 UV detector, and a Bioscan (Washington, DC) NaI scintillation detector. The radio-detector was connected to a Bioscan B-FC-1000 Flow-count system, and the output from the Bioscan Flow-count system was fed into an Agilent 35900E interface which converted the analog signal to digital signal. Operation of the Agilent HPLC system was controlled using the Agilent ChemStation software. Radioactivity of $^{18}$F-labeled tracers was measured using a Capintec (Ramsey, NJ) CRC®-25R/W dose calibrator, and the radioactivity of mouse tissues collected from biodistribution studies were counted using a Packard (Meriden, CT) Cobra II 5000 Series auto-gamma counter.
4.2.1 HPLC Analysis

The following table lists the different HPLC conditions used during purification, QC and plasma stability assays.

<table>
<thead>
<tr>
<th>Condition</th>
<th>Column</th>
<th>Solvent system (containing 0.1% TFA)</th>
<th>Flow rate (mL/min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Phenomenex Luna C18, 5 µm, 10 × 250 mm semi-prep</td>
<td>11% CH₃CN in water</td>
<td>4.5</td>
</tr>
<tr>
<td>B</td>
<td>Phenomenex Luna C18, 5 µm, 10 × 250 mm semi-prep</td>
<td>10% CH₃CN in water</td>
<td>4.5</td>
</tr>
<tr>
<td>C</td>
<td>Agilent Eclipse XDB-C18, 5 µm, 9.2 × 250 mm semi-prep</td>
<td>0 to 5 min, 5 to 25% CH₃CN in water; 5 to 15 min, 25 to 45% CH₃CN in water</td>
<td>3.0</td>
</tr>
<tr>
<td>D</td>
<td>Agilent Eclipse XDB-C18, 5 µm, 9.2 × 250 mm semi-prep</td>
<td>0 to 5 min, 10 to 20% CH₃CN in water; 5 to 15 min, 20 to 60% CH₃CN in water</td>
<td>3.0</td>
</tr>
<tr>
<td>E</td>
<td>Phenomenex Luna C18, 5 µm, 4.6 × 250 mm analytical</td>
<td>13% CH₃CN in water</td>
<td>2.0</td>
</tr>
<tr>
<td>F</td>
<td>Phenomenex Luna C18, 5 µm, 4.6 × 250 mm analytical</td>
<td>11% CH₃CN in water</td>
<td>2.0</td>
</tr>
<tr>
<td>G</td>
<td>Phenomenex Jupiter, 10 µm, C18 4.6 × 250 mm analytical</td>
<td>0 to 2 min, 5% CH₃CN in water; 2 to 7 min, 5 to 20% CH₃CN in water; 7 to 15 min, 20% CH₃CN in water to 100% CH₃CN</td>
<td>2.0</td>
</tr>
<tr>
<td>H</td>
<td>Phenomenex Luna C18, 5 µm, 10 × 250 mm semi-prep</td>
<td>14% CH₃CN in water</td>
<td>4.5</td>
</tr>
<tr>
<td>I</td>
<td>Phenomenex Luna C18, 5 µm, 10 × 250 mm semi-prep</td>
<td>12% CH₃CN in water</td>
<td>4.5</td>
</tr>
</tbody>
</table>

4.2.2 Synthesis of Azidoacetyl-AEBS (1)

A solution of azidoacetic acid (101 mg, 1.0 mmol), 1,3-dicyclohexylcarbodiimide (248 mg, 1.2 mmol) and N-hydroxysuccinimide (138 mg, 1.2 mmol) in DMF (2 mL) was stirred at room temperature for 1 h. After filtration, AEBS (220 mg, 1.1 mmol) in DMF (1 mL) was added. The resulting solution was stirred at room temperature overnight, diluted with water (25 mL), and extracted with DCM (125 mL). The organic layer was dried with anhydrous MgSO₄, concentrated under reduced pressure, and chromatographed on silica gel using 9:1 ethyl acetate/hexane to obtain the desired product as a white solid (210 mg, 74%). ESI-MS: calculated
for azidoacetyl-AEBS 1 C₁₀H₁₃N₅O₃S 283.07, found [M+H]^+ 284.07. \(^1\)H-NMR (CD₂CN-D₂O): δ 2.85 (t, 3.7 Hz, 2H), 3.47 (m, 4.4 Hz, 2H), 5.67 (s, 2H), 7.43 (d, 7.5 Hz, 2H), 7.78 (d, 7.5 Hz, 2H).

4.2.3 Synthesis of Azidoacetyl-ABS (2)

A mixture of 2-chloro-N-(4-sulfamoyl-phenyl)-acetamide (353 mg, 1.4 mmol) and sodium azide (102 mg, 1.6 mmol) in DMSO (5 mL) was stirred at room temperature overnight. The reaction mixture was diluted with water (12.5 mL) and extracted with ether (75 mL). The organic layer was dried with anhydrous MgSO₄, concentrated under reduced pressure, and recrystallized with water to obtain the desired product as a white solid (313 mg, 60%). ESI-MS: calculated for azidoacetyl-ABS 2 C₈H₉N₅O₃S 255.04, found [M+H]^+ 256.04. \(^1\)H-NMR (DMSO-d₆): δ 4.07 (s, 2H), 7.25 (s, 2H), 7.75 (m, 4H), 10.5 (s, 1H).

4.2.4 Synthesis of AmBF₃-AEBS

A 1.5-mL Eppendorf tube was loaded with AmBF₃-conjugated alkyne 3 (10 mg, 61 µmol), azidoacetyl-AEBS 1 (10 mg, 35 µmol), aqueous CuSO₄ (1.0 M, 56.3 µL), sodium ascorbate (1.0 M, 140.7 µL) and DMF (150 µL). This mixture was allowed to react at 45 °C for 2 h and then purified by HPLC (Condition A, \(t_R = 22.3\) min) to obtain AmBF₃-AEBS in 41% yield. ESI-MS: calculated for AmBF₃-AEBS C₁₆H₂₄BF₃N₆O₃S 448.2, found [M+Na]^+ 471.2. \(^1\)H-NMR (DMSO-d₆): δ 2.23 (m, 2H), 2.50 (m, 2H), 2.82 (t, 7.1 Hz, 2H), 2.93 (s, 6H), 4.53 (s, 2H), 5.16 (s, 2H), 7.31 (s, 2H), 7.41 (d, 8.3 Hz, 2H), 7.75 (d, 8.3 Hz, 2H), 8.30 (s, 1H), 8.48 (t, 5.5 Hz, 1H).

4.2.5 Synthesis of AmBF₃-ABS

A 1.5-mL Eppendorf tube was loaded with AmBF₃-conjugated alkyne 3 (10 mg, 61 µmol), azidoacetyl-ABS 2 (10 mg, 39 µmol), aqueous CuSO₄ (1.0 M, 62.7 µL), sodium ascorbate (1.0 M, 156.8 µL) and DMF (150 µL). This mixture was allowed to react at 45 °C for 2 h and then purified by HPLC (Condition B, \(t_R = 22.1\) min) to obtain AmBF₃-ABS in 40% yield. ESI-MS: calculated for AmBF₃-ABS C₁₄H₂₀BF₃N₆O₃S 420.1, found [M+Na]^+ 443.2. \(^1\)H-NMR (DMSO-
$d_3$: δ 2.24 (m, 2H), 2.95 (s, 6H), 4.57 (s, 2H), 5.47 (s, 2H), 7.27 (s, 2H), 7.76 (q, 8.0 Hz, 9.0 Hz, 4H), 8.41 (s, 1H), 10.86 (s, 1H).

4.2.6 Synthesis of AmBF$_3$-(AEBS)$_3$

A 1.5-mL Eppendorf tube was loaded with AmBF$_3$-conjugated alkyne 4 (5 mg, 12.3 µmol), azidoacetyl-AEBS 1 (12.1 mg, 44 µmol), aqueous CuSO$_4$ (1.0 M, 5 µL), sodium ascorbate (1.0 M, 12.5 µL) and 5% NH$_4$OH (in 1:1 CH$_3$CN/H$_2$O, 50 µL). This mixture was allowed to react at 45 °C for 2 h and then purified by HPLC (Condition C, $t_R = 12.8$ min) to obtain AmBF$_3$-(AEBS)$_3$ in 47% yield. ESI-MS: calculated for AmBF$_3$-(AEBS)$_3$ C$_{49}$H$_{68}$BF$_3$N$_{16}$O$_{13}$S$_3$ 1252.44, found [M+H]$^+$ 1253.49. $^1$H-NMR (CD$_3$CN-D$_2$O): δ 2.71 (s, 2H), 2.88 (m, 8H), 3.17 (s, 6H), 3.47 (q, 4.4 Hz, 6H), 3.63 (t, 2.7 Hz, 2H), 3.80 (s, 8H), 4.19 (s, 6H), 5.67 (s, 6H), 7.43 (d, 7.4 Hz, 2H), 7.78 (d, 7.4 Hz, 2H).

4.2.7 Synthesis of AmBF$_3$-(ABS)$_3$

A 1.5-mL Eppendorf tube was loaded with AmBF$_3$-conjugated alkyne 4 (5 mg, 12.3 µmol), azidoacetyl-ABS 2 (11.0 mg, 44 µmol), aqueous CuSO$_4$ (1.0 M, 5 µL), sodium ascorbate (1.0 M, 12.5 µL) and 5% NH$_4$OH (in 1:1 CH$_3$CN/H$_2$O, 50 µL). The mixture was allowed to react at 45 °C for 2 h, and then purified by HPLC (Condition D, $t_R = 13.1$ min) to obtain AmBF$_3$-(ABS)$_3$ in 55% yield. ESI-MS: calculated for AmBF$_3$-(ABS)$_3$ C$_{43}$H$_{56}$BF$_3$N$_{16}$O$_{13}$S$_3$ 1168.34, found [M+H]$^+$ 1169.40 $^1$H-NMR (CD$_3$CN-D$_2$O): δ 4.16 (s, 6H), 4.30 (s, 2H), 4.61 (m, 4H), 4.72 (s, 8H), 5.77 (s, 6H), 6.54 (s, 6H), 8.94 (d, 9.0 Hz, 6H), 9.03 (d, 9.0 Hz, 6H), 9.16 (s, 3H).

4.2.8 Binding Affinity Measurements

Inhibition constants ($K_i$) of AmBF$_3$-AEBS, AmBF$_3$-ABS, and AmBF$_3$-(AEBS)$_3$ and AmBF$_3$-(ABS)$_3$ for CA-I, -II, -IX and -XII were determined using the CA catalyzed CO$_2$ hydration stopped-flow assays following published procedures.$^{178}$

55
4.2.9 Radiolabeling

100-150 nmol of $^{19}$F-AmBF$_3$-AEBS, $^{19}$F-AmBF$_3$-ABS, $^{19}$F-AmBF$_3$-(AEBS)$_3$ or $^{19}$F-AmBF$_3$-(ABS)$_3$ was resuspended with aqueous pyridazine-HCl buffer (15-20 µL, 1M, pH = 2) and DMF (15-20 µL) in a polypropylene tube. No carrier-added $^{18}$F-fluoride was obtained by bombardment of H$_2^{18}$O with 18 MeV protons, followed by trapping on an anion exchange column (9 mg, QMA, chloride form). The $^{18}$F-fluoride was eluted off with saline (100 µL) into the reaction vial. The reaction mixture was heated at 80 °C for 20 min, and quenched with 5% aqueous NH$_4$OH (2 mL). The quenched solution was loaded onto a C18 light Sep-Pak cartridge. $^{18}$F-Fluoride was removed by washing the cartridge with DI water (5 mL × 2). $^{18}$F-AmBF$_3$-AEBS, $^{18}$F-AmBF$_3$-ABS, $^{18}$F-AmBF$_3$-(AEBS)$_3$ or $^{18}$F-AmBF$_3$-(ABS)$_3$ was eluted off the cartridge with 0.5 mL 4:1 ethanol/saline and diluted with saline (5 mL) for stability and biodistribution/imaging studies. Samples were removed for QC analysis by HPLC using Condition E for $^{18}$F-AmBF$_3$-AEBS ($t_R = 8.0$ min), Condition F for $^{18}$F-AmBF$_3$-ABS ($t_R = 7.9$ min), or Condition G for $^{18}$F-AmBF$_3$-(AEBS)$_3$ ($t_R = 12.4$ min) and $^{18}$F-AmBF$_3$-(ABS)$_3$ ($t_R = 11.9$ min).

4.2.10 Stability in Mouse Plasma

20 µL of $^{18}$F-AmBF$_3$-AEBS, $^{18}$F-AmBF$_3$-ABS, $^{18}$F-AmBF$_3$-(AEBS)$_3$ or $^{18}$F-AmBF$_3$-(ABS)$_3$ was added to mouse plasma (500 µL) and incubated at 37 °C for 2 h. The reaction was quenched by adding 1 mL CH$_3$CN to the plasma solution. The quenched solution was centrifuged, and the supernatant was collected, filtered and analyzed by HPLC using Condition H for $^{18}$F-AmBF$_3$-AEBS ($t_R = 13.0$ min), Condition I for $^{18}$F-AmBF$_3$-ABS ($t_R = 15.4$ min), or Condition G for $^{18}$F-AmBF$_3$-(AEBS)$_3$ ($t_R = 12.4$ min) and $^{18}$F-AmBF$_3$-(ABS)$_3$ ($t_R = 11.9$ min).

4.2.11 LogD$_{7.4}$ measurements

An aliquot of $^{18}$F-AmBF$_3$-AEBS, $^{18}$F-AmBF$_3$-ABS, $^{18}$F-AmBF$_3$-(AEBS)$_3$ or $^{18}$F-AmBF$_3$-(ABS)$_3$ was added to a Falcon tube containing 4 mL of octanol and 1.5 mL of phosphate buffer (0.1 M, pH = 7.4). The mixture was vortexed for 2 min and centrifuged at 5,000 rpm for 2 min. Samples of the octanol (3.5 mL) and buffer (1 mL) layers were taken and counted. LogD$_{7.4}$ was calculated using the following equation: LogD$_{7.4} = \log_{10}[(\text{counts in octanol phase/3.5})/(\text{counts in buffer}]$. 

56
phase)]. The major portion of the phosphate buffer layer (1 mL) was diluted with 0.5 mL of phosphate buffer and mixed with octanol (4 mL). The equilibration procedure described above was repeated until a constant value of LogD$_{7.4}$ was obtained.

4.2.12 In Vivo Experiments

4.2.12.1 Cell Line and Animal Model

All animal studies were performed in accordance with the Canadian Council on Animal Care guidelines and approved by the Animal Care Committee of the University of British Columbia. HT-29 human colorectal cancer cells were obtained as a gift from Dr. Donald Yapp (BC Cancer Research Centre, Vancouver, Canada). HT-29 cells were cultured in Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin-streptomycin, and non-essential amino acids. Male NOD.Cg-Prkdcsid Il2rg$^{m1Wjl}$/SzJ (NSG) mice bred in-house at the Animal Research Centre, BC Cancer Research Centre were used. Mice were subcutaneously inoculated with $5 \times 10^6$ HT-29 cells in the right dorsal flank. Biodistribution studies and PET/CT imaging were performed when tumours reached 7-9 mm in diameter.

4.2.12.2 Biodistribution Studies

Tumour bearing mice were injected with $\sim 0.37$ MBq of $^{18}$F-labeled tracer (100 – 200 µL in saline, i.v.). For blocking experiments, mice were intravenously pre-injected with 10 mg/kg acetazolamide 1 h (100 – 200 µL in saline, i.v.) before administering the radiotracer. After an uptake period of 0.5, 1, or 2 h, mice were euthanized by CO$_2$ asphyxiation. Blood was promptly withdrawn, and organs/tissues of interest were harvested, rinsed with saline, blotted dry and weighed. Radioactivity in collected tissues was counted, normalized to the injected dose and expressed as the percentage of the injected dose per gram of tissue (%ID/g).

4.2.12.3 PET/CT Imaging

Imaging experiments were performed using a Siemens (Erlangen, Germany) Inveon micro PET/CT scanner. Tumour bearing mice were injected with $\sim 3.7$ MBq of $^{18}$F-labeled tracer (100 – 200 µL in saline, i.v.). For blocking experiments, mice were intravenously pre-injected with 10
mg/kg acetazolamide 1 h (100 – 200 µL in saline, i.v.) before administering the radiotracer. At 0.5, 1, or 2 h p.i., a 10-min PET acquisition scan was performed, which was preceded by a 10-min CT scan. Body temperature of mice was maintained at 37 °C with the use of thermal pads. PET data were acquired in list mode acquisition, reconstructed using the 3d-OSEM-MAP algorithm with CT-based attenuation correction, and co-registered for alignment. At the conclusion of the imaging study, mice were euthanized and processed for biodistribution as described above.

4.2.12.4 Data Analysis

All statistics were performed using Prism 6 software (GraphPad). For Table 4.3, $P$ values for the difference of tracer uptake in mouse tissues between unblocked and blocked groups were calculated using a Student’s $t$-test (unpaired, one-tailed) and values < 0.05 were considered statistically significant. For Figure 4.4, $P$ values for the difference of tumour/muscle ratios between monomer and trimer were calculated using a Student’s $t$-test (unpaired, two-tailed) and values < 0.05 were considered statistically significant.

4.3 Results and Discussion

The highly conserved catalytic domain of CA isoforms represents a major challenge for the design of CA-IX selective imaging agents\textsuperscript{131}. Off-target binding to intracellular CAs can significantly reduce tumour binding and image contrast\textsuperscript{203}. Strategies to confer CA-IX selectivity for small molecule inhibitors have focused on limiting transport across the plasma membrane. These include incorporating bulky entities like FITC, albumin-binders, sugar derivatives, or charged species to CA targeting pharmacophores\textsuperscript{207-211}. Based on these findings, we initiated the development of multivalent PET tracers for imaging CA-IX expression in tumours.

Previously, our group reported the synthesis of a dual-mode imaging agent by coupling rhodamine and cycloRGD to an AmBF$_3$-conjugated alkyne\textsuperscript{4} amendable for $^{18}$F-labeling\textsuperscript{212}. Using the modular adaptability of this synthon, we coupled three AEBS/ABS moieties via copper-catalyzed azide alkyne cycloaddition to target CA-IX expression. To the best of our knowledge, there are few examples of such multimeric inhibitors that have been labeled for
imaging and none has been labeled with $^{18}$F nor used to visualize tumour-associated CA-IX activity. For comparison and as controls, we coupled AEBS/ABS to AmBF$_3$-conjugated alkyne 3 to synthesize monovalent tracers to determine if trimerization is essential to selectively target CA-IX in vivo.

The preparation of non-radioactive $^{19}$F-AmBF$_3$-AEBS, $^{19}$F-AmBF$_3$-ABS, $^{19}$F-AmBF$_3$-(AEBS)$_3$, and $^{19}$F-AmBF$_3$-(ABS)$_3$ followed synthetic schemes as shown in Figure 4.2. Azidoacetyl-AEBS 1 was obtained in 74% yield by coupling AEBS with azidoacetic acid, whereas azidoacetyl-ABS 2 was prepared in 60% yield by the displacement of the chloro group of 2-chloro-N-(4-sulfamoyl-phenyl)-acetamide with azide. The coupling of 1 and 2 to AmBF$_3$-conjugated alkyne 3 via the Cu$^+$-catalyzed click reaction afforded the desired AmBF$_3$-AEBS and AmBF$_3$-ABS in 41 and 40% yields, while coupling to alkyne 4 generated AmBF$_3$-(AEBS)$_3$ and AmBF$_3$-(ABS)$_3$ in 47 and 55% yields, respectively.

![Figure 4.2](image-url)

Figure 4.2 Synthesis of (A) azidoacetyl-AEBS 1, (B) azidoacetyl-ABS 2, (C) AmBF$_3$-AEBS and AmBF$_3$-ABS, and (D) AmBF$_3$-(AEBS)$_3$ and AmBF$_3$-(ABS)$_3$. 
The binding affinities of the synthesized compounds to CA-I, -II, -IX and -XII are summarized in Table 4.2. Whereas more specific inhibitors can be designed to enhance selectivity to CA-IX, we sought to test the use of a trivalent scaffold with very simple and rather non-specific inhibitors to demonstrate that in vivo selectivity can be generated simply by altering cell-permeability of the tracer to reduce uptake in blood. AEBS and ABS are known to inhibit CA-IX; however, they by themselves lack isoform selectivity. According to literature, the $K_i$ values of AEBS and ABS for CA-IX are 33 and 294 nM, respectively\textsuperscript{213-215}. For reasons unknown, incorporation of AEBS or ABS into AmBF$_3$-conjugated radiosynthons resulted in consistent or significantly improved binding affinities for CA-IX. AmBF$_3$-AEBS and AmBF$_3$-ABS exhibited binding affinities of 8.0 and 6.6 nM, while AmBF$_3$-(AEBS)$_3$ and AmBF$_3$-(ABS)$_3$ had binding affinities of 35.7 and 8.5 nM. Despite retaining good binding affinity to CA-I and –II, the in vivo binding of bulky $^{18}$F-AmBF$_3$-(AEBS)$_3$ and $^{18}$F-AmBF$_3$-(ABS)$_3$ to these two intracellular off-target CA isoforms is highly unlikely. Trimerization of AEBS and ABS to form AmBF$_3$-(AEBS)$_3$ and AmBF$_3$-(ABS)$_3$ respectively, affords cell-impermeability due to the high molecular weight (> 1 kDa). On the other hand, the high binding affinity of AmBF$_3$-(AEBS)$_3$ and AmBF$_3$-(ABS)$_3$ to CA-XII is advantageous as CA-XII is also found up-regulated in hypoxic tumours\textsuperscript{216}.

\begin{table}[h]
\centering
\begin{tabular}{lcccc}
\hline
\textbf{Compound} & \textbf{$K_i$ (nM)} \\
& \textbf{CA-I} & \textbf{CA-II} & \textbf{CA-IX} & \textbf{CA-XII} \\
\hline
AmBF$_3$-AEBS & 137 & 27.5 & 8.0 & 0.76 \\
AmBF$_3$-ABS & 65.6 & 59.8 & 6.6 & 0.49 \\
AmBF$_3$-(AEBS)$_3$ & 34.8 & 26.5 & 35.7 & 8.6 \\
AmBF$_3$-(ABS)$_3$ & 100.3 & 8.6 & 8.5 & 8.6 \\
Acetazolamide & 250 & 12 & 25 & 6.0 \\
\hline
\end{tabular}
\caption{Inhibition constants of $^{18}$F-AmBF$_3$-sulfonamides to human CA isoenzymes I, II, IX and XII.}
\end{table}

Errors in the range of ± 5% of the reported data from three different assays

We used the facile $^{18}$F-$^{19}$F isotopic exchange reaction on AmBF$_3$-bioconjugates for the preparation of tracers (Figure 4.3)\textsuperscript{202}. Features of this radiolabeling strategy include: one-step synthesis without azeotropic drying, good radiochemical yields, high purity, specific activity and
in vitro/vivo stability, and relative ease of purification without HPLC. This approach for \(^{18}\text{F}\)-labeling has been successfully applied to RGD and somatostatin analogs for cancer imaging. Starting with 23.3 – 38.5 GBq of \(^{18}\text{F}\)-fluoride, \(^{18}\text{F}\)-AmBF\(_3\)-AEBS, \(^{18}\text{F}\)-AmBF\(_3\)-ABS, \(^{18}\text{F}\)-AmBF\(_3\)-(AEBS)\(_3\), and \(^{18}\text{F}\)-AmBF\(_3\)-(ABS)\(_3\) were obtained in 24.8 ± 2.2%, 26.4 ± 10.2%, 28.0 ± 3.5% and 26.9 ± 5.6% nondecay-corrected radiochemical yields (\(n = 3\)) with corresponding specific activities of 185 ± 22, 141 ± 11, 66 ± 9, and 49 ± 12 GBq/µmol, respectively. After C18 Sep-Pak purification, > 95% radiochemical purity was obtained for all tracers based on HPLC radio-chromatograms. These radiosynthesis data (radiochemical yield and specific activity) are comparable with those previously reported for other AmBF\(_3\)-conjugates.
Figure 4.3 Radiosynthesis of (A) $^{18}$F-AmBF$_3$-AEBS and $^{18}$F-AmBF$_3$-ABS, and (B) $^{18}$F-AmBF$_3$-(AEBS)$_3$ and $^{18}$F-AmBF$_3$-(ABS)$_3$ via $^{18}$F-$^{19}$F isotope exchange reaction.
To assess stability, tracers were incubated in mouse plasma and analyzed by HPLC. No metabolites of $^{18}$F-AmBF$_3$-AEBS, $^{18}$F-AmBF$_3$-ABS, $^{18}$F-AmBF$_3$-(AEBS)$_3$, and $^{18}$F-AmBF$_3$-(ABS)$_3$ were observed after 2 h incubation at 37 °C. Using shake flask extraction method, the LogD$_{7.4}$ values of $^{18}$F-AmBF$_3$-AEBS, $^{18}$F-AmBF$_3$-ABS, $^{18}$F-AmBF$_3$-(AEBS)$_3$, and $^{18}$F-AmBF$_3$-(ABS)$_3$ were measured to be -1.9, -1.8, -2.1 and -2.5, respectively.

For in vivo evaluations, studies were conducted with immunodeficient mice inoculated with HT-29 human colorectal cancer cells. HT-29 cells express high levels of CA-IX under hypoxic conditions$^{217}$. Biodistribution (Table 4.3) showed that tracers cleared rapidly through the hepatobiliary and renal pathways. At 1 h p.i., $^{18}$F-AmBF$_3$-AEBS and $^{18}$F-AmBF$_3$-ABS had higher tumour accumulation (0.56 ± 0.11 and 0.64 ± 0.08 %ID/g) than their trimeric counterparts (0.30 ± 0.10 and 0.33 ± 0.07 %ID/g); however tumour-to-background ratios were substantially lower (Figure 4.4). Most importantly, tumour-to-blood ratios were 1.01 ± 0.25 and 1.24 ± 0.12 for $^{18}$F-AmBF$_3$-AEBS and $^{18}$F-AmBF$_3$-ABS, respectively, suggesting that both tracers may have bound intracellular CAs in blood. Although monomers may be more pertinent for traversing through aberrant tumour vasculature and binding to CA-IX, they appear to be unable to differentiate between CA isoforms. In regards to the trimers, $^{18}$F-AmBF$_3$-(ABS)$_3$ demonstrated superior tumour-to-muscle (9.55 ± 2.96 vs. 4.94 ± 2.76) and tumour-to-blood (3.93 ± 1.26 vs. 2.88 ± 1.81) ratios. The difference may be explained by tracer lipophilicity. With three additional ethylene moieties, $^{18}$F-AmBF$_3$-(AEBS)$_3$ proved more lipophilic and had a higher LogD$_{7.4}$ value compared to $^{18}$F-AmBF$_3$-(ABS)$_3$. With the exception of testes, stomach, kidney and bone, uptake in nontarget tissues was higher for $^{18}$F-AmBF$_3$-(AEBS)$_3$. Based on this observation, it appears that image contrast may be improved by selecting more hydrophilic CA-IX-targeting pharmacophores$^{218}$. Since $^{18}$F-AmBF$_3$-(ABS)$_3$ yielded the most promising results of the evaluated tracers, additional biodistribution studies were performed at 2 h p.i. to determine if tumour uptake and/or contrast would improve over time. Although tumour uptake for $^{18}$F-AmBF$_3$-(ABS)$_3$ decreased slightly from 0.33 ± 0.07 %ID/g at 1 h p.i. to 0.24 ± 0.05 %ID/g at 2 h p.i., tumours were readily visualized in PET images. Pre-injection with 10 mg/kg of acetazolamide significantly reduced the uptake of $^{18}$F-AmBF$_3$-(ABS)$_3$ in tumours to 0.06 ± 0.01 %ID/g, as well as its tumour-to-background ratios at 1 h p.i.
Table 4.3 Biodistribution and tumour-to-nontarget ratios for $^{18}$F-AmBF$_3$ sulfonamides.

<table>
<thead>
<tr>
<th>Organ</th>
<th>$^{18}$F-AmBF$_3$-AEBS</th>
<th>$^{18}$F-AmBF$_3$-ABS</th>
<th>$^{18}$F-AmBF$_3$-(AEBS)$_3$</th>
<th>$^{18}$F-AmBF$_3$-(ABS)$_3$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 h p.i.</td>
<td>1 h p.i.</td>
<td>1 h p.i.</td>
<td>0.5 h p.i.</td>
</tr>
<tr>
<td>Blood</td>
<td>0.56 ± 0.05</td>
<td>0.51 ± 0.05</td>
<td>0.19 ± 0.20</td>
<td>0.26 ± 0.02</td>
</tr>
<tr>
<td>Fat</td>
<td>0.08 ± 0.03</td>
<td>0.08 ± 0.03</td>
<td>0.04 ± 0.05</td>
<td>0.16 ± 0.08</td>
</tr>
<tr>
<td>Testes</td>
<td>0.14 ± 0.05</td>
<td>0.23 ± 0.15</td>
<td>0.04 ± 0.05</td>
<td>0.30 ± 0.11</td>
</tr>
<tr>
<td>Stomach</td>
<td>0.54 ± 0.39</td>
<td>2.32 ± 2.14</td>
<td>1.03 ± 0.27</td>
<td>4.66 ± 4.06</td>
</tr>
<tr>
<td>Spleen</td>
<td>0.38 ± 0.03</td>
<td>0.54 ± 0.31</td>
<td>0.55 ± 0.73</td>
<td>0.68 ± 0.24</td>
</tr>
<tr>
<td>Liver</td>
<td>10.87 ± 0.53</td>
<td>13.64 ± 2.49</td>
<td>0.98 ± 0.67</td>
<td>9.64 ± 3.66</td>
</tr>
<tr>
<td>Pancreas</td>
<td>0.59 ± 0.07</td>
<td>0.57 ± 0.18</td>
<td>0.07 ± 0.05</td>
<td>0.22 ± 0.10</td>
</tr>
<tr>
<td>Adrenals</td>
<td>0.32 ± 0.10</td>
<td>0.54 ± 0.27</td>
<td>0.34 ± 0.50</td>
<td>0.97 ± 1.02</td>
</tr>
<tr>
<td>Kidney</td>
<td>74.33 ± 19.64</td>
<td>52.70 ± 14.09</td>
<td>0.94 ± 0.32</td>
<td>18.63 ± 3.41</td>
</tr>
<tr>
<td>Lungs</td>
<td>0.90 ± 0.18</td>
<td>1.97 ± 0.11</td>
<td>0.48 ± 0.54</td>
<td>2.75 ± 0.52</td>
</tr>
<tr>
<td>Heart</td>
<td>0.29 ± 0.04</td>
<td>0.27 ± 0.02</td>
<td>0.10 ± 0.07</td>
<td>0.32 ± 0.05</td>
</tr>
<tr>
<td>Muscle</td>
<td>0.18 ± 0.05</td>
<td>0.32 ± 0.11</td>
<td>0.07 ± 0.03</td>
<td>0.26 ± 0.08</td>
</tr>
<tr>
<td>Bone</td>
<td>2.05 ± 0.36</td>
<td>0.85 ± 0.11</td>
<td>0.18 ± 0.12</td>
<td>0.52 ± 0.09</td>
</tr>
<tr>
<td>Brain</td>
<td>0.05 ± 0.02</td>
<td>0.04 ± 0.00</td>
<td>0.02 ± 0.02</td>
<td>0.09 ± 0.02</td>
</tr>
<tr>
<td>Tumour</td>
<td>0.56 ± 0.11</td>
<td>0.64 ± 0.08</td>
<td>0.30 ± 0.10</td>
<td>0.70 ± 0.13</td>
</tr>
<tr>
<td>Tumour/liver</td>
<td>0.05 ± 0.01</td>
<td>0.05 ± 0.01</td>
<td>0.37 ± 0.14</td>
<td>0.07 ± 0.03</td>
</tr>
<tr>
<td>Tumour/blood</td>
<td>1.01 ± 0.25</td>
<td>1.24 ± 0.12</td>
<td>2.88 ± 1.81</td>
<td>2.74 ± 0.68</td>
</tr>
<tr>
<td>Tumour/muscle</td>
<td>3.18 ± 0.63</td>
<td>2.15 ± 0.66</td>
<td>4.94 ± 2.76</td>
<td>2.87 ± 1.43</td>
</tr>
</tbody>
</table>

*Blocked by pre-injection of 10 mg/kg of acetazolamide 1 h before administering radiotracer.
†Pre-injection significantly reduced uptake of the same organ/ratio ($p < 0.05$).
Values (%ID/g) are presented as mean ± SD (n ≥ 4)
Figure 4.4 Tumour-to-muscle ratios for $^{18}$F-AmBF$_3$ sulfonamides at 1 h p.i. Trimerization of ABS statistically significantly improved tumour-to-muscle contrast. ***$p <0.001$

PET/CT images obtained at 1 h p.i. (Figure 4.5 and 4.6) were consistent with the biodistribution data. Higher uptake was observed in kidneys, liver, and gastrointestinal tract. HT-29 tumour xenografts were clearly visualized after injecting $^{18}$F-AmBF$_3$-AEBS (Figure 4.5A), $^{18}$F-AmBF$_3$-ABS (Figure 4.5B), $^{18}$F-AmBF$_3$-(AEBS)$_3$ (Figure 4.6A) or $^{18}$F-AmBF$_3$-(ABS)$_3$ (Figure 4.6B). Blocking studies were performed for $^{18}$F-AmBF$_3$-(ABS)$_3$ that generated highest tumour-to-background contrast. Pre-injection of acetazolamide effectively blocked uptake of $^{18}$F-AmBF$_3$-(ABS)$_3$ in tumour and reduced tumour-to-background contrast (Figure 4.6C).

Figure 4.5 PET/CT images of monomeric $^{18}$F-sulfonamides at 1 h p.i. (A) $^{18}$F-AmBF$_3$-AEBS, and (B) $^{18}$F-AmBF$_3$-ABS. Tumours are indicated by arrows. Scale bar unit is %ID/g.
Given the prognostic and therapeutic value of CA-IX, the development of CA-IX imaging agents will have a significant clinical impact. Notwithstanding somewhat low tumour uptake, both $^{18}$F-AmBF$_3$-(AEBS)$_3$ and $^{18}$F-AmBF$_3$-(ABS)$_3$ enabled clear visualization of CA-IX expressing HT-29 tumour xenografts to provide some of the highest tumour-to-blood and tumour-to-muscle ratios ever reported. Pre-injection of acetazolamide significantly blocked tumour uptake to near background levels for $^{18}$F-AmBF$_3$-(ABS)$_3$ demonstrating target specificity. These data represent a great advancement over previous attempts, and demonstrate the effectiveness of increasing cell-impermeability to achieve CA-IX selectivity. Further synthetic modifications to reduce gastrointestinal uptake as well as the use of more specific inhibitors to increase tumour uptake are ongoing. In the meantime, we suggest that this method has great potential to enhance in vivo imaging of extracellular enzymatic activity through the simple application of a multivalent approach that mitigates generalized uptake.

4.4 Conclusion

We synthesized and evaluated four $^{18}$F-labeled sulfonamides as PET imaging agents targeting CA-IX. Trimerization of sulfonamide derivatives improved tumour-to-nontarget ratios, suggesting that a level of CA isoform selectivity was achieved in vivo. $^{18}$F-AmBF$_3$-(ABS)$_3$
showed specific and selective uptake in CA-IX expressing tumour xenografts with good contrast. The use of multivalent enzyme inhibitors represents a viable strategy to selectively image extracellular enzyme activity with PET.
Chapter 5: Polyaminocarboxylate Conjugated Sulfonamides for $^{68}$Ga-labeling and PET Imaging

5.1 Introduction

Carbonic anhydrases (CA) are a large family of zinc metalloenzymes that share a highly conserved protein domain for catalysis.\textsuperscript{131} Whereas most CAs are found intracellularly (ex. CA-I and CA-II are expressed in high abundance in erythrocytes), CA-IX and CA-XII are the two isoforms that reside at the extracellular surface\textsuperscript{6, 15}. Although CA-XII is also ectopically expressed by cancers in response to hypoxia, it has lower expression profile and catalytic activity than CA-IX\textsuperscript{219}. Based on the spatial distribution of the various CA isoforms, small molecule inhibitors that are cell impermeable have enhanced selectivity for CA-IX. Different strategies to confer CA-IX selectivity include introducing bulk (fluorophores, albumin binders, glycosylation, multimeric design)\textsuperscript{207-210, 220} net charge (pyridinio sulfonamides)\textsuperscript{221, 222}, and/or enhancing hydrophilicity (polyaminocarboxylate chelators)\textsuperscript{223-225}. Rami et al. synthesized several series of aromatic sulfonamides conjugated to DTPA, DOTA, and TETA chelators for Cu\textsuperscript{2+} complexation, and proposed their application for PET imaging\textsuperscript{223}. While these Cu\textsuperscript{2+} sulfonamide complexes retained binding affinity to CA-I/II (K\textsubscript{i}: 54-81 nM), negligible amounts were detected in red blood cells after direct incubation for 3 h due to cell impermeability\textsuperscript{223}.


Joseph Lau\textsuperscript{1*}, Zhengxing Zhang\textsuperscript{1*}, Silvia Jenni\textsuperscript{1}, Hsiou-Ting Kuo\textsuperscript{1}, Zhibo Liu\textsuperscript{2}, Daniella Vullo\textsuperscript{3}, Claudiu T. Supuran\textsuperscript{3}, Kuo-Shyan Lin\textsuperscript{1,4}, Francois Benard\textsuperscript{14}

\textsuperscript{1} Department of Molecular Oncology, BC Cancer Research Centre, BC Cancer Agency, Vancouver, BC, Canada
\textsuperscript{2} Department of Chemistry, University of British Columbia, Vancouver, BC, Canada
\textsuperscript{3} Dipartimento Neurofarba and Laboratorio di Chimica Bioinorganica, Università degli Studi di Firenze, Florence, Italy
\textsuperscript{4} Department of Radiology, University of British Columbia, Vancouver, BC, Canada

JL, ZZ, KSL, and FB designed the study. JL, ZZ, SJ, HTK, ZL, and DV were involved in the experiments. CTS provided the affinity measurements. JL and ZZ were involved in acquisition of data and interpretation of the analysis. JL and ZZ wrote the manuscript.

\*Co-First Author
For our study, we synthesized monomeric (DOTA-AEBSA), dimeric (DOTA-(AEBSA)$_2$) and trimeric (NOTGA(AEBSA)$_3$) sulfonamide inhibitors and radiolabeled them with $^{68}$Ga (Figure 5.1). $^{68}$Ga has a short radioactive half-life (67.7 min) that makes it suitable for labeling pharmaceuticals that have rapid targeting and clearance profiles\textsuperscript{226}. As an imaging isotope, $^{68}$Ga decays 89\% via positron emission with an average 740 keV ($E_{\beta_{\text{max}}} = 1.899$ MeV) positron energy per disintegration\textsuperscript{226}. $^{68}$Ga-DOTA/NOTGA complexes are highly stable\textsuperscript{227}, and several $^{68}$Ga-DOTA peptide derivatives have successfully entered the clinic setting for targeting somatostatin receptors in neuroendocrine tumours\textsuperscript{228}. More significantly, as $^{68}$Ga can be eluted from $^{68}$Ge/$^{68}$Ga generators for on-demand synthesis, this allows facilities without access to a cyclotron to readily synthesize these tracers. We hypothesized that a multivalent approach may increase binding avidity to CA-IX, and cell impermeability can be achieved through the hydrophilicity and bulk of the metal/chelator complex.
5.2 Methods

5.2.1 Reagents and Instrumentation

All chemicals and solvents unless otherwise specified were obtained from commercial sources, and used without further purification. Tri-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (1) was purchased from TCI America (Portland, OR). 1,7-Di-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate (5) and 1,4,7-triazacyclononane-1,4,7-tris-glutamic acid-α-tert-butyl ester-γ-succinimidyl ester (9) were synthesized according to literature methods\textsuperscript{229, 230}. Proton NMR spectra were obtained using a Bruker (Billerica, MA) Avance 300 spectrometer, and were reported in parts per million downfield from the peak of internal tetramethylsilane. High resolution electrospray-ionization mass spectrometry (ESI-MS) was performed on a Waters Micromass LCT TOF instrument. Purification and quality control of \textsuperscript{68}Ga-labeled CA-IX inhibitors were performed on an Agilent (Santa Clara, CA) HPLC system equipped with a model 1200 quaternary pump, a model 1200 UV absorbance detector (wavelength preset at 220 nm), and a Bioscan (Washington, DC) NaI scintillation detector. The HPLC columns used were a semipreparative column (Phenomenex C18, 5 µ, 250 × 10 mm) and an analytical column (Phenomenex Luna C18, 5 µ, 250 × 4.6 mm). The HPLC conditions used for the purification and quality control of cold and radiolabeled compounds are shown in Table 5.1. \textsuperscript{68}GaCl\textsubscript{3} was eluted from either a 30-mCi \textsuperscript{68}Ge/\textsuperscript{68}Ga generator from Eckert & Ziegler (Berlin, Germany) or a 50-mCi generator from iThemba LABS (Faure, South Africa). Radioactivity of \textsuperscript{68}Ga-labeled tracers were measured using a Capintec (Ramsey, NJ) CRC\textsuperscript{®}-25R/W dose calibrator.
Table 5.1 HPLC conditions used for purification, QC and plasma stability assays.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Column</th>
<th>Solvent system (containing 0.1% TFA)</th>
<th>Flow rate (mL/min)</th>
<th>Retention time (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>3, 4</td>
<td>Phenomenex Luna C18, 5 µm, 10 × 250 mm semi-prep</td>
<td>5% CH$_3$CN in water</td>
<td>4.5</td>
<td>14.8, 16.5</td>
</tr>
<tr>
<td>7, 8</td>
<td>Phenomenex Luna C18, 5 µm, 10 × 250 mm semi-prep</td>
<td>0-30 min, 0 to 30% CH$_3$CN in water</td>
<td>4.5</td>
<td>20.0, 21.4</td>
</tr>
<tr>
<td>11, 12</td>
<td>Phenomenex Luna C18, 5 µm, 10 × 250 mm semi-prep</td>
<td>21% CH$_3$CN in water</td>
<td>4.5</td>
<td>16.5, 16.5</td>
</tr>
<tr>
<td>$^{68}$Ga-DOTA-AEBSA</td>
<td>Phenomenex Luna C18, 5 µm, 10 × 250 mm semi-prep</td>
<td>5% EtOH in PBS</td>
<td>4.5</td>
<td>10.0</td>
</tr>
<tr>
<td>$^{68}$Ga-DOTA-(AEBSA)$_2$</td>
<td>Phenomenex Luna C18, 5 µm, 10 × 250 mm semi-prep</td>
<td>7% EtOH in PBS</td>
<td>4.5</td>
<td>16.5</td>
</tr>
<tr>
<td>$^{68}$Ga-NOTGA-(AEBSA)$_3$</td>
<td>Phenomenex Luna C18, 5 µm, 10 × 250 mm semi-prep</td>
<td>20% CH$_3$CN in PBS</td>
<td>4.5</td>
<td>17.5</td>
</tr>
<tr>
<td>$^{68}$Ga-DOTA-AEBSA (QC and plasma stability)</td>
<td>Phenomenex Luna C18, 5 µm, 4.6 × 250 mm analytical</td>
<td>5% EtOH in PBS</td>
<td>2.0</td>
<td>4.3</td>
</tr>
<tr>
<td>$^{68}$Ga-DOTA-(AEBSA)$_2$ (QC and plasma stability)</td>
<td>Phenomenex Luna C18, 5 µm, 4.6 × 250 mm analytical</td>
<td>7% EtOH in PBS</td>
<td>2.0</td>
<td>6.7</td>
</tr>
<tr>
<td>$^{68}$Ga-NOTGA-(AEBSA)$_3$ (QC and plasma stability)</td>
<td>Phenomenex Luna C18, 5 µm, 4.6 × 250 mm analytical</td>
<td>19% CH$_3$CN in PBS</td>
<td>2.0</td>
<td>10.5</td>
</tr>
</tbody>
</table>

5.2.2 Chemistry and Radiolabeling

5.2.2.1 Synthesis of 1,4,7,10-tetraazacyclododecane-1,4,7-tris(t-butylacetate)-10-p-sulfonamidophenylethylacetamide (2)

A mixture of tri-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate 1 (100 mg, 0.18 mmol), 4-(2-aminoethyl)benzenesulfonamide (35 mg, 0.18 mmol), EDC•HCl (34 mg, 0.18 mol),
ethyldiisopropylamine (30 µL, 0.18 mmol), and HOBt (hydroxybenzotriazole)•H₂O (27 mg, 0.18 mmol) in DMF (5 mL) was stirred at room temperature for 24 h, and then the solvent was removed under reduced pressure. Ethyl acetate (50 mL) was added to the residue, and then the mixture was washed successively with 0.5 M NaOH (50 mL × 2), saturated aqueous NaHCO₃ solution (50 mL), and brine (50 mL). The organic layer was dried over magnesium sulfate before evaporation. The residue was obtained as a white powder and used for the next reaction without further purification. Yield: 71 mg (0.09 mmol, 52%). ¹H NMR (300 MHz, CDCl₃) δ 9.09 (s, 1H, CONH), 7.86 (d, J = 8.1 Hz, 2H, Ar–H), 7.48 (d, J = 8.1 Hz, 2H, Ar–H), 5.59 (s, 2H, NH₂), 3.78 – 3.28 (m, 6H, CH₂), 3.14 – 2.65 (m, 10H, CH₂), 2.31 – 1.92 (m, 12H, CH₂), 1.47 (s, 27H, CH₃); HRMS(ESI) Calcd. for C₃₆H₆₂N₆O₉S: m/z 755.4377 ([M+H]+); Found: m/z 755.4373 ([M+H]+).

5.2.2.2 Synthesis of 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid, 10-p-sulfonamidophenylethylacetamide (DOTA-AEBSA, 3)

A solution of 2 (20 mg, 0.026 mmol) in 1:1 TFA/CH₂Cl₂ (2 mL) was stirred at room temperature overnight. Solvent was evaporated and CH₂Cl₂ (10 mL × 2) was added and subsequently removed under reduced pressure to remove excess TFA. The residue was dissolved in de-ionized water and purified by HPLC to yield 3·xTFA as a white solid (17 mg). ¹H NMR (D₂O, 300 MHz) δ 7.86 (d, J = 8.0 Hz, 2H, Ar–H), 7.51 (d, J = 8.0 Hz, 2H, Ar–H), 4.11 – 3.65 (m, 6H, CH₂), 3.64 – 3.48 (m, 4H, CH₂), 3.42 – 3.00 (m, 14H, CH₂), 2.98 – 2.82 (m, 4H, CH₂); HRMS(ESI) Calcd. for C₂₄H₃₈N₆O₉S: m/z 587.2499 ([M+H]+); Found: m/z 587.2507 ([M+H]+).

5.2.2.3 Synthesis of 1,4,7,10-tetraazacyclododecane-1,4-bis(tert-butylacetate)-7,10-bis-p-sulfonamidophenylethylacetamide (6)

A mixture of 1,7-di-tert-butyl 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate 5 (150 mg, 0.29 mmol), 4-(2-aminoethyl)benzenesulfonamide (116 mg, 0.58 mmol), EDC•HCl (111 mg, 0.58 mol), ethyldiisopropylamine (101 µL, 0.58 mmol), and HOBt•H₂O (89 mg, 0.58 mmol) in DMF (5 mL) was stirred at room temperature for 24 h, and solvent was removed under reduced pressure. Ethyl acetate (50 mL) was added to the residue, and then the mixture was washed successively with 0.5 M NaOH (50 mL × 2), saturated aqueous NaHCO₃ solution (50 mL), and
brine (50 mL). The organic layer was dried over magnesium sulfate before evaporation. The residue was obtained as a white powder and used for next reaction without further purification. Yield: 57 mg (0.06 mmol, 22%). \(^1\)H NMR (300 MHz, \(d_6\)-DMSO) \(\delta\) 8.27 (s, 2H, CONH), 7.82 – 7.67 (m, 4H, Ar–H), 7.47 – 7.35 (m, 4H, Ar–H), 5.80 (s, 4H, NH₂), 3.27 – 3.10 (m, 6H, CH₂), 3.05 – 2.90 (m, 6H, CH₂), 2.87 – 2.75 (m, 6H, CH₂), 2.72 – 2.57 (m, 6H, CH₂), 2.30 – 1.94 (m, 8H, CH₂), 1.41 (s, 18H, CH₃); HRMS(ESI) Calcd. for C₄₀H₆₄N₈O₁₀S₂: m/z 881.4265 ([M+H]+); Found: m/z 881.4277 ([M+H]+).

5.2.2.4 Synthesis of 1,4,7,10-tetraazacyclododecane-1,7-diacetic acid, 4,10-bis-p-sulfonamidophenylethylacetamide (DOTA-(AEBSA)₂, 7)

A solution of 6 (50 mg, 0.06 mmol) in 1:1 TFA/CH₂Cl₂ (2 mL) was stirred at room temperature overnight. Solvent was evaporated and CH₂Cl₂ (10 mL × 2) was added and then removed under reduced pressure to remove excess TFA. The residue was dissolved in de-ionized water and purified by HPLC to give 7·xTFA as a white solid (26 mg). \(^1\)H NMR (D₂O, 300 MHz) \(\delta\) 7.81 (d, \(J = 8.0\) Hz, 4H, Ar–H), 7.44 (d, \(J = 8.0\) Hz, 4H, Ar–H), 3.90 – 3.59 (m, 4H, CH₂), 3.59 – 3.33 (m, 8H, CH₂), 3.33 – 2.98 (m, 12H, CH₂), 2.96 – 2.74 (m, 8H, CH₂); HRMS(ESI) Calcd. for C₃₂H₄₈N₈O₁₀S₂: m/z 769.3013 ([M+H]+); Found: m/z 769.3028 ([M+H]+).

5.2.2.5 Synthesis of 1,4,7-triazacyclononane-1,4,7-tris-glutamic acid-\(\alpha\)-tert-butyl ester-\(\gamma\)-p-sulfonamidophenylethylamide (10)

A mixture of 1,4,7-triazacyclononane-1,4,7-tris-glutamic acid-\(\alpha\)-tert-butyl ester-\(\gamma\)-succinimidyl ester 9 (680 mg, 0.70 mmol), 4-(2-aminoethyl)benzenesulfonamide (459 mg, 2.29 mmol) and ethyldiisopropylamine (399 µL, 2.29 mmol) in DMF (50 mL) was initially stirred at room temperature for 24 h before incubation at 50°C for an additional 24 h. Excess solvent was removed under reduced pressure. Water (100 mL) was added and the resultant mixture was extracted with CHCl₃ (100 mL × 3). The combined organic phase was dried over magnesium sulfate before evaporation. Residue was loaded onto a silica gel column and eluted using a mixture of EtOAc/methanol (10:1 to 5:1). The product was obtained as a white foam. Yield: 283 mg (0.23 mmol, 33%). \(^1\)H NMR (300 MHz, \(d_6\)-DMSO) \(\delta\) 7.95 (s, 3H, CO₂NH), 7.73 (d, \(J = 8.2\) Hz, 3H, CONH), 7.70 (d, \(J = 8.0\) Hz, 3H, CONH).
Hz, 6H, Ar–H), 7.37 (d, J = 8.2 Hz, 6H, Ar–H), 7.28 (s, 6H, NH$_2$), 3.14 – 3.00 (m, 4H, CH$_2$), 2.85 – 2.75 (m, 10H, CH$_2$), 2.69 – 2.55 (m, 6H, CH$_2$), 2.25 – 2.05 (m, 7H, CH$_2$), 1.83 – 1.55 (m, 12H, CH$_2$), 1.40 (s, 27H, CH$_3$); HRMS(ESI) Calcd. for C$_{57}$H$_{87}$N$_9$O$_{15}$S$_3$: m/z 1234.5562 ([M+H]$^+$); Found: m/z 1234.5559 ([M+H]$^+$).

5.2.2.6 **Synthesis of 1,4,7-triazacyclononane-1,4,7-tris-glutamic acid-$\gamma$-p-sulfonamidophenylethylamide (NOTGA-(AEBSA)$_3$, 11)**

A solution of 10 (100 mg, 0.081 mmol) in 1:1 TFA/CH$_2$Cl$_2$ (2 mL) was stirred at room temperature overnight. The solvent was evaporated and CH$_2$Cl$_2$ (10 mL × 2) was added and then removed under reduced pressure to remove excess TFA. The residue was dissolved in de-ionized water and purified by HPLC to yield 11·xTFA as a white solid (70 mg). $^1$H NMR (300 MHz, DMSO) $\delta$ 8.08 (s, 3H, CO NH), 7.74 (d, J = 8.1 Hz, 6H, Ar–H), 7.37 (d, J = 8.1 Hz, 6H, Ar–H), 7.30 (s, 6H, NH$_2$), 3.37 – 3.14 (m, 11H, CH$_2$), 3.13 – 2.87 (m, 9H, CH$_2$), 2.84 – 2.70 (m, 7H, CH$_2$), 2.37 – 2.18 (m, 6H, CH$_2$), 2.06 – 1.88 (m, 6H, CH$_2$); HRMS(ESI) Calcd. for C$_{45}$H$_{63}$N$_9$O$_{15}$S$_3$: m/z 1065.3684 ([M+H]$^+$); Found: m/z 1066.3666 ([M+H]$^+$).

5.2.2.7 **General Procedure for the Synthesis of Cold Gallium Standard**

A solution of the corresponding precursor in sodium acetate buffer (0.5 mL, 0.1 M, pH = 4.0) and 5 equiv. of natGaCl$_3$ was stirred at 80 °C for 15 min. The mixture was purified by HPLC to give the corresponding gallium complexes as a white fluffy solid.

natGa-DOTA-AEBSA (4) Yield: 69%. $^1$H NMR (D$_2$O, 300 MHz) $\delta$ 7.95 (d, J = 8.2 Hz, 2H, Ar–H), 7.60 (d, J = 8.2 Hz, 2H, Ar–H), 4.21 – 3.85 (m, 8H, CH$_2$), 3.78 – 3.32 (m, 16H, CH$_2$), 3.14 – 2.92 (m, 4H, CH$_2$); HRMS(ESI) Calcd. for C$_{24}$H$_{35}$GaN$_6$O$_9$S: m/z 653.1520 ([M+H]$^+$); Found: m/z 653.1516 ([M+H]$^+$).

natGa-DOTA-(AEBSA)$_2$ (8) Yield: 61%. $^1$H NMR (300 MHz, D$_2$O) $\delta$ 7.94 (d, J = 8.2 Hz, 4H, Ar–H), 7.59 (d, J = 8.0 Hz, 4H, Ar–H), 4.06 – 3.88 (m, 4H, CH$_2$), 3.79 – 3.50 (m, 16H, CH$_2$),
3.48 – 3.23 (m, 4H, CH₂), 3.17 – 2.91 (m, 8H, CH₂); HRMS(ESI) Calcd. for C₃₂H₄₆Ga₈O₁₀S₂: m/z 835.2034 ([M⁺]); Found: m/z 835.2039 ([M⁺]).

natGa-NOTGA-(AEBSA)₃ (12) Yield: 72%. ¹H NMR (300 MHz, DMSO) δ 8.02 (s, 3H, CONH), 7.74 (d, J = 8.2 Hz, 6H, Ar–H), 7.40 (d, J = 8.2 Hz, 6H, Ar–H), 7.29 (s, 6H, NH₂), 3.30 – 3.19 (m, 10H, CH₂), 3.17 – 2.90 (m, 10H, CH₂), 2.90 – 2.67 (m, 10H, CH₂), 2.41 – 2.26 (m, 3H, CH₂), 2.18 – 1.98 (m, 3H, CH₂), 1.95 – 1.77 (m, 3H, CH₂); HRMS(ESI) Calcd. for C₄₅H₆₀Ga₉O₁₅S₃: m/z 1130.2549 ([M-H]-); Found: m/z 1130.2570 ([M-H]-).

5.2.2.8 General Procedure for the Synthesis of ⁶⁸Ga Tracers

⁶⁸GaCl₃ was purified following published procedures. A HEPES buffer (0.50 mL, 2 M, pH = 5.0) solution of the corresponding precursor (30 µg for ⁶⁸Ga-DOTA-AEBSA, and 40 µg for ⁶⁸Ga-DOTA-(AEBSA)₂ and ⁶⁸Ga-NOTGA-(AEBSA)₃) and purified ⁶⁸GaCl₃ (0.19-1.30 GBq for ⁶⁸Ga-DOTA-AEBSA, 0.19-1.41 GBq for ⁶⁸Ga-DOTA-(AEBSA)₂, and 0.19-0.70 GBq for ⁶⁸Ga-NOTGA-(AEBSA)₃) was heated in the microwave for 1 min. Reaction mixtures were purified by HPLC. ⁶⁸Ga-DOTA-AEBSA and ⁶⁸Ga-DOTA-(AEBSA)₂ were collected in fractions and used directly for in vitro and in vivo studies. ⁶⁸Ga-NOTGA-(AEBSA)₃ was collected, diluted with water, and loaded onto a C18 Sep-Pak cartridge to remove acetonitrile. The trapped ⁶⁸Ga-NOTGA-(AEBSA)₃ was eluted off the cartridge with ethanol and diluted with saline for in vitro and in vivo studies.

5.2.3 Binding Affinity Measurement

Inhibition constants (Kᵢ) of AmBF₃-AEBS, AmBF₃-ABS, and AmBF₃-(AEBS)₃ and AmBF₃-(ABS)₃ for CA-I, -II, -IX and -XII were determined using the CA catalyzed CO₂ hydration stopped-flow assays following published procedures.

5.2.4 Stability in Mouse Plasma

Following published procedures, 100 µL aliquots of tracer were incubated with 400 µL of BALB/c mouse plasma (Innovative Research) for 2 h at 37 °C. After incubation, sample was
quenched with 70% CH\textsubscript{3}CN, passed through a 0.45 µm filter, and loaded on to a radio-HPLC system for analysis.

5.2.5 Lipophilicity Measurement

Values of octanol:water distribution coefficient at pH 7.4 (LogD\textsubscript{7.4}) were determined for the radiotracers using a shake flask method as previously described\textsuperscript{231}. Aliquots (2 µL) of the \textsuperscript{68}Ga-labeled tracers were added to 15 mL conical centrifuge tubes containing 3 mL of octanol and 3 mL of phosphate buffer (0.1 M, pH 7.4). The mixture was vortexed for 1 min and centrifuged at 5,000 rpm for 10 min. Samples of the octanol (1 mL) and aqueous (1 mL) phases were taken and counted on a gamma counter. LogD\textsubscript{7.4} was calculated using the following equation: LogD\textsubscript{7.4} = \log_{10}\left(\frac{\text{counts in octanol phase}}{\text{counts in buffer phase}}\right).

5.2.6 Cell Line

HT-29 human colorectal cancer cells were obtained as a gift from Dr. Donald Yapp (BC Cancer Research Centre, Vancouver, Canada). Cells were cultured in Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin-streptomycin, and non-essential amino acids. Cells were incubated at 37 °C in an atmosphere containing 5% CO\textsubscript{2} and used for in vitro or in vivo experiments when 80-90% confluence was reached.

5.2.7 Immunofluorescence of HT-29 Colonies

This study was performed following published procedures\textsuperscript{232}. Matrigel (52 µL) was added to individual wells of an 8-well chamber slide and allowed to solidify at 37 °C for 30 min. Cells (~1000) cultured in media + 2% matrigel in 300 µL were seeded per well. Cultures were incubated at 37 °C in an atmosphere containing 5% CO\textsubscript{2} for 21 days before fixation for immunocytochemistry. Growth medium was refreshed every four days with media + 2% matrigel. For immunofluorescence, colonies were fixed with 2% paraformaldehyde for 25 min at room temperature and permeabilized with PBS + 0.5% Triton-X for 10 min at 4 °C. After three rinses with PBS + 0.1 M glycine for 10 min, samples were rinsed once for 5 min with IF buffer (130 mM NaCl, 7 mM Na\textsubscript{2}HPO\textsubscript{4}, 3.5 mM NaH\textsubscript{2}PO\textsubscript{4}, 7.7 mM NaN\textsubscript{3}, 0.1% bovine serum
albumin, 0.2% Triton X-100, 0.05% Tween-20) and blocked for 2.5 h in IF buffer containing 10% serum. CA-IX was stained with phycoerythrin-conjugated mouse-anti CA-IX antibody (R&D Systems) at 4 °C overnight. Cells were counterstained with Oregon Green 488 phalloidin (Invitrogen) for 20 min and Draq5 (Biostatus Limited) for 5 min. Imaging was performed on a Nikon Eclipse C1 confocal laser scanning microscope (Melville, NY) equipped with 488 nm, 561 nm, and 638 nm lasers.

5.2.8 PET Imaging and Biodistribution Studies

All animal studies were performed in accordance with the Canadian Council on Animal Care guidelines and approved by the Animal Care Committee of the University of British Columbia. Male immunodeficient NOD.Cg-Prkdcsknll2rgtm1Wjl/SzJ (NSG) mice bred in-house at the Animal Research Centre, BC Cancer Research Centre were used for this study. Under anesthesia with 2.5% isoflurane in 2.0 L/min of oxygen, mice were subcutaneously inoculated with 5 × 10⁶ HT-29 cells (in 100 µL PBS and BD Matrigel Matrix at 1:1 ratio) under the right dorsal flank. Biodistribution studies and PET/CT imaging were performed when tumours reached 7-9 mm in diameter.

PET imaging studies of ⁶⁸Ga-labeled tracers were conducted using a Siemens Inveon microPET/CT scanner. Under 2.5% isoflurane anesthesia in oxygen at 2.0 L/min, 3.7-7.4 MBq of ⁶⁸Ga-DOTA-AEBSA, ⁶⁸Ga-DOTA-(AEBSA)₂ or ⁶⁸Ga-NOTA-(AEBSA)₃ in a volume of 200 µL was administered intravenously through the caudal vein. For blocking experiments, mice were intravenously pre-injected with 10 or 20 mg/kg acetazolamide 1 h (100 – 200 µL in saline, i.v.) before administering the radiotracer. At 1 h post-injection (p.i.), a 10 min PET scan was performed. For anatomical localization, a 10 min CT scan was performed prior to each PET acquisition. The body temperature of mice was maintained at 37 °C with the use of thermal pads. PET data were acquired in list mode acquisition, reconstructed using the 3d-OSEM-MAP algorithm with CT-based attenuation correction. Three-dimensional regions of interests (ROIs) were placed on the reconstructed images to determine the %ID/g of tissue using the Inveon Acquisition Workplace software (conversion factor was predetermined using a ⁶⁸Ge/⁶⁸Ga source).
Biodistribution studies were performed to confirm the quantitative ROI uptake values observed from PET scans. At 1 h p.i., mice were euthanized by cervical dislocation. Tissues of interest (blood, testes, stomach, intestine, spleen, liver, pancreas, kidney, lung, heart, tumour, muscle, bone and brain) were collected. Tissues were rinsed with PBS (except blood), blotted dry, weighed, and measured on a Packard Cobra II 5000 Series auto-gamma counter.

5.2.9 Statistical Analysis

All statistics were performed using Prism 6 software (GraphPad). For Figure 5.6, \( P \) values for the differences between tumour/muscle ratio, kidney and liver uptake were calculated using a two-way ANOVA test adjusted for multiple comparisons using the Holm-Šídák method. Values < 0.05 were considered statistically significant. For Table 5.4, \( P \) values for the difference of tracer uptake in mouse tissues between unblocked and blocked groups were calculated using a two-tailed \( t \)-test adjusted for multiple comparisons using the Holm-Šídák method. Values < 0.05 were considered statistically significant.

5.3 Results and Discussion

The synthesis scheme for the precursors and standards are shown in Figure 5.2. One to three 4-(2-aminoethyl)benzenesulfonamide (AEBSA) moieties were conjugated to either DOTA (monomer and dimer) or NOTGA (trimer) chelators to obtain the radiolabeling precursors. Results of the radiolabeling experiments are summarized in Table 5.2. All three tracers were successfully radiolabeled with \( ^{68}\text{Ga} \) with average decay-corrected isolated yields of \( \geq 64\% \) (\( n \geq 3 \)). The specific activities measured were \( 536.5 \pm 187.1 \), \( 269.5 \pm 176.9 \), and \( 50.9 \pm 8.4 \) GBq/\( \mu \)mol for \( ^{68}\text{Ga-DOTA-AEBSA} \), \( ^{68}\text{Ga-DOTA-(AEBSA)}_2 \), and \( ^{68}\text{Ga-NOTGA-(AEBSA)}_3 \) respectively. After purification by radio-HPLC, tracers were obtained in \( \geq 97.5\% \) average radiochemical purity for in vitro and in vivo experiments.
Figure 5.2 Synthetic scheme for precursors and cold standards. (A) $^{\text{n}}$Ga-DOTA-AEBSA; (B) $^{\text{n}}$Ga-DOTA-(AEBSA)$_2$ and (C) $^{\text{n}}$Ga-NOTGA-(AEBSA)
Table 5.2 Molecular weight and radiolabeling data of $^{68}$Ga CA-IX inhibitors.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Molecular weight (Dalton)</th>
<th>% Isolated radiochemical yield</th>
<th>% Radiochemical purity</th>
<th>Specific activity (GBq/µmol)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$^{68}$Ga-DOTA-AEBSA</td>
<td>653.36</td>
<td>91 ± 3</td>
<td>97.5 ± 1.9</td>
<td>536.5 ± 187.1</td>
</tr>
<tr>
<td>$^{68}$Ga-DOTA-(AEBSA)$_2$</td>
<td>835.6</td>
<td>84 ± 4</td>
<td>97.8 ± 1.8</td>
<td>269.5 ± 176.9</td>
</tr>
<tr>
<td>$^{68}$Ga-NOTGA-(AEBSA)$_3$</td>
<td>1132.93</td>
<td>64 ± 8</td>
<td>99.3 ± 0.3</td>
<td>50.9 ± 8.4</td>
</tr>
</tbody>
</table>

Data are presented as mean values ± standard deviation (n ≥ 3).

$^a$Decay-corrected.

The stability of the tracers was assessed by incubating the tracers in mouse plasma. Tracers were highly stable in plasma, as > 90% of them remained intact after 2 h incubation at 37 °C (Figure 5.3). The LogD$_{7.4}$ values of $^{68}$Ga-DOTA-AEBSA, $^{68}$Ga-DOTA-(AEBSA)$_2$, and $^{68}$Ga-NOTGA-(AEBSA)$_3$ were measured to be -4.37 ± 0.08, -3.52 ± 0.01, and -2.39 ± 0.01, respectively.

![HPLC traces](image)

Figure 5.3 Stability of $^{68}$Ga CA-IX inhibitors in mouse plasma. HPLC traces of $^{68}$Ga CA-IX inhibitors before (top) and after 2 h incubation in mouse plasma (bottom). The Y-axis denotes radioactivity while the X-axis denotes retention time.
Table 5.3 Binding affinity (Kᵢ) of sulfonamide inhibitors to CA-I, CA-II, CA-IX and CA-XII were determined via a stopped-flow CO₂ hydration assay.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Binding affinity (Kᵢ, nM)</th>
<th>CA-I</th>
<th>CA-II</th>
<th>CA-IX</th>
<th>CA-XII</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ga-DOTA-AEBSA</td>
<td></td>
<td>38.0</td>
<td>136.8</td>
<td>10.8</td>
<td>30.7</td>
</tr>
<tr>
<td>Ga-DOTA-(AEBSA)₂</td>
<td></td>
<td>37.6</td>
<td>41.2</td>
<td>25.4</td>
<td>7.4</td>
</tr>
<tr>
<td>Ga-NOTGA-(AEBSA)₃</td>
<td></td>
<td>34.4</td>
<td>7.2</td>
<td>7.7</td>
<td>6.5</td>
</tr>
<tr>
<td>Acetazolamide</td>
<td></td>
<td>250</td>
<td>12.0</td>
<td>25.0</td>
<td>6.0</td>
</tr>
</tbody>
</table>

Errors in the range of 5-10% of the reported value from three different assays.

Sulfonamide derivatives inhibit CA-IX enzymatic activity by forming coordination with Zn²⁺ ion of the catalytic domain and displacing H₂O₁³¹. The primary concern with incorporating a multidentate chelator into our structural design was the possibility of steric hindrance. To ensure that our compounds can bind to CA-IX after coupling to either DOTA (monomer and dimer) or NOTGA (trimer), we first evaluated their binding affinity (Kᵢ) using a CA catalyzed CO₂ stopped-flow hydration assay (Table 5.3). The Kᵢ value of ⁶⁸Ga-DOTA-(AEBSA)₂ was similar to acetazolamide (25.4 nM vs 25.0 nM), while ⁶⁸Ga-DOTA-AEBSA and ⁶⁸Ga-NOTGA-(AEBSA)₃ exhibited 2-3 folds better binding affinity than acetazolamide (10.8 nM and 7.7 nM, respectively). For this study, the conjugation of sulfonamide moieties to polyaminocarboxylate chelators did not hinder CA-IX binding and inhibition.

The HT-29 xenograft model has been used extensively for evaluating prospective CA-IX radiotracers, and we have confirmed expression of CA-IX with immunofluorescence (Figure 5.4) and immunohistochemistry. Representative decay-corrected PET images of HT-29 tumour-bearing mice at 1 h p.i. are shown in Figure 5.5. ⁶⁸Ga-labeled sulfonamides generated good-contrast PET images in CA-IX expressing tumour xenografts. Absolute uptake appeared to correlate positively with the number of targeting moieties as well as molecular weight of the tracers. In addition to tumour, uptake was observed in excretory organs like the kidneys (⁶⁸Ga-DOTA-AEBSA, ⁶⁸Ga-DOTA-(AEBSA)₂, and ⁶⁸Ga-NOTGA-(AEBSA)₃) or liver (mostly for ⁶⁸Ga-DOTA-(AEBSA)₂, and ⁶⁸Ga-NOTGA-(AEBSA)₃). While ⁶⁸Ga-DOTA-AEBSA was excreted predominantly through the kidneys, ⁶⁸Ga-DOTA-(AEBSA)₂ and ⁶⁸Ga-NOTGA-(AEBSA)₃ were cleared by both renal and hepatobiliary pathways. The differences in pharmacokinetic profile between the tracers may be attributed to tracer lipophilicity. The
incorporation of each additional benzenesulfonamide moiety increased overall lipophilicity. As $^{68}$Ga-DOTA-AEBSA generated the highest contrasted images, blocking studies were performed by pre-injecting acetazolamide (10 and 20 mg/kg, intravenous) before tracer administration. Uptake in HT-29 tumours was successfully blocked compared to baseline studies indicating tracer specificity (Table 5.4).

Figure 5.4 CA-IX expression in HT-29 colorectal cancer model. CA-IX expression in cell model was confirmed in vitro and with 3D colony immunofluorescence (red = CA-IX, blue = nucleus and green = F-actin). Left: Merged. Right: CA-IX alone.

Figure 5.5 Maximal intensity projections of PET/CT and PET with $^{68}$Ga tracers at 1 h p.i. (A) $^{68}$Ga-DOTA-AEBSA; (B) $^{68}$Ga-DOTA-AEBSA pre-blocked with 10 mg/kg of acetazolamide; (C) $^{68}$Ga-DOTA-(AEBSA)$_2$; and (D) $^{68}$Ga-NOTGA-(AEBSA)$_3$. t = tumour; l = liver; k = kidney; bl = bladder
Biodistribution analysis corroborated observations of the PET images (Table 5.4). Tumour uptake of $^{68}$Ga-DOTA-AEBSA, $^{68}$Ga-DOTA-(AEBSA)$_2$, and $^{68}$Ga-NOTGA-(AEBSA)$_3$ were $0.81 \pm 0.15$, $1.93 \pm 0.26$, and $2.30 \pm 0.53$ %ID/g at 1 h.p.i. Although not statistically significant, $^{68}$Ga-DOTA-AEBSA managed to generate the highest tumour-to-muscle contrast at $5.02 \pm 0.22$ when compared to $^{68}$Ga-DOTA-(AEBSA)$_2$ ($4.07 \pm 0.87$) and $^{68}$Ga-NOTGA-(AEBSA)$_3$ ($4.18 \pm 0.84$) (Figure 5.6). For $^{68}$Ga-DOTA-AEBSA, minimal uptake was noted in non-target tissue with kidneys being the only organ with higher uptake ($4.37 \pm 1.04$ %ID/g) than tumour at 1 h.p.i. For $^{68}$Ga-DOTA-(AEBSA)$_2$ and $^{68}$Ga-NOTGA-(AEBSA)$_3$, enhanced tumour uptake is accompanied by an increase of radioactivity in kidneys ($14.84 \pm 7.21$ and $14.40 \pm 1.65$) and in liver ($3.78 \pm 1.06$ and $8.01 \pm 3.58$). Uptake in latter indicated the involvement of the hepatobiliary pathway in the excretion profiles of both the dimer and trimer. Pre-injection with 10 mg/kg of acetazolamide significantly reduced the uptake of $^{68}$Ga-DOTA-AEBSA in tumours to $0.41 \pm 0.10$ %ID/g. Injection of a higher dose of acetazolamide (20 mg/kg) led to further reduction in non-target tissues, but similar reduction in tumour uptake ($0.35 \pm 0.17$ %ID/g) relative to the 10 mg/kg dose. It is possible that the activity reduction observed in kidneys and liver is due to the indirect effect of acetazolamide as a diuretic$^{233}$.

![Figure 5.6](image)

**Figure 5.6** Two-way ANOVA analysis of tumour/muscle ratio, kidney and liver uptake for $^{68}$Ga CA-IX inhibitors. There are no statistically significant differences for tumour/muscle ratio. In contrast, there are statistically significant differences for both renal and hepatobiliary uptake for the tracers. *$p < 0.05$, **$p < 0.01$, ***$p < 0.001$, ****$p < 0.0001$
### Table 5.4 Biodistribution and tumour-to-nontarget ratios for $^{68}$Ga CA-IX inhibitors

<table>
<thead>
<tr>
<th>Organ</th>
<th>$^{68}$Ga-DOTA-AEBSA</th>
<th>$^{68}$Ga-DOTA-(AEBSA)$_2$</th>
<th>$^{68}$Ga-NOTGA-(AEBSA)$_3$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Unblocked (n = 5)</td>
<td>10 mg/kg AZA$^a$ (n = 5)</td>
<td>20 mg/kg AZA$^a$ (n = 4)</td>
</tr>
<tr>
<td>Blood</td>
<td>0.63 ± 0.15</td>
<td>0.33 ± 0.13</td>
<td>0.25 ± 0.08$^b$</td>
</tr>
<tr>
<td>Fat</td>
<td>0.09 ± 0.04</td>
<td>0.08 ± 0.07</td>
<td>0.04 ± 0.01</td>
</tr>
<tr>
<td>Testes</td>
<td>0.16 ± 0.05</td>
<td>0.10 ± 0.05</td>
<td>0.06 ± 0.02</td>
</tr>
<tr>
<td>Stomach</td>
<td>0.17 ± 0.07</td>
<td>0.14 ± 0.12</td>
<td>0.24 ± 0.33</td>
</tr>
<tr>
<td>Spleen</td>
<td>0.25 ± 0.05</td>
<td>0.16 ± 0.07</td>
<td>0.07 ± 0.02$^b$</td>
</tr>
<tr>
<td>Liver</td>
<td>0.83 ± 0.29</td>
<td>0.48 ± 0.08</td>
<td>0.32 ± 0.10</td>
</tr>
<tr>
<td>Pancreas</td>
<td>0.15 ± 0.04</td>
<td>0.08 ± 0.02</td>
<td>0.05 ± 0.01$^b$</td>
</tr>
<tr>
<td>Adrenals</td>
<td>0.40 ± 0.06</td>
<td>0.32 ± 0.25</td>
<td>0.08 ± 0.03$^b$</td>
</tr>
<tr>
<td>Kidney</td>
<td>4.37 ± 1.04</td>
<td>1.92 ± 0.46$^b$</td>
<td>1.28 ± 0.32$^b$</td>
</tr>
<tr>
<td>Lungs</td>
<td>0.56 ± 0.13</td>
<td>0.32 ± 0.13</td>
<td>0.16 ± 0.05$^b$</td>
</tr>
<tr>
<td>Heart</td>
<td>0.20 ± 0.07</td>
<td>0.12 ± 0.04</td>
<td>0.12 ± 0.04</td>
</tr>
<tr>
<td>Muscle</td>
<td>0.16 ± 0.03</td>
<td>0.08 ± 0.03$^b$</td>
<td>0.09 ± 0.11</td>
</tr>
<tr>
<td>Bone</td>
<td>0.20 ± 0.05</td>
<td>0.22 ± 0.16</td>
<td>0.04 ± 0.01$^b$</td>
</tr>
<tr>
<td>Brain</td>
<td>0.05 ± 0.01</td>
<td>0.04 ± 0.03</td>
<td>0.01 ± 0.00$^b$</td>
</tr>
</tbody>
</table>

**Tumour**

<table>
<thead>
<tr>
<th></th>
<th>$^{68}$Ga-DOTA-AEBSA</th>
<th>$^{68}$Ga-DOTA-(AEBSA)$_2$</th>
<th>$^{68}$Ga-NOTGA-(AEBSA)$_3$</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.81 ± 0.15</td>
<td>0.41 ± 0.10$^b$</td>
<td>0.35 ± 0.17$^b$</td>
</tr>
<tr>
<td>Tumour/liver</td>
<td>1.03 ± 0.21</td>
<td>0.85 ± 0.16</td>
<td>1.04 ± 0.22</td>
</tr>
<tr>
<td>Tumour/blood</td>
<td>1.29 ± 0.11</td>
<td>1.31 ± 0.26</td>
<td>1.37 ± 0.24</td>
</tr>
<tr>
<td>Tumour/muscle</td>
<td>5.02 ± 0.22</td>
<td>5.63 ± 1.52</td>
<td>6.26 ± 2.74</td>
</tr>
</tbody>
</table>

Biodistribution and ratios are at 1 h post-injection. Values (%ID/g) are presented as mean ± standard deviation.

$^a$Blocked by pre-injection of acetazolamide (AZA) 1 h before administering radiotracer.

$^b$Pre-injection significantly reduced uptake of the same organ for the tracer (p<0.05)
Positive correlation between hypoxia and CA-IX expression has previously been demonstrated using PET hypoxia tracers and CA-IX immunohistochemical staining, but not vice versa due to the lack of suitable CA-IX tracers. Using $^{68}$Ga-DOTA-AEBSA as the imaging tracer, PET studies were performed at 17, 24 and 33 days after cell-inoculation for one mouse which exhibited slower initial tumour growth compared to other subjects (Figure 5.7). Absolute uptake and overall contrast improved as the tumour grew over the three imaging sessions. Tumour size and hottest $2 \times 2$ voxel cluster (based on drawn ROIs) were 91.8 mm$^3$ and 0.21 %ID/g, 830.9 mm$^3$ and 0.40 %ID/g, and 1225.1 mm$^3$ and 0.65 %ID/g for 17, 24, and 33 days, respectively. By the second and third imaging session, distribution of radioactivity in tumour is visibly heterogeneous with several areas of focality. While additional studies are needed to determine if uptake of $^{68}$Ga-DOTA-AEBSA corresponds to the degree of hypoxia, the clinical utility of tracers will be improved if they can serve as surrogate hypoxia imaging agents. As CA-IX is an endogenous marker of hypoxia, tumours that express CA-IX are not only susceptible to emergent CA-IX inhibitors, but to hypoxia-targeting therapies as well.

Figure 5.7 Longitudinal study: uptake of $^{68}$Ga-DOTA-AEBSA in HT-29 tumour xenograft increases as tumour grows. This tumour bearing mouse was imaged 17, 24 and 33 days post-cell inoculation with $^{68}$Ga-DOTA-AEBSA.
Historically the clinical detection of CA-IX has mainly been facilitated by the mAb cG250. cG250 binds to the proteoglycan-like domain of CA-IX and have been explored for imaging\textsuperscript{127-129} and therapy\textsuperscript{172, 173}. \textsuperscript{124}I-cG250 advanced to phase III clinical trials for the diagnosis of CCRCC with PET,\textsuperscript{127} but whether this antibody will be available for clinical use remains unclear. The high molecular weight of mAbs combined with slow uptake kinetics and high cost of \textsuperscript{124}I, could limit their usefulness or clinical acceptance. On the other hand, there is significant interest in developing small molecule inhibitors for imaging CA-IX in vivo.

The development of CA-IX inhibitors as PET imaging agents have been met with limited success. Those that have been evaluated in the pre-clinical setting have shown low tumour uptake, lack of isoform selectivity, and/or instability in vivo.\textsuperscript{196, 235-237} Recently, we reported the synthesis and biological evaluations of four \textsuperscript{18}F-labeled sulfonamide derivatives for CA-IX imaging.\textsuperscript{220} For each tracer, HT-29 tumour xenografts were readily visualized with good contrast (tumour-to-muscle ratios of 3.18-9.55). In vivo selectivity for CA-IX was achieved through the use of a multivalent design; however, absolute uptake in tumour remained low (0.30-0.64 %ID/g at 1 h p.i.). Furthermore, high sequestration of activity in liver and GI tract precludes their use for imaging lesions in these organs. By comparison, all three tracers presented in this chapter had higher absolute uptake with comparable contrasts. \textsuperscript{68}Ga-DOTA-AEBSA and to a lesser extent \textsuperscript{68}Ga-DOTA-(AEBSA)\textsubscript{2} showed favourable pharmacokinetic profiles that will enable detection of lesions within the abdominal thorax. Given the prognostic and therapeutic significance of CA-IX, we believe that polyaminocarboxylate chelator-conjugated sulfonamides warrant further investigation as promising imaging agents. Further optimization could be possible by tailoring charge properties or hydrophilicity of the multimeric compounds to decrease liver accumulation and hepatobiliary clearance.

\section*{5.4 Conclusion}

We have demonstrated that \textsuperscript{68}Ga-labeled benzenesulfonamide inhibitors can be used for non-invasive imaging of CA-IX. Easily produced, with favourable pharmacokinetics and rapid tumour targeting, these tracers represent attractive alternatives to conventional mAb-based imaging systems. Clinically, these nanomolar affinity compounds could enable physicians to determine if patients’ tumours express sufficiently high levels of CA-IX to evaluate their
suitability for treatments. As CA-IX is considered an endogenous marker for hypoxia in certain cancer subtypes, these compounds might be useful for hypoxia imaging. Further validation is warranted to assess the suitability of these compounds for this application.
Chapter 6: Antibodies and Antibody Mimetics for Imaging – Pilot Studies

6.1 Introduction

The advent of hybridoma technology in conjunction with advancements in serological techniques has made mAbs one of the more powerful pharmacological tools for basic research and medicine\(^{123, 238}\). The tumouricidal effects of mAbs are derived from several mechanisms\(^{105}\). mAbs can cause direct cell death by abrogating cell signaling and inducing apoptosis\(^{105}\), or by delivering cytotoxic drugs or radiation as antibody conjugates\(^{239, 240}\). Additionally, mAbs can elicit indirect immune-mediated cell killing through antibody-dependent cell-mediated cytotoxicity (ADCC), complement dependent cytotoxicity (CDC), or antibody-dependent cell phagocytosis (ADCP)\(^{241-243}\).

Since its discovery in 1986, the mAb cG250 has been investigated extensively for CA-IX targeted therapy\(^{244, 245}\). cG250 was evaluated as adjuvant therapy for CCRCC patients in a phase III clinical study; however, it failed to meet primary endpoint as no improvement in median disease-free survival was observed compared to placebo\(^{172, 246}\). While cG250 has been shown to facilitate ADCC\(^{247}\), it does not inhibit CA-IX enzymatic activity as it binds to the PG-like domain. It has been hypothesized that mAbs that can inhibit CA-IX activity and induce immune-mediated cell killing would be more efficacious than cG250\(^{220}\). As such, different research groups have focused on developing mAbs that target the catalytic site of CA-IX\(^{248-251}\). In collaboration with Drs. Shoukat Dedhar (BCCA), Anne Lenferink (NRC) and Maureen O’Connor (NRC) who are interested in developing therapeutic agents targeting CA-IX, we evaluated 3 high-affinity mAbs raised against the extracellular domain of CA-IX (Table 6.1). Two of these mAbs bind the PG-like domain of CA-IX, while the epitope for the remaining mAb was determined to be the catalytic domain. We conjugated these antibodies with DTPA as a chelator, followed by radiolabeling with \(^{111}\)In, using non-selective polyclonal IgG as a negative control. SPECT imaging studies were performed to evaluate mAb uptake in vivo and to guide therapeutic development of ADCs.

---

The work presented in this chapter is not published. The mAbs used for radiolabeling and imaging experiments were obtained from our collaborators Drs. Shoukat Dedhar (BCCA), Anne Lenferink (NRC), and Maureen O’Connor (NRC).
Table 6.1 Characterization of mAbs raised against the extracellular domain of CA-IX

<table>
<thead>
<tr>
<th>Name</th>
<th>Isotype</th>
<th>Epitope</th>
<th>Internalization</th>
<th>$K_i$ (nM)(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ab01</td>
<td>Mouse IgG1</td>
<td>PG-like domain</td>
<td>No</td>
<td>0.12</td>
</tr>
<tr>
<td>Ab02</td>
<td>Mouse IgG1</td>
<td>PG-like domain</td>
<td>Yes</td>
<td>0.76</td>
</tr>
<tr>
<td>Ab03</td>
<td>Mouse IgG1</td>
<td>Catalytic domain</td>
<td>Yes</td>
<td>0.33</td>
</tr>
</tbody>
</table>

\(^a\)Binding affinity determined by surface plasmon resonance

In addition to mAbs, we investigated the use of an affibody as an alternative protein scaffold for CA-IX imaging. Affibody and other antibody mimetics offer high affinity antigen recognition, tissue penetrance, stability, and quick pharmacokinetics (Figure 6.1). As discussed in Chapter 1, Honarvar et al. reported the successful affibody-mediated imaging of CA-IX expression in SK-RC-52 xenograft mice with $^{99}$mTc-HEHEHE-ZCAIX:1\(^1^{154}\). ZCAIX:1, also known as Z09781 in a patent application, had good binding affinity to CA-IX with a $K_d$ value of 1.3 nM\(^2^{252}\). Biodistribution data showed high and sustained tumour uptake: 22.3 ± 3.2 and 9.7 ± 0.7 %ID/g at 1 and 4 h p.i., respectively. This corresponded to tumour-to-blood and tumour-to-muscle ratios of 26 ± 4 and 61 ± 14 at 1 h p.i., and 53 ± 1 and 104 ± 52 at 4 h p.i., respectively\(^1^{154}\). Since a CCRCC cancer cell line was used, we were interested to see if Z09781 would yield similar results in a hypoxia CA-IX model. Therefore, we proceeded to radiolabel Z09781 with $^{68}$Ga for PET imaging studies using HT-29 tumour xenograft mice.

![Figure 6.1 Engineered protein scaffolds.](image)

**Figure 6.1 Engineered protein scaffolds.** This figure shows representative protein models of antibody mimetics that have been engineered for antigen recognition and targeting. Figure reproduced with permission from Nuttall and Walsh\(^2^{253}\).
6.2 Materials and Methods

All chemicals and solvents unless otherwise specified were obtained from commercial sources, and used without further purification. The three CA-IX mAbs were obtained from the National Research Council (NRC). Mouse polyclonal IgG1 control was purchased commercially from Sigma. Purification and quality control of precursors and radiotracers were performed on an Agilent (Santa Clara, CA) HPLC system equipped with a model 1200 quaternary pump, a model 1200 UV absorbance detector, and a Bioscan (Washington, DC) NaI scintillation detector. The HPLC columns used were a size exclusion column (Phenomenex SEC-3000, 5 µ, 300 × 7.8 mm), a semipreparative column (Phenomenex C18, 5 µ, 250 × 10 mm), and an analytical column (Phenomenex Luna C18, 5 µ, 250 × 4.6 mm). [68Ga]GaCl3 was eluted from either a 30-mCi 68Ge/68Ga generator from Eckert & Ziegler (Berlin, Germany) or a 50-mCi generator from iThemba LABS (Faure, South Africa). Radioactivity of tracers were measured using a Capintec (Ramsey, NJ) CRC®-25R/W dose calibrator. The radioactivity of mouse tissues collected from biodistribution studies were counted using a Perkin Elmer (Waltham, MA) Wizard2 2480 automatic gamma counter.

6.2.1 Conjugation of p-SCN-Bn-DTPA to mAbs

mAbs with excipients were first washed with PBS and recovered by centrifugal purification. For each mAb, 1 mg was conjugated with p-SCN-Bn-DTPA (Macrocyclics) in 500 µL of PBS (buffered to pH 8.9 with 0.1 M Na2CO3). A 5:1 molar ratio of chelator to mAb was used and the reactions were allowed to proceed overnight at room temperature with gentle agitation. After incubation, the reactant mixtures were purified using using 50 kDa amicon filters (Millipore) to remove any unconjugated chelator. p-SCN-Bn-DTPA-mAb conjugates were washed thrice with PBS before being resuspended in 0.15 M ammonium acetate (pH 5.5) and stored as 0.1 mg aliquots at -20 °C.

6.2.2 111In Radiolabeling for p-SCN-Bn-DTPA-mAbs

111In was purchased from Nordion (Vancouver, Canada) as [111In]InCl3 solution. 0.9% NaCl solution was added to create a ~185 MBq/100 µL stock solution. In a reaction vial, 500 µL of
0.1 M HEPES solution (pH 5.5) was added to 100 µL of $[^{111}\text{In}]\text{InCl}_3$. For each mAb, 0.4 mg of $p$-SCN-Bn-DTPA-mAb conjugates were added to the $^{111}\text{In}$/HEPES solution and incubated for 1 h at room temperature. The crude reactions were purified using 50 kDa amicon filters (Millipore) and radiochemical purity was determined by SEC HPLC analysis per published procedures.$^{254}$

### 6.2.3 Synthesis of Cys-Z09781

The synthesis of Cys-Z09781 was performed using the standard Fmoc solid-phase approach on an AAPPTec Endeavor 90 peptide synthesizer (Louisville, KT). Starting with Fmoc-Lys(Boc)-Rink-Amide-MBHA resin, the $N^\alpha$-Fmoc protecting group was removed by 20% piperidine in DMF. Subsequently, each Fmoc-protected aa was coupled to the sequence with standard in situ activating reagent HBTU (3 eq), HOBT (3 eq), DIEA (6 eq), in DMF. The process was repeated until the sequence was completed (CAEAKYAKENLFAGWEIDDLPNLTEDQRNAFIYKLWDDPSQSSELLSEAKKLNDSQAPK). At the end of elongation, the peptides were cleaved from resin and all protecting groups were concomitantly removed by treatment TFA/TIS/DI water/EDT/Thioanisole/Phenol at 81.5/1.0/5.0/2.5/5.0/5.0 ratio for 4 h at room temperature. The solution was filtered and the peptide was precipitated with 10 times volume of diethyl ether. The precipitate was collected by centrifugation, dissolved in water, and lyophilized. The dried product was resuspended in water and purified by HPLC on a semipreparative column using 25-35% acetonitrile gradient containing 0.1% TFA in 30 min at a flow rate of 4.5 mL/min ($t_R$: 24.3 min). MS(ESI) Calcd. for Cys-Z09781: m/z 6741.67; Found: m/z 6746.80 ([M+5H]$^{5+}$).

### 6.2.4 Conjugation of NOTA to Cys-Z09781

A cysteine residue was introduced at the $N$-terminus of the affibody to facilitate site-specific conjugation with thiol-maleimide chemistry. In a 4-mL reaction vial, 1.9 mg of purified Cys-Z09781 was dissolved in 950 µL of 0.2 M ammonium acetate (pH 6.5) and incubated with 10 µL of 0.5 M TCEP and 0.46 mg of maleimido-mono-amide-NOTA (Macroyclics). The reaction was allowed to proceed at 40 °C for 2 h with gentle agitation under inert conditions (vial filled with N$_2$ gas). The reaction was purified by HPLC on a semipreparative column using 20-40%
acetonitrile gradient containing 0.1% TFA in 30 min at a flow rate of 4.5 mL/min ($t_R$: 22.1 min).

MS(ESI) Calcd. for Cys[NOTA]-Z09781: m/z 7167.15; Found: m/z 7173.59 ([M+5H]$^{5+}$).

6.2.5 $^{68}$Ga Radiolabeling for Cys[NOTA]-Z09781

$^{68}$GaCl$_3$ was purified following published procedures$^{231}$. Purified $^{68}$GaCl$_3$ (806 – 899 MBq in 0.5 mL) was added to 100 µg of Cys[NOTA]-Z09781 in 0.7 mL of 2 M HEPES buffer (pH 5.0) with 5% glycerol. Reaction was heated using a Danby DMW7700WDB microwave (Finday, OH) at power setting 2 for 1 min. For purification, the reaction was loaded onto a PD10 column, and eluted with 0.9% saline in fractions. The fractions containing the radiolabeled product were pooled and a small aliquot was subsequently taken for QC HPLC. Radiochemical yield, purity and specific activity, was determined by HPLC on an analytical column eluted with 31% acetonitrile at a flow rate of 2 mL/min ($t_R$: 10.8 min).

6.2.6 In Vivo Evaluations

All animal studies were performed in accordance with the Canadian Council on Animal Care guidelines and approved by the Animal Care Committee of the University of British Columbia. Male immunodeficient NOD.Cg-Prkdc$^{scid}$/Il2rg$^{m1Wjl}$/SzJ (NSG) mice bred in-house at the Animal Research Centre, BC Cancer Research Centre were used for this study. Under anesthesia with 2.5% isoflurane in 2.0 L/min of oxygen, mice were subcutaneously inoculated with $5 \times 10^6$ HT-29 cells (in 100 µL PBS and BD Matrigel Matrix at 1:1 ratio) under the right dorsal flank. Biodistribution studies and imaging were performed when tumours reached 7-9 mm in diameter.

6.2.6.1 Biodistribution Studies

Tumour bearing mice were injected intravenously with $\sim$0.37 MBq of $^{68}$Ga-Cys[NOTA]-Z09781 or $\sim$3.7 MBq of $^{111}$In-labeled mAb. After an uptake period of either 2, 72, or 168 h, mice were euthanized by CO$_2$ asphyxiation. Blood was promptly withdrawn, and organs/tissues of interest were harvested, rinsed with saline, blotted dry and weighted. Radioactivity in collected tissues was counted, normalized to the injected dose and expressed as the percentage of the injected dose per gram of tissue (%ID/g).
6.2.6.2 SPECT/CT Imaging

Tumour bearing mice were injected intravenously with ~37 MBq of $^{111}$In-labeled mAb. After injection, mice were allowed to recover and roam freely in their cages. At selected time points, mice were sedated with 2% isoflurane inhalation and placed in a MILabs (Utrecht, Netherlands) U-SPECT II/CT scanner for image acquisition. Body temperature was maintained by a heating pad during acquisition. A 5 min baseline CT scan was obtained for localization with voltage setting at 60 kV and current at 615 μA. A single static emission scan was acquired for 1 h using an ultra-high-resolution multi-pinhole rat-mouse (1 mm pinhole size) collimator. Data were acquired in list mode acquisition, reconstructed using the U-SPECT II software, and co-registered for alignment. The SPECT images were reconstructed using maximum-likelihood expectation maximization (3 iterations), pixel-based ordered subset expectation maximization (16 subsets) and a post-processing filter (Gaussian blurring) of 0.5mm centered at photopeaks 171 keV and 245 keV with a 20% window width. Imaging files were visualized with either PMOD or Inveon Research Workplace software. At the conclusion of the final imaging time point, mice were euthanized and processed for biodistribution as described above.

6.2.6.3 PET/CT Imaging

PET imaging studies of $^{68}$Ga-Cys[NOTA]-Z09781 were conducted using a Siemens Inveon microPET/CT scanner. Under 2.5% isoflurane anesthesia in oxygen at 2.0 L/min, 3.7-7.4 MBq of $^{68}$Ga-Cys[NOTA]-Z09781 in a volume of 200 μL was administered intravenously through the caudal vein. Under 2.5% isoflurane anesthesia in oxygen at 2.0 L/min, 3.7-7.4 MBq of $^{68}$Ga-Cys[NOTA]-Z09781 in a volume of 200 μL was administered intravenously through the caudal vein. At 2 h p.i., a CT-based attenuation scan was performed with exposure settings of 60kV, 500 μA and 500 ms, using three sequential bed positions with a 33% overlap, and 220 degree continuous rotation prior to the 10 min PET acquisition. The body temperature of mice was maintained at 37 °C with the use of thermal pads. The PET list mode data were converted into a sinogram file with default 3D histogram settings prior to reconstruction using 2 iterations of 3D - Ordered Subset-Expectation Maximization (3D OSEM) and 18 iterations of Maximum A Priori (MAP). At the conclusion of the final imaging time point, mice were euthanized and processed for biodistribution as described above.
6.3 Results and Discussion

We evaluated three novel mAbs raised against the extracellular domain of CA-IX for SPECT/CT imaging. These mAbs were initially developed at the NRC for therapeutic applications. These mAbs target either the PG-domain or catalytic domain of CA-IX with subnanomolar affinity (Table 6.1). Based on in vitro assays done at the NRC, Ab02 and Ab03 were found to undergo internalization upon binding to CA-IX, while Ab01 is considered a non-internalizing mAb. For mAbs that are designed to deliver drugs or radiation, internalization can bring the therapeutic payload closer to intracellular targets (microtubule, DNA etc.)\textsuperscript{124}. If the mechanism of action of a mAb is to bind the target receptor to inhibit signalling, or to elicit immunomodulatory response (ADCC, CDC, or ADCP), it is desirable for the antigen-mAb complex to not be rapidly internalized\textsuperscript{124}. This enables the Fab region of the mAb to continue signal blockade of the receptor, and maximizes the availability of the Fc region to interact with immune effector cells\textsuperscript{124}.

For each mAb, we performed conjugation with \textit{p}-SCN-Bn-DTPA to facilitate \textsuperscript{111}In labeling (Figure 6.2). With a physical \textit{t}_1/2 of 2.80 d, \textsuperscript{111}In has long been used for mAb-based imaging\textsuperscript{255,256} and is a biological surrogate for therapeutic radionuclides, \textsuperscript{90}Y and \textsuperscript{177}Lu\textsuperscript{257,258}. In recent years, in addition to imaging \textsuperscript{111}In-bioconjugates have received significant interest as Auger electron emitting radiotherapeutics\textsuperscript{259,260}. As a residualizing radionuclide, \textsuperscript{111}In will reside in the cell even if the radiolabeled mAb is internalized and degraded\textsuperscript{261,262}. Radiolabeling procedures were adapted from published procedures\textsuperscript{263}. Based on SEC HLPC analysis, we obtained good radiochemical yields (70-80\%, \textit{n} = 3) and radiochemical purity (> 95\%) after centrifugal purification for the radiolabeled mAbs. With limited quantity of each mAb, the immunoreactivity fractions were not determined for this pilot study.

![Figure 6.2 DTPA conjugation for mAbs.](image)

The bifunctional chelator \textit{p}-SCN-Bn-DTPA was conjugated to the CA-IX mAbs for \textsuperscript{111}In labeling.
Figure 6.3 Representative radiochromatogram of an $^{111}$In radiolabeled mAb, before and after centrifugal filtration to remove unbound radioisotopes. Top panel is radioactivity (mAu), while bottom panel is absorbance at 280 nm (mAU). $t_R$ of radiolabeled mAb is approximately 9.4 min.

As absolute tumour uptake is determined in part by the clearance rate of a radiopharmaceutical, large molecules like mAbs generally display higher uptake than small molecule agents. The enhanced permeability and retention (EPR) effect$^{264}$ is beneficial for macromolecule-based therapeutics; however, it obscures evaluation of targeted imaging by overestimating specific uptake. In order to discern the contribution of the EPR effect, we included the use of a non-specific polyclonal IgG for in vivo studies. Imaging experiments were performed in immunodeficient mice bearing HT-29 colon carcinoma xenografts (Figures 6.4 and 6.5). From the SPECT/CT images, there was significant accumulation of Ab02 in tumour compared to Ab01, Ab03, and non-specific polyclonal IgG. As early as 24 h p.i., Ab02 was readily taken up by tumour with high penetrance enabling the acquisition of high contrast images. Radioactivity was retained in the tumour over the course of 7 days, while progressive clearance was observed for non-target tissues including the heart, liver and spleen. Conversely, the accumulation of Ab01 and Ab03 in tumour was observed predominantly at the peripheral boundaries similar to IgG control.
Figure 6.4 Sequential SPECT/CT images obtained with $^{111}$In-SCN-Bn-DTPA-Ab01 and $^{111}$In-SCN-Bn-DTPA-Ab02. $^{111}$In-SCN-Bn-DTPA-Ab01 uptake was primarily observed at the peripheral boundaries, while $^{111}$In-SCN-Bn-DTPA-Ab02 showed significant retention and accumulation of in tumours with progressive decrease in background. t = tumour; h = heart; l = liver; s = spleen
Figure 6.5 Sequential SPECT/CT images obtained with $^{111}$In-SCN-Bn-DTPA-Ab03 and $^{111}$In-SCN-Bn-DTPA-IgG. $^{111}$In-SCN-Bn-DTPA-Ab03 uptake was initially observed at the peripheral boundaries but showed progressive clearance from tumour. By day 3, uptake of $^{111}$In-SCN-Bn-DTPA-Ab03 was similar to $^{111}$In-SCN-Bn-DTPA-IgG. t = tumour; h = heart; l = liver; s = spleen

$^{111}$In-SCN-Bn-DTPA-Ab03 (internalizing; $K_i = 0.33\text{nM}$)
Since mAbs circulate in the blood for many days, this provides opportunities for repeated antigen-mAb interactions and progressive accumulation of tumour-specific mAbs. In contrast, non-specific mAbs typically exhibit transient passive accumulation followed by progressive clearance from the tumours. Biodistribution studies were performed to determine absolute uptake in tumour and non-target tissues (Table 6.2). Of the evaluated mAbs, the highest tumour uptake was observed for Ab02 (37.84 ± 4.69 %ID/g at 72 h p.i.). The uptake of Ab02 in tumour was approximately two-fold higher than Ab01 (19.09 ± 4.81 %ID/g) and Ab03 (18.38 ± 3.07 %ID/g). With the exception of blood, spleen, and tumour, uptake in non-target tissues were relatively consistent for each mAb. A potential reason for the enhanced uptake of Ab02 is its slow rate of clearance from blood (20.62 ± 4.33 %ID/g at 72 h p.i.). At 168 h p.i., uptake in tumour for Ab02 was 35.64 %ID/g, suggesting that there is retention at the tumour site. By comparison, the uptake of the polyclonal IgG control was 14.01 ± 0.23 %ID/g at 168 h p.i. While Ab02 yielded promising data, further studies are needed to fully assess its potential for targeting CA-IX (greater sample size at multiple time points).

As cG250 is considered the metric novel mAbs targeting CA-IX are evaluated against, an overview of the different radiolabeled cG250 immunoconjugates that have been investigated in preclinical setting is provided in Table 6.3. In the most comprehensive study to date, Brouwers et al. demonstrated that radionuclide and chelation selection can affect stability, biodistribution and therapeutic efficacy of radioimmunotherapy with cG250265. Depending on the radioisotope/chelator combination used, tumour uptake ranged from 14.0 ± 3.0 %ID/g (for 125I-cG250) to 113.3 ± 24.7 %ID/g (for 177Lu-SCN-Bz-DTPA-cG250) at 3 d p.i. Brouwers et al. evaluated 111In-DTPA-cG250 for targeting SK-RC-52 tumour xenografts (4.9 ± 2.9 %ID/g at 3 d p.i.); however the studies were performed in nude rats266. The study that offers the fairest comparison would be the one performed by Carlin et al. using 111In-DOTA-cG250 with the HT-29 model (20.1 ± 4.8 %ID/g at 2 d p.i.)217. Ideally, for future studies we will be able to obtain cG250 and perform a side-by-side comparison with our CA-IX mAbs while holding variables like isotope, chelator, tumour model, host, and timepoint consistent.
Table 6.2 Biodistribution and tumour-to-nontarget ratios for $^{111}$In-SCN-Bn-DTPA-mAbs.

<table>
<thead>
<tr>
<th>Organ</th>
<th>$^{111}$In-SCN-Bn-DTPA-Ab01</th>
<th>$^{111}$In-SCN-Bn-DTPA-Ab02</th>
<th>$^{111}$In-SCN-Bn-DTPA-Ab03</th>
<th>$^{111}$In-SCN-Bn-DTPA-IgG</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>72 h p.i. (n = 4)</td>
<td>72 h p.i. (n = 3)</td>
<td>168 h p.i. (n = 1)</td>
<td>72 h p.i. (n = 3)</td>
</tr>
<tr>
<td>Blood</td>
<td>6.68 ± 1.41</td>
<td>20.62 ± 4.33</td>
<td>11.06</td>
<td>7.56 ± 0.60</td>
</tr>
<tr>
<td>Fat</td>
<td>1.97 ± 0.69</td>
<td>1.88 ± 0.47</td>
<td>2.34</td>
<td>1.50 ± 0.15</td>
</tr>
<tr>
<td>Intestine</td>
<td>3.05 ± 0.40</td>
<td>3.25 ± 0.30</td>
<td>1.76</td>
<td>2.69 ± 0.41</td>
</tr>
<tr>
<td>Stomach</td>
<td>2.12 ± 0.38</td>
<td>2.21 ± 0.44</td>
<td>1.98</td>
<td>1.88 ± 0.24</td>
</tr>
<tr>
<td>Spleen</td>
<td>78.16 ± 48.53</td>
<td>37.84 ± 4.69</td>
<td>32.12</td>
<td>53.88 ± 12.50</td>
</tr>
<tr>
<td>Liver</td>
<td>18.66 ± 4.42</td>
<td>18.68 ± 2.22</td>
<td>14.41</td>
<td>17.46 ± 4.05</td>
</tr>
<tr>
<td>Pancreas</td>
<td>2.69 ± 0.53</td>
<td>2.95 ± 0.59</td>
<td>2.09</td>
<td>2.36 ± 0.28</td>
</tr>
<tr>
<td>Kidney</td>
<td>10.83 ± 2.78</td>
<td>12.86 ± 2.54</td>
<td>6.75</td>
<td>5.06 ± 0.80</td>
</tr>
<tr>
<td>Lungs</td>
<td>5.88 ± 1.52</td>
<td>9.54 ± 0.92</td>
<td>9.55</td>
<td>5.22 ± 0.42</td>
</tr>
<tr>
<td>Heart</td>
<td>5.49 ± 1.52</td>
<td>6.74 ± 1.04</td>
<td>3.50</td>
<td>4.77 ± 0.56</td>
</tr>
<tr>
<td>Muscle</td>
<td>1.87 ± 0.38</td>
<td>2.26 ± 0.29</td>
<td>1.35</td>
<td>1.37 ± 0.02</td>
</tr>
<tr>
<td>Bone</td>
<td>6.25 ± 2.98</td>
<td>4.46 ± 1.62</td>
<td>2.83</td>
<td>3.05 ± 0.86</td>
</tr>
<tr>
<td>Brain</td>
<td>0.18 ± 0.05</td>
<td>0.33 ± 0.04</td>
<td>0.20</td>
<td>0.16 ± 0.04</td>
</tr>
</tbody>
</table>

Tumour: 19.09 ± 4.81  37.84 ± 4.69  35.64  18.38 ± 3.07  8.20  14.01 ± 0.23

Tumour/muscle: 10.43 ± 2.81  15.22 ± 0.64  26.38  13.37 ± 2.14  24.07  10.47 ± 3.72

Values are presented as mean ± SD where possible.
For the remainder of this chapter, the discussion will primarily be focused on the synthesis and biological evaluations of the CA-IX affibody, $^{68}$Ga-Cys[NOTA]–Z09781. As an antibody mimetic, affibodies have many advantages including protein solubility, thermodynamic stability, single polypeptide chain format, ease of production, and functionality in the absence of disulfide bridges. We synthesized the affibody Z09781 (Figure 6.6) using a solid-phase approach and added a Cys residue at the N-terminus to facilitate site-specific conjugation of the NOTA chelator via thiol-maleimide chemistry. To complement the rapid pharmacokinetics, we selected $^{68}$Ga as our imaging radionuclide. For radiolabeling experiments, $^{68}$Ga-Cys[NOTA]–Z09781 was obtained in 64–73% decay-corrected radiochemical yields with 16.7 MBq/µg specific activity and > 99% radiochemical purity.
Figure 6.6 Site-specific conjugation of NOTA to Cys-Z09781. The complete amino acid sequence of Cys-Z09781 is provided on the right.

Imaging and biodistribution studies (Figures 6.7 and 6.8) showed that $^{68}$Ga-Cys[NOTA]-Z09781 was predominantly excreted through the renal pathway, with the kidneys retaining majority of the radioactivity (96.1 ± 10.4 %ID/g at 2 h p.i.). The clearance profile is consistent with other affibodies used for imaging$^{149-154}$. $^{68}$Ga-Cys[NOTA]-Z09781 allowed for clear delineation of HT-29 tumour xenografts in PET/CT images. With the exception of the kidneys and bladder, the highest uptake of activity was observed in tumour (1.05 ± 0.15 %ID/g at 2 h p.i.). The corresponding tumour-to-muscle and tumour-to-blood ratios were 11.8 ± 3.35 and 9.78 ± 1.59 respectively. The uptake of $^{68}$Ga-Cys[NOTA]-Z09781 in tumour was similar to that achieved with the $^{68}$Ga-labeled sulfonamides in Chapter 5, but with improved contrast. However, when compared to the results previously obtained by Honarvar et al. (22.3 ± 3.2 and 9.7 ± 0.7 %ID/g at 1 and 4 h p.i. for with $^{99m}$Tc-HEHEHE-ZCAIX:1 with SK-RC-52 tumours), we observed substantially lower uptake values$^{154}$. Due to the biological processes that drive CA-IX expression in HT-29 (hypoxia dependent) and SK-RC-52 (hypoxia independent; constitutive), we anticipated lower uptake for this study. Additionally, although the introduction of a cysteine residue for site-specific chelator conjugation and radiolabeling is a robust strategy$^{269, 270}$, it is possible that the change in radiometal/chelator composition negatively affected tumour uptake.
Figure 6.7 PET/CT images of $^{68}$Ga-Cys[NOTA]-Z09781 at 2 h p.i. t = tumour; k = kidney; bl = bladder

Figure 6.8 Biodistribution of $^{68}$Ga-Cys[NOTA]-Z09781 in tumour and selected organs at 2 h p.i. (n=6).

6.4 Conclusion

In Chapter 6, we evaluated three novel mAbs as well as an affibody for CA-IX targeted SPECT and PET imaging. For each compound class, tracer pharmacokinetics and uptake was assessed in a human hypoxia cancer model. The mAbs were conjugated to $p$-SCN-Bn-DTPA and successfully radiolabeled with $^{111}$In. $^{111}$In-SCN-Bn-DTPA-Ab02 showed good tumour penetrance and yielded high contrast images as early as 24 h p.i. Conversely, neither Ab01 nor
Ab03 showed any significant accumulation in tumour compared to Ab02. As for affibody imaging, $^{68}$Ga-Cys[NOTA]-Z09781 enabled clear visualization of HT-29 tumour xenografts with good contrast. Blocking studies are needed to determine tracer specificity of $^{68}$Ga-Cys[NOTA]-Z09781.
Chapter 7: Conclusion

7.1 Summary of Study and Findings

Cancer is one of the leading causes of morbidity and mortality worldwide. According to the World Health Organization (WHO) 14.1 million individuals were diagnosed with cancer with 8.2 million succumbing to the disease in 2012, based on the most recent GLOBOCAN data. By 2025, the incidence level is expected to increase to 20 million cases annually. This global burden emphasizes the need for improved evidence-based strategies in cancer prevention, diagnosis and therapeutics. The goal of this thesis was to identify different molecular antigen recognition molecules that may serve as potential radiotracers for targeting CA-IX for cancer diagnosis. CA-IX is considered a surrogate marker for tumour hypoxia, and its expression is negatively correlated with patient survival. Hypoxic tumours can develop resistance to radiation and selected chemotherapies; therefore, the treatment for these cancers often involves combinatorial treatments especially at a disseminated stage. CA-IX represents a potential co-target, in synergy with other chemotherapies (ex. anti-VEGF therapies). We believe the establishment of a non-invasive companion diagnostic will accelerate the clinical adoption of CA-IX therapies.

In Chapters 2, 3, 4, and 5, we synthesized and evaluated a total of 12 small molecule inhibitors for imaging CA-IX expression in vivo. Initial efforts to image CA-IX expression based on literature-published inhibitors were unsuccessful due to tracer instability and lack of target specificity. Subsequently, we identified several 18F/68Ga-labeled sulfonamide derivatives that effectively targeted CA-IX expressing tumour xenografts with good contrast. Isoform selectivity, the major challenge for the development of sulfonamide-based imaging agents, was achieved via a multivalent approach or by conjugating pharmacophores to polyaminocarboxylate chelators. In Chapter 6, we evaluated 3 high affinity mAbs raised against the extracellular domain of CA-IX, as well as a recently reported affibody for imaging studies. High and sustained uptake was observed for 111In-SCN-Bn-Ab02, which yielded excellent contrast images as early as 24 h p.i. As an antibody mimetic, Z09781 generated good tumour to background ratios for imaging.
hypoxia-induced CA-IX expression but absolute uptake was substantially lower than mAb-based imaging.

7.2 Strengths and Limitations of this Study

There were a number of strengths and limitations associated with this study. Our study represents a comprehensive evaluation of different antigen recognition molecules targeting CA-IX. With small molecule inhibitors, we explored two distinct strategies (valency and hydrophilicity) to confer CA-IX specificity. Through this process, we produced several tracers that not only enabled tumour visualization, but represented significant advancement over previous attempts. We pursued radiolabeling strategies that incorporated either $^{18}$F or $^{68}$Ga. Both radionuclides have short $t_{1/2}$, which are well-suited for biomolecules that display fast pharmacokinetics. Just as important, the general availability of $^{18}$F (cyclotron) or $^{68}$Ga (generator) suggests that these compounds can be readily adopted by other radiopharmaceutical facilities. Another strength in our research is the ability to guide development of emerging CA-IX therapeutics. SPECT imaging with $^{111}$In-SCN-Bn-DTPA-mAbs provided meaningful information regarding targeting efficiency, tissue penetrance, and pharmacokinetics. Collectively, this thesis has strong translational components that can drive the growth of CA-IX diagnostics and therapeutics, which is important for personalizing medicine. As potential surrogates for hypoxia imaging, CA-IX tracers hold advantages for tumour-to-nontarget ratios and pharmacokinetics compared to established hypoxia PET agents (ex. FMISO, etc).

We used the HT-29 human colorectal cancer cell line for the evaluation of our radiotracers. Although this enabled us to compare our findings with previously published reports, further validation with additional cancer cell lines or patient derived xenograft (PDX) models are needed to confirm tracer utility. PDX models can better recapitulate the phenotype of cancer patients in terms of genomics, metastatic potential, and drug responsiveness; however, long tumour graft latency and variable engraftment rates may be limiting factors. In Chapter 5, we performed a longitudinal imaging study with $^{68}$Ga-DOTA-AEBSA for one mouse and observed increase in focal uptake over three imaging sessions. We hypothesized that the non-homogeneous distribution of activity corresponded with CA-IX expression within hypoxic niches, but validation studies are required. Finally in Chapter 6, we evaluated three mAbs raised...
against the extracellular domain of CA-IX as potential imaging agents. While promising results were obtained, the hybridoma cells producing the mAbs were low yielding and we did not have enough samples to complete analytical/imaging studies.

7.3 Overall Significance and Implications of Research Finding

Due to its role in mediating cell survival and distant metastasis under hypoxic conditions, CA-IX has emerged as a promising therapeutic and imaging biomarker. Although cG250 failed to meet primary endpoint in the phase III ARISER study, retrospective subset analysis revealed that patients with high CA-IX scores (> 2.0) experienced statistically significant improvement in disease-free survival after receiving treatment\textsuperscript{172, 246}. CA-IX scoring for each patient was derived by multiplying staining intensity (1-3) by the fraction of positive cells (0-1). This finding highlights the potential effectiveness of anti-CA-IX therapies in the clinic, given proper patient stratification. Our research serves as a quantitative and non-invasive imaging platform for physicians to determine if patients’ tumours express sufficiently high levels of CA-IX to make them candidates for treatments targeting this protein. Additionally, radiotracers may be useful for optimizing therapeutic dosage, and for assessing patients’ response to treatments. Given the broad expression profile of CA-IX in solid cancers we anticipate that our findings will have a positive impact on cancer management leading to improved patient outcomes and quality of life.

7.4 Future Research Directions

7.4.1 Design of Cationic Sulfonamides

Leveraging the cell-surface expression of CA-IX, the design of CA-IX imaging agents has revolved around membrane impermeability. In this thesis, we pursued two approaches for developing cell-impermeable small molecule inhibitors. In Chapter 4, we used click chemistry to synthesize two trivalent sulfonamide inhibitors. The accumulation of MW served to limit passive perfusion into the cell. In Chapter 5, we conjugated a sulfonamide derivative to different polyaminocarboxylate chelators to enhance tracer hydrophilicity. With both strategies, we were able to observe uptake in HT-29 tumour xenografts with good visualization in PET images. A third strategy that we are interested in exploring is the introduction of a cationic motif onto
fluorinated sulfonamide derivatives. The transcellular uptake across the plasma membrane for charged or ionized species is generally limited\textsuperscript{275}. Our collaborator, Dr. Supuran, reported the synthesis of several cationic sulfonamides using quaternary ammonium sulfates and observed favourable CA inhibition profiles\textsuperscript{221,222}.

### 7.4.2 CA-IX Tracers as Surrogate Hypoxia Imaging Agents

One of the potential avenues for future research is to investigate if tracers designed for CA-IX imaging can be used as general hypoxia agents. One simple approach would be to take a CA-IX tracer (ex. \textsuperscript{68}Ga-DOTA-AEBSA) and perform spatial correlation studies with \textsuperscript{18}F-FMISO and determine if they co-localize in tumours (Figure 7.1). Another approach would be to evaluate changes in uptake and tumour-to-nontarget ratios under artificially induced conditions. Tumour-bearing mice can be divided into 4 groups prior in vivo studies (7% O\textsubscript{2} breathing, carbogen breathing + nicotinamide, 7% O\textsubscript{2} breathing followed by carbogen breathing + nicotinamide, non-treatment/control group). Mice in the 7% O\textsubscript{2} breathing group will represent the hypoxia-induced cohort, while mice assigned to carbogen breathing + nicotinamide treatment will represent the normoxia-induced cohort. The combination of carbogen breathing and nicotinamide administration has been used to reduce tumour hypoxia in clinical settings\textsuperscript{276-278}. The third cohort of mice will be used to evaluate tracer uptake after reoxygenation (7% O\textsubscript{2} breathing followed by carbogen breathing + nicotinamide), while the last group will serve as baseline controls.

![Figure 7.1 Maximal intensity projections of PET/CT (Left) and PET alone (Right) with \textsuperscript{18}F-FMISO at 3 h p.i. Preliminary studies conducted with HT-29 tumour xenograft mice. t = tumour; gb = gallbladder; l = liver; i = gastrointestinal tract](image)

7.4.2 CA-IX Tracers as Surrogate Hypoxia Imaging Agents

One of the potential avenues for future research is to investigate if tracers designed for CA-IX imaging can be used as general hypoxia agents. One simple approach would be to take a CA-IX tracer (ex. \textsuperscript{68}Ga-DOTA-AEBSA) and perform spatial correlation studies with \textsuperscript{18}F-FMISO and determine if they co-localize in tumours (Figure 7.1). Another approach would be to evaluate changes in uptake and tumour-to-nontarget ratios under artificially induced conditions. Tumour-bearing mice can be divided into 4 groups prior in vivo studies (7% O\textsubscript{2} breathing, carbogen breathing + nicotinamide, 7% O\textsubscript{2} breathing followed by carbogen breathing + nicotinamide, non-treatment/control group). Mice in the 7% O\textsubscript{2} breathing group will represent the hypoxia-induced cohort, while mice assigned to carbogen breathing + nicotinamide treatment will represent the normoxia-induced cohort. The combination of carbogen breathing and nicotinamide administration has been used to reduce tumour hypoxia in clinical settings\textsuperscript{276-278}. The third cohort of mice will be used to evaluate tracer uptake after reoxygenation (7% O\textsubscript{2} breathing followed by carbogen breathing + nicotinamide), while the last group will serve as baseline controls.
7.4.3 Radiotherapy

Promising CA-IX tracers should be tested for their usefulness as radiotherapeutic agents. This can be done by replacing imaging radionuclides with therapeutic radionuclides. Alpha (α), beta (β⁻), Auger electron emitters, and conversion electron emitters are classes of radionuclides that exert tumouricidal effects through radiation-induced DNA damage²⁷⁹-²⁸⁶. α-Particle emitters have the highest linear energy transfer (LET) and can cause more irreparable double-stranded DNA breaks²⁸⁰. They have a short tissue range (µm), which is advantageous for treating micrometastasis where there are concerns of depositing energy beyond anatomical boundaries²⁸⁰. α-Particles are not dependent on tumour oxygenation²⁷⁹, which is ideal considering CA-IX’s expression in hypoxic niches. Although a higher concentration of β⁻ emitters is needed for comparable cell kill compared to α emitters, β⁻ emitters have a longer tissue range (mm)²⁸¹. The long range of β⁻ emitters results in a “crossfire” effect where multiple cells can be targeted when only one binding event occurs²⁸¹. Implicitly the crossfire effect decreases the need to target every cell, which is a challenge given the intrinsic heterogeneity of cancer. Auger electrons are low-energy electrons that are ejected from the atom in response to a downward transition of electrons within orbital shells²⁸², ²⁸³. Since they have subcellular range (nm), Auger electrons must enter target cells to ensure proper delivery of radiation dose²⁸², ²⁸³. Conversion electrons are monoenergetic orbital electrons that are ejected from unstable nuclei during the process of internal conversion. With high LET and a limited tissue range (nm), conversion electrons deliver high localized dose to diseased tissues²⁸⁵, ²⁸⁷. The radiometals used for therapy applications, ²²⁵Ac, ²¹²Pb, and ²¹³Bi (α), ⁹⁰Y and ¹⁷⁷Lu (β⁻), ¹¹¹In (Auger), and ¹¹⁴mSn (conversion electron) can be labeled onto CA-IX targeting moieties via bifunctional chelators²⁸⁷-²⁸⁹. For example, ¹¹¹In-SCN-Bn-DTPA-Ab02 investigated for SPECT imaging in Chapter 6 can be used for Auger-electron emitting therapy.

7.4.4 Clinical Translation of CA-IX Imaging Agents

To translate research findings into clinical setting, radiopharmaceuticals require dosimetry and acute toxicity studies for IND applications²⁹⁰. For dosimetry, biodistribution data can be used to estimate potential radiation absorbed doses for humans using the OLINDA/EXM software²⁹¹. On the other hand, acute toxicity studies are more comprehensive. Healthy rats are
intravenously administered the radiotracer at 100-1000 times the expected human dose or saline solution (control group). Animals are monitored, weighed on a daily basis, with blood chemistry (complete blood cell count, hematocrit, hemoglobin, serum creatinine, and alanine aminotransferase) and necropsy performed after 14 days to discern potential differences between the treated and control groups\textsuperscript{292}. We have an in-house Investigational Drug Program at the BCCA that is well-equipped to perform biodistribution and toxicology studies under GLP conditions. Pending optimization to prolong bioavailability to increase overall uptake and contrast, we believe that $^{68}$Ga-DOTA-AEBSA discussed in Chapter 5 is an encouraging candidate for future clinical translation.
Bibliography

47. Bennewith KL, Dedhar S. Targeting hypoxic tumour cells to overcome metastasis. BMC Cancer 2011;11: 504.


259. Kong G, Johnston V, Ramdave S, Lau E, Rischin D, Hicks RJ. High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of
Appendix

This appendix lists awards received, and publications that were published, were accepted, or currently under review, for my graduate degree.

AWARDS AND SCHOLARSHIPS

2015  BC Cancer Agency Lloyd Skarsgard Research Excellence Prize
2015  UBC Interdisciplinary Graduate Student Network Travel Award
2014  UBC Faculty of Graduate Studies Travel Award
2014  World Molecular Imaging Congress Student Travel Stipend
2014  UBC Faculty of Medicine Graduate Award
2014-2017  UBC Four Year Doctoral Fellowship
2014-2016  CIHR Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
2013  Canadian Cancer Society Research Institute Travel Award
2013  CIHR Institute of Cancer Research Travel Award
2013  BC Cancer Foundation John Jambor Knowledge Fund
2013  International Symposium on Radiopharmaceutical Sciences Travel Bursary
2013  CIHR Institute Community Support Travel Award
2013  UBC Interdisciplinary Oncology Program Travel Award
2013  UBC College for Interdisciplinary Studies Graduate Award
2012-2016  RIX Family Leading Edge Student Award
2011  UBC Graduate Entrance Scholarship

PUBLICATIONS

Published Refereed Journal Articles


**Manuscript in Review**


†Denotes shared first author

**Accepted Abstracts**

1) **Liu J**, Kuo HT, Pan J, Zhang C, Lin KS, Bénard F. “Synthesis and evaluation of a \(^{68}\)Ga-labeled affibody for imaging carbonic anhydrase IX expression,” accepted to The Annual Congress of the European Association of Nuclear Medicine, Barcelona, Spain, 2016.


Oral Presentations


4) “Synthesis and evaluation of monomeric, dimeric and trimeric benzenesulfonamide derivatives for imaging carbonic anhydrase IX with PET”. Society of Nuclear Medicine and Molecular Imaging Annual Meeting, St. Louis, USA, June 10th 2014.


6) “Synthesis and evaluation of 18F-labeled tertiary sulfonamides for imaging carbonic anhydrase IX expression in tumors with positron emission tomography”. European Symposium on Radiopharmacy and Radiopharmaceuticals, Pamplona, Spain, April 25th 2014.
